PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
19380832-1	2009	Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.	Imiquimod	23-32	toll like receptor 7	Homo sapiens	42-46
20230025-3	2010	To increase recognition and subsequent stimulatory effects of TLR 7, imiquimod was encapsulated in acetalated dextran (Ac-DEX) microparticles.	Imiquimod	69-78	toll like receptor 7	Homo sapiens	62-67
19527683-3	2009	Recently, the pro-apoptotic activities of IMQ occurring via the modulation of bcl-2 family have been reported in several tumor cells.	Imiquimod	42-45	BCL2 apoptosis regulator	Homo sapiens	78-83
19527683-4	2009	In this study, we first observed IMQ-initiated autophagy determined by vesicular organelle formation and the generation of LC3-II in Caco-2 human colonic adenocarcinoma cells, which expressing functional TLR7.	Imiquimod	33-36	toll like receptor 7	Homo sapiens	204-208
22848514-5	2012	However, imiquimod-adjuvanted vaccine elicited higher levels of serum IgG2a antibodies and increased hemagglutination inhibition titers compared to vaccine alone, suggesting enhanced induction of functional antibodies.	Imiquimod	9-18	immunoglobulin heavy variable V1-9	Mus musculus	70-75
22848514-6	2012	In addition, imiquimod-adjuvanted vaccine induced a robust IFN-gamma cellular response.	Imiquimod	13-22	interferon gamma	Mus musculus	59-68
21389872-6	2011	Aldara treatment was associated with a reduction in the number CD4(+)Foxp3(+) regulatory T cells in the blood and brain tumor site.	Imiquimod	0-6	CD4 antigen	Mus musculus	63-66
21389872-7	2011	Mice treated with Aldara exhibited a generalized lymphopenia in the blood amidst an increase in brain tumor infiltrating CD4(+) and CD8(+) T cells and dendritic cells.	Imiquimod	18-24	CD4 antigen	Mus musculus	121-124
21646801-10	2011	Budesonide significantly inhibited R-837-induced IL-8 production in a concentration-dependent manner, and procaterol potentiated inhibition by budesonide although single-agent procaterol had no effect.	Imiquimod	35-40	C-X-C motif chemokine ligand 8	Homo sapiens	49-53
19887600-7	2009	Moreover, treatment with imiquimod downregulated MHC class I molecules on tumor cells possibly resulting in a reduced binding affinity for inhibitory receptor NKG2A expressed on gammadelta T cells.	Imiquimod	25-34	killer cell lectin like receptor C1	Homo sapiens	159-164
19380832-1	2009	Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.	Imiquimod	34-37	toll like receptor 7	Homo sapiens	42-46
19380832-3	2009	We hypothesized that IMQ-induced dermatitis in mice can serve as a model for the analysis of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency.	Imiquimod	21-24	interleukin 23, alpha subunit p19	Mus musculus	161-166
19380832-3	2009	We hypothesized that IMQ-induced dermatitis in mice can serve as a model for the analysis of pathogenic mechanisms in psoriasis-like dermatitis and assessed its IL-23/IL-17 axis dependency.	Imiquimod	21-24	interleukin 17A	Mus musculus	167-172
19380832-6	2009	IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.	Imiquimod	0-3	interleukin 23, alpha subunit p19	Mus musculus	36-41
19380832-6	2009	IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.	Imiquimod	0-3	interleukin 17A	Mus musculus	43-49
19380832-6	2009	IMQ induced epidermal expression of IL-23, IL-17A, and IL-17F, as well as an increase in splenic Th17 cells.	Imiquimod	0-3	interleukin 17F	Mus musculus	55-61
19380832-7	2009	IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis.	Imiquimod	0-3	interleukin 23, alpha subunit p19	Mus musculus	220-225
19380832-7	2009	IMQ-induced dermatitis was partially dependent on the presence of T cells, whereas disease development was almost completely blocked in mice deficient for IL-23 or the IL-17 receptor, demonstrating a pivotal role of the IL-23/IL-17 axis.	Imiquimod	0-3	interleukin 17A	Mus musculus	226-231
19412422-7	2009	However, the synergism between ABT-737 and imiquimod or dacarbazine required endogenous Noxa, as demonstrated by experiments with Noxa-specific RNAi.	Imiquimod	43-52	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	88-92
19412422-7	2009	However, the synergism between ABT-737 and imiquimod or dacarbazine required endogenous Noxa, as demonstrated by experiments with Noxa-specific RNAi.	Imiquimod	43-52	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	130-134
19361784-2	2009	Highly purified lipopolysaccharide (upLPS) combined with imiquimod (IQ) synergistically induced IL-10 production by DCs, while each ligand alone showed a slight effect on the IL-10 production.	Imiquimod	57-66	interleukin 10	Mus musculus	96-101
19361784-2	2009	Highly purified lipopolysaccharide (upLPS) combined with imiquimod (IQ) synergistically induced IL-10 production by DCs, while each ligand alone showed a slight effect on the IL-10 production.	Imiquimod	57-66	interleukin 10	Mus musculus	175-180
18205196-5	2008	The changes in the surface expression of CD62L and HLA-DQ on pDCs in whole blood samples after 24-h treatment with imiquimod, a toll-like receptor 7 agonist, were analyzed.	Imiquimod	115-124	selectin L	Homo sapiens	41-46
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	forkhead box P3	Homo sapiens	98-103
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	ectonucleoside triphosphate diphosphohydrolase 1	Homo sapiens	105-109
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	5'-nucleotidase ecto	Homo sapiens	111-115
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	interleukin 10	Homo sapiens	117-122
18794336-7	2008	Treatment of T reg cells in vitro with imiquimod inhibited their suppressive activity and reduced FOXP3, CD39, CD73, IL-10, and TGF-beta by indirect mechanisms.	Imiquimod	39-48	transforming growth factor beta 1	Homo sapiens	128-136
15611427-4	2004	Since imiquimod induces large amounts of type I interferon production from TLR7-expressing plasmacytoid dendritic cell precursors (PDCs), the natural interferon-producing cells of the peripheral blood, we asked whether PDCs are present in psoriatic skin.	Imiquimod	6-15	toll like receptor 7	Homo sapiens	75-79
18569271-4	2008	METHODS: Nine individuals with biopsy-proven sBCC treated with 5% imiquimod cream 1 year previously and who remained clinically clear were recruited.	Imiquimod	66-75	GTF2I repeat domain containing 1	Homo sapiens	76-83
16844522-2	2006	OBJECTIVE: Our aim was to evaluate the efficacy and tolerability of imiquimod 5% cream for treatment of Bowen"s disease and invasive squamous cell carcinoma (SCC) in patients who were unsuitable candidates for surgery.	Imiquimod	68-77	serpin family B member 3	Homo sapiens	158-161
16844522-3	2006	METHOD: Five Bowen"s disease lesions and 7 invasive SCC lesions on 10 patients were treated with imiquimod once daily 5 times a week for a maximum of 16 weeks.	Imiquimod	97-106	serpin family B member 3	Homo sapiens	52-55
16844522-8	2006	CONCLUSION: Topical application of imiquimod 5% cream might represent an alternative topical treatment to surgery in selected cases of Bowen"s disease and invasive SCC.	Imiquimod	35-44	serpin family B member 3	Homo sapiens	164-167
15663652-11	2005	CONCLUSIONS: Antiangiogenic effect of imiquimod was found to be mediated by IL-18, probably through promoting production of INFgamma, the most important inhibitor of angiogenesis.	Imiquimod	38-47	interleukin 18	Mus musculus	76-81
17535975-1	2007	Imiquimod (IMQ), a synthetic agonist to Toll-like receptor (TLR) 7, is being successfully used for the treatment of certain skin neoplasms, but the exact mechanisms by which this compound induces tumor regression are not yet understood.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	60-63
17535975-1	2007	Imiquimod (IMQ), a synthetic agonist to Toll-like receptor (TLR) 7, is being successfully used for the treatment of certain skin neoplasms, but the exact mechanisms by which this compound induces tumor regression are not yet understood.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	60-63
17368633-0	2007	Treatment of a patient with epidermodysplasia verruciformis carrying a novel EVER2 mutation with imiquimod.	Imiquimod	97-106	transmembrane channel like 8	Homo sapiens	77-82
17368633-3	2007	We describe a patient with EV and a novel homozygous gene mutation of EVER2 gene who was treated successfully with topical imiquimod.	Imiquimod	123-132	transmembrane channel like 8	Homo sapiens	70-75
17222352-1	2007	BACKGROUND: Imiquimod is a Toll-like receptor-7 agonist capable of inducing complete clearance of basal cell carcinoma (BCC) and other cutaneous malignancies.	Imiquimod	12-21	toll like receptor 7	Homo sapiens	27-47
16575388-4	2006	We demonstrate here that imiquimod induces activation of the transcription factor NF-kappaB and the downstream production of proinflammatory cytokines in the absence of TLR7 and TLR8.	Imiquimod	25-34	nuclear factor kappa B subunit 1	Homo sapiens	82-91
16439962-1	2006	Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a TLR7 agonist that induces cytokine production in TLR7 bearing antigen-presenting cells (APCs), including IL-12, a cytokine that has been demonstrated to be a critical effector molecule for contact hypersensitivity (CHS).	Imiquimod	0-9	toll-like receptor 7	Mus musculus	70-74
16439962-1	2006	Imiquimod (1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine) is a TLR7 agonist that induces cytokine production in TLR7 bearing antigen-presenting cells (APCs), including IL-12, a cytokine that has been demonstrated to be a critical effector molecule for contact hypersensitivity (CHS).	Imiquimod	0-9	toll-like receptor 7	Mus musculus	119-123
16254370-6	2005	In the vaginal mucosa of imiquimod-treated monkeys, we documented a massive mononuclear cell infiltrate consisting of activated CD4(+) T cells, DC, and beta-chemokine-secreting cells.	Imiquimod	25-34	CD4 molecule	Homo sapiens	128-131
15491436-9	2004	During topical application of imiquimod 5% cream a depletion of epidermal and dermal CD1a+ dendritic cells was observed.	Imiquimod	30-39	CD1a molecule	Homo sapiens	85-89
14766263-2	2004	METHODS: The effect of imiquimod treatment on C/EBPbeta binding activity to its consensus sequence as well as to two specific regions of the HPV-16 NCR was determined by electromobility shift assay (EMSA) in CaSki cervical cancer cells.	Imiquimod	23-32	CCAAT enhancer binding protein beta	Homo sapiens	46-55
15214911-0	2004	Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).	Imiquimod	62-71	TNF receptor superfamily member 8	Homo sapiens	18-22
15214911-0	2004	Primary cutaneous CD30+ T-cell lymphoma responsive to topical imiquimod (Aldara).	Imiquimod	73-79	TNF receptor superfamily member 8	Homo sapiens	18-22
15214911-3	2004	We describe two patients with nonregressing primary cutaneous CD30+ T-cell lymphoma that was successfully treated with topical imiquimod 5% cream (Aldara, 3M) three times weekly for 6 weeks.	Imiquimod	127-136	TNF receptor superfamily member 8	Homo sapiens	62-66
15262305-4	2004	Tazarotene and imiquimod show potential in the treatment of early CTCL.	Imiquimod	15-24	TSPY like 2	Homo sapiens	66-70
15129316-5	2004	In this case report, imiquimod cream 5% (Aldara), which induces interferon and in turn inhibits TGF-beta, was employed to treat morphea.	Imiquimod	21-30	transforming growth factor beta 1	Homo sapiens	96-104
15129316-5	2004	In this case report, imiquimod cream 5% (Aldara), which induces interferon and in turn inhibits TGF-beta, was employed to treat morphea.	Imiquimod	41-47	transforming growth factor beta 1	Homo sapiens	96-104
15072849-1	2004	Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	33-53
15072849-1	2004	Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	55-60
15072849-1	2004	Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	33-53
15072849-1	2004	Imiquimod (IMQ), an activator of Toll-like receptor-7 (TLR-7), induces by several routes a profound anti-viral and anti-tumor effect in vivo.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	55-60
14616354-1	2003	Treatment with imiquimod 5% cream, capable of inducing interferon (IFN)-alpha, effectively cures basal cell carcinoma (BCC), both clinically and histologically.	Imiquimod	15-24	interferon alpha 1	Homo sapiens	55-77
15009713-0	2004	Imiquimod-induced interleukin-1 alpha stimulation improves barrier homeostasis in aged murine epidermis.	Imiquimod	0-9	interleukin 1 alpha	Mus musculus	18-37
12219723-1	2001	Imiquimod (1-(2-methylpropyl)-1 H-imidazo[4,5-c]quinolin-4-amine) and its analogues are a class of non-nucleoside imidazoquinolinamines (hetero-cyclic amine) that activate the immune system through localised induction of cytokines, such as IFN-alpha, -beta, and a number of endogenous interleukins.	Imiquimod	0-9	interferon alpha 1	Homo sapiens	240-249
10547268-8	1999	Treatment of mice with imiquimod, a potent inducer of IFN, led to induced expression of FRAG-6 mRNA in various organs from wild type or IRF-1-deficient mice, but not from STAT-1 or type I IFN receptor deficient animals.	Imiquimod	23-32	interferon regulatory factor 1	Mus musculus	136-141
11207687-3	2001	OBJECTIVE: To determine if combination therapy using topical imiquimod cream 5% and the oral cyclooxygenase (COX) inhibitor are useful in the therapy of squamous cell carcinoma in situ (SCC in situ)/Bowen"s disease in patients with long-standing CLL.	Imiquimod	61-70	serpin family B member 3	Homo sapiens	186-189
7811019-11	1994	Additionally, 21-day imiquimod treatment enhanced HSV antigen-specific interleukin 2 production and proliferative responses by mononuclear cells (P < 0.001) for 4 weeks after treatment.	Imiquimod	21-30	interleukin-2	Cavia porcellus	71-84
1377595-1	1992	The low-molecular-weight imidazoquinolinamine derivative, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine (imiquimod, previously described as R-837), induced alpha-interferon (IFN-alpha) in mice.	Imiquimod	147-152	interferon alpha	Mus musculus	181-190
8221654-1	1993	Imiquimod [1-(2-methylpropyl)-1H-imidazo[4,5c]quinolin-4-amine] is a compound of low molecular weight that, when administered p.o., induces interferon-alpha in several animal species and inhibits tumor growth in mice.	Imiquimod	0-9	interferon alpha	Mus musculus	140-156
1377595-8	1992	The antitumor effects of imiquimod were significantly abrogated by an antiserum to murine IFN-alpha, suggesting that the antitumor effect was to a substantial extent mediated by IFN induction.	Imiquimod	25-34	interferon alpha	Mus musculus	90-99
1377595-15	1992	Imiquimod is an oral IFN-alpha inducer with antitumor effectiveness for transplantable murine tumors.	Imiquimod	0-9	interferon alpha	Mus musculus	21-30
33769697-4	2021	Nedd4l significantly inhibits imiquimod (IMQ)-induced skin hyperplasia, and this effect is attributed to the inhibitory effect of NEDD4L on IL-6/GP130 signaling in keratinocytes.	Imiquimod	30-39	NEDD4 like E3 ubiquitin protein ligase	Homo sapiens	0-6
33769697-4	2021	Nedd4l significantly inhibits imiquimod (IMQ)-induced skin hyperplasia, and this effect is attributed to the inhibitory effect of NEDD4L on IL-6/GP130 signaling in keratinocytes.	Imiquimod	30-39	NEDD4 like E3 ubiquitin protein ligase	Homo sapiens	130-136
33940589-5	2021	Docking studies showed them to occupy the same binding pocket on TLR7 and 8 as the known agonists, imiquimod and resiquimod.	Imiquimod	99-108	toll-like receptor 7	Mus musculus	65-69
33769697-6	2021	Moreover, the expression of NEDD4L is downregulated in the epidermis from IMQ-treated mice and psoriasis patients and negatively correlates with the protein levels of GP130 and p-STAT3 in clinical samples.	Imiquimod	74-77	neural precursor cell expressed, developmentally down-regulated gene 4-like	Mus musculus	28-34
33769697-4	2021	Nedd4l significantly inhibits imiquimod (IMQ)-induced skin hyperplasia, and this effect is attributed to the inhibitory effect of NEDD4L on IL-6/GP130 signaling in keratinocytes.	Imiquimod	41-44	NEDD4 like E3 ubiquitin protein ligase	Homo sapiens	0-6
33769697-6	2021	Moreover, the expression of NEDD4L is downregulated in the epidermis from IMQ-treated mice and psoriasis patients and negatively correlates with the protein levels of GP130 and p-STAT3 in clinical samples.	Imiquimod	74-77	interleukin 6 cytokine family signal transducer	Homo sapiens	167-172
33769697-4	2021	Nedd4l significantly inhibits imiquimod (IMQ)-induced skin hyperplasia, and this effect is attributed to the inhibitory effect of NEDD4L on IL-6/GP130 signaling in keratinocytes.	Imiquimod	41-44	NEDD4 like E3 ubiquitin protein ligase	Homo sapiens	130-136
33769697-6	2021	Moreover, the expression of NEDD4L is downregulated in the epidermis from IMQ-treated mice and psoriasis patients and negatively correlates with the protein levels of GP130 and p-STAT3 in clinical samples.	Imiquimod	74-77	signal transducer and activator of transcription 3	Homo sapiens	179-184
33769841-5	2021	Imiquimod (TLR7 agonist) was incubated with HUC-MSCs for immune activation, and the expression of MSC-specific markers and immune inflammatory molecules was measured by quantitative real-time polymerase chain reaction.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	11-15
33811359-16	2021	AFL + imiquimod treatment increased CXCL12 serum levels threefold at Day 14 (P = 0.0200).	Imiquimod	6-15	chemokine (C-X-C motif) ligand 12	Mus musculus	36-42
33806288-9	2021	Both IMQ and ethanol induced the expression of TRAIL and its death receptor.	Imiquimod	5-8	TNF superfamily member 10	Homo sapiens	47-52
33806288-10	2021	In addition, TRAIL-neutralizing monoclonal antibodies blocked both imiquimod (IMQ) and ethanol induced neuronal death.	Imiquimod	67-76	TNF superfamily member 10	Homo sapiens	13-18
33806288-10	2021	In addition, TRAIL-neutralizing monoclonal antibodies blocked both imiquimod (IMQ) and ethanol induced neuronal death.	Imiquimod	78-81	TNF superfamily member 10	Homo sapiens	13-18
33232788-4	2021	MER and AXL upregulation was more efficiently induced by a vaccine containing Imiquimod than by a poly(I:C)-containing vaccine.	Imiquimod	78-87	MER proto-oncogene tyrosine kinase	Mus musculus	0-3
33799349-4	2021	Here we report, for the first time to our knowledge, a clinical case where a melanoma patient harboring the SMO p.Gln216Arg mutation has been treated with imiquimod, showing a complete and durable response.	Imiquimod	155-164	smoothened, frizzled class receptor	Homo sapiens	108-111
33799349-5	2021	To better explain this outstanding response to the treatment, we transfected a melanoma cell line (MeWo) with the SMO p.Gln216Arg mutation in order to evaluate its role in response to the imiquimod treatment.	Imiquimod	188-197	smoothened, frizzled class receptor	Homo sapiens	114-117
33799349-6	2021	Moreover, to better demonstrate that the antitumor activity of imiquimod was due to its role in suppressing the oncogenic SMO signaling pathway, independently of its immune modulating function, an in vivo experiment has been performed.	Imiquimod	63-72	smoothened, frizzled class receptor	Homo sapiens	122-125
33232788-4	2021	MER and AXL upregulation was more efficiently induced by a vaccine containing Imiquimod than by a poly(I:C)-containing vaccine.	Imiquimod	78-87	AXL receptor tyrosine kinase	Mus musculus	8-11
33232788-6	2021	TAM blockade improved Imiquimod-induced DC activation in vitro and in vivo, resulting in increased vaccine-induced T-cell responses, which were further reinforced by concomitant IL-10 inhibition.	Imiquimod	22-31	interleukin 10	Mus musculus	178-183
34959691-5	2021	First, we used functionalized liposomes to determine that imidazoquinoline TLR agonists Imiquimod, Resiquimod, and Gardiquimod are substrates for P-gp.	Imiquimod	88-97	phosphoglycolate phosphatase	Homo sapiens	146-150
25092341-3	2014	Here we identify critical roles of CIKS/Act1-mediated signaling in imiquimod-induced psoriatic inflammation, a mouse model that shares features with the human disease.	Imiquimod	67-76	TRAF3 interacting protein 2	Mus musculus	35-39
25092341-3	2014	Here we identify critical roles of CIKS/Act1-mediated signaling in imiquimod-induced psoriatic inflammation, a mouse model that shares features with the human disease.	Imiquimod	67-76	actin related gene 1	Mus musculus	40-44
34427853-4	2022	Here, we report that miR-214-3p, one of the downregulated miRNAs identified in the skin of psoriatic patients and imiquimod (IMQ)-induced mouse models, can negatively regulate the expression of forkhead box M1 (FOXM1).	Imiquimod	114-123	forkhead box M1	Mus musculus	194-209
34427853-4	2022	Here, we report that miR-214-3p, one of the downregulated miRNAs identified in the skin of psoriatic patients and imiquimod (IMQ)-induced mouse models, can negatively regulate the expression of forkhead box M1 (FOXM1).	Imiquimod	114-123	forkhead box M1	Mus musculus	211-216
34427853-4	2022	Here, we report that miR-214-3p, one of the downregulated miRNAs identified in the skin of psoriatic patients and imiquimod (IMQ)-induced mouse models, can negatively regulate the expression of forkhead box M1 (FOXM1).	Imiquimod	125-128	forkhead box M1	Mus musculus	194-209
34427853-4	2022	Here, we report that miR-214-3p, one of the downregulated miRNAs identified in the skin of psoriatic patients and imiquimod (IMQ)-induced mouse models, can negatively regulate the expression of forkhead box M1 (FOXM1).	Imiquimod	125-128	forkhead box M1	Mus musculus	211-216
34613627-4	2022	More importantly, in dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) and imiquimod-induced psoriasis mouse models, we observe a significantly high accumulation of MSC-sEVs-PD-L1 in the inflamed tissues compared to the PD-L1+ MSCs.	Imiquimod	86-95	CD274 antigen	Mus musculus	185-190
34553380-4	2022	In the results, KYNU is upregulated in psoriatic skin samples from patients or animal models compared with normal skin control which was assayed in psoriatic patient samples, IMQ-induced psoriasis-like skin inflammation in BABL/c mice and M5-stimulated keratinocyte cell lines by immunohistochemistry (IHC).	Imiquimod	175-178	kynureninase	Homo sapiens	16-20
34553380-7	2022	Furthermore, miR-203a exhibited an inversed expression kinetics to KYNU during the development of IMQ-induced psoriasis-like skin inflammation in BABL/c mice.	Imiquimod	98-101	microRNA 203a	Homo sapiens	13-21
34553380-7	2022	Furthermore, miR-203a exhibited an inversed expression kinetics to KYNU during the development of IMQ-induced psoriasis-like skin inflammation in BABL/c mice.	Imiquimod	98-101	kynureninase	Mus musculus	67-71
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interleukin 1 beta	Mus musculus	57-61
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	tumor necrosis factor	Mus musculus	63-67
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interleukin 6	Mus musculus	69-72
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interleukin 23, alpha subunit p19	Mus musculus	80-84
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interleukin 17A	Mus musculus	86-90
34364883-9	2022	Gene expression analysis identified upregulation of Mxa, Il1b, Tnfa, Il6, Il12, Il23, Il17 and Ifng in TG>WT>KO following IMQ treatment.	Imiquimod	122-125	interferon gamma	Mus musculus	95-99
34364883-10	2022	Further, IMQ increased CD8+ and CD4+ T cell infiltration in TG>WT>KO mice.	Imiquimod	9-12	CD4 antigen	Mus musculus	32-35
34936223-2	2022	We found that the Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) was highly expressed in both psoriatic patients and imiquimod (IMQ)-induced psoriasis-like mice.	Imiquimod	141-150	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	18-81
34936223-2	2022	We found that the Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) was highly expressed in both psoriatic patients and imiquimod (IMQ)-induced psoriasis-like mice.	Imiquimod	141-150	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	83-87
34936223-2	2022	We found that the Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) was highly expressed in both psoriatic patients and imiquimod (IMQ)-induced psoriasis-like mice.	Imiquimod	152-155	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	18-81
34936223-2	2022	We found that the Src homology-2 domain-containing protein tyrosine phosphatase-2 (SHP2) was highly expressed in both psoriatic patients and imiquimod (IMQ)-induced psoriasis-like mice.	Imiquimod	152-155	protein tyrosine phosphatase non-receptor type 11	Homo sapiens	83-87
34936223-8	2022	Importantly, Tlr7 point-mutant knock-in mice showed an attenuated psoriasis-like phenotype compared to wild-type littermates following IMQ treatment.	Imiquimod	135-138	toll-like receptor 7	Mus musculus	13-17
33762935-7	2021	The results showed that LXJDF could significantly improve the psoriasiform skin lesions of IMQ-induced ApoE-/- mice, including the reduction of PASI, thinning of epidermal thickness, inhibition of hyperkeratosis and parakeratosis, and inflammatory infiltration in the dermis, and reduce lipid accumulation in the epidermal.	Imiquimod	91-94	apolipoprotein E	Mus musculus	103-107
32795468-5	2020	In vivo, EDIL3 recombinant protein was injected into IMQ cream-induced psoriasis-like skin lesions of mouse and EDIL3-associated tube formation were determined using Image J software.	Imiquimod	53-56	EGF-like repeats and discoidin I-like domains 3	Mus musculus	9-14
34614305-11	2022	RESULTS: Imiquimod significantly inhibited the activity of tyrosinase activity and decreased melanin content in melanocytes and significantly increased apoptosis and IL-6, IL-8, and sICAM-1 production in melanocytes.	Imiquimod	9-18	tyrosinase	Homo sapiens	59-69
34614305-11	2022	RESULTS: Imiquimod significantly inhibited the activity of tyrosinase activity and decreased melanin content in melanocytes and significantly increased apoptosis and IL-6, IL-8, and sICAM-1 production in melanocytes.	Imiquimod	9-18	interleukin 6	Homo sapiens	166-170
34614305-11	2022	RESULTS: Imiquimod significantly inhibited the activity of tyrosinase activity and decreased melanin content in melanocytes and significantly increased apoptosis and IL-6, IL-8, and sICAM-1 production in melanocytes.	Imiquimod	9-18	C-X-C motif chemokine ligand 8	Homo sapiens	172-176
34923236-0	2022	Terrestrosin D ameliorates skin lesions in an imiquimod-induced psoriasis-like murine model by inhibiting the interaction between Substance P and Dendritic cells.	Imiquimod	46-55	tachykinin 1	Mus musculus	130-141
34992404-0	2021	Effect of Total Glucosides of Paeony on Imiquimod-Induced Psoriatic Skin Lesions by Regulating VEGF.	Imiquimod	40-49	vascular endothelial growth factor A	Mus musculus	95-99
34931339-0	2022	Decreased microRNA-126 expression in psoriatic CD4+ T cells promotes T-helper 17 cell differentiation and the formation of dermatitis in imiquimod-induced psoriasis-like mice.	Imiquimod	137-146	microRNA 126a	Mus musculus	10-22
34931339-0	2022	Decreased microRNA-126 expression in psoriatic CD4+ T cells promotes T-helper 17 cell differentiation and the formation of dermatitis in imiquimod-induced psoriasis-like mice.	Imiquimod	137-146	CD4 antigen	Mus musculus	47-50
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	173-182	microRNA 126a	Mus musculus	12-18
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	173-182	CD4 antigen	Mus musculus	37-40
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	184-187	microRNA 126a	Mus musculus	12-18
34931339-4	2022	Conditional Mir126 knockout in mouse CD4+ T cells can obviously aggravate the psoriasis-like dermatitis and promote T-helper (Th)1 and Th17 cells" infiltration in spleen of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	184-187	CD4 antigen	Mus musculus	37-40
34959691-6	2021	Interestingly, the least potent imidazoquinoline (Imiquimod) was the best P-gp substrate.	Imiquimod	50-59	phosphoglycolate phosphatase	Homo sapiens	74-78
34950134-2	2021	We sought to investigate if imiquimod, a TLR7 agonist, exhibits such dual actions in ex vivo cultured human bronchial epithelial cells (HBECs), targets for SARS-CoV-2 infectivity.	Imiquimod	28-37	toll like receptor 7	Homo sapiens	41-45
34950134-7	2021	Results: Imiquimod reduced ACE2 expression at baseline and after poly(I:C) stimulation.	Imiquimod	9-18	angiotensin converting enzyme 2	Homo sapiens	27-31
34950134-8	2021	Imiquimod also reduced poly(I:C)-induced pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and IL-33.	Imiquimod	0-9	interleukin 1 alpha	Homo sapiens	78-86
34950134-8	2021	Imiquimod also reduced poly(I:C)-induced pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and IL-33.	Imiquimod	0-9	interleukin 6	Homo sapiens	88-92
34950134-8	2021	Imiquimod also reduced poly(I:C)-induced pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and IL-33.	Imiquimod	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	94-98
34950134-8	2021	Imiquimod also reduced poly(I:C)-induced pro-inflammatory cytokines including IL-1beta, IL-6, IL-8, and IL-33.	Imiquimod	0-9	interleukin 33	Homo sapiens	104-109
34950134-9	2021	Furthermore, imiquimod increased IFN-beta expression, an effect potentiated in presence of poly(I:C) or SP1.	Imiquimod	13-22	IFN1@	Homo sapiens	33-41
34950134-12	2021	Conclusion: Imiquimod triggers viral resistance mechanisms in HBECs by decreasing ACE2 and increasing IFN-beta expression.	Imiquimod	12-21	angiotensin converting enzyme 2	Homo sapiens	82-86
34950134-12	2021	Conclusion: Imiquimod triggers viral resistance mechanisms in HBECs by decreasing ACE2 and increasing IFN-beta expression.	Imiquimod	12-21	IFN1@	Homo sapiens	102-110
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	vascular endothelial growth factor A	Mus musculus	184-190
34464701-27	2021	CONCLUSIONS: FJDH may attenulated imiquimod-induced psoriasis-like skin inflammation in mice by inhibiting IL-23/Th17 cell axis.	Imiquimod	34-43	interleukin 23, alpha subunit p19	Mus musculus	107-112
34884834-11	2021	Specifically, in ATCC12228EVs, we found the proteins glutamate dehydrogenase, ornithine carbamoyltransferase, arginine deiminase, carbamate kinase, catalase, superoxide dismutase, phenol-soluble beta1/beta2 modulin, and polyglycerol phosphate alpha-glucosyltransferase, which could be involved in the reduction of lesions in the murine imiquimod-induced psoriasis skin.	Imiquimod	336-345	catalase	Mus musculus	78-156
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 6	Mus musculus	192-196
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 23, alpha subunit p19	Mus musculus	202-207
34884834-11	2021	Specifically, in ATCC12228EVs, we found the proteins glutamate dehydrogenase, ornithine carbamoyltransferase, arginine deiminase, carbamate kinase, catalase, superoxide dismutase, phenol-soluble beta1/beta2 modulin, and polyglycerol phosphate alpha-glucosyltransferase, which could be involved in the reduction of lesions in the murine imiquimod-induced psoriasis skin.	Imiquimod	336-345	brain protein 1	Mus musculus	195-206
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 17F	Mus musculus	209-215
34884834-8	2021	Moreover, in vivo imiquimod-induced psoriatic skin treated with ATCC12228EVs reduced the characteristic psoriatic skin features, such as acanthosis and cellular infiltrate, as well as VEGF-A, IL-6, KC, IL-23, IL-17F, IL-36gamma, and IL-36R expression in a more efficient manner than 983EVs; however, in contrast, Foxp3 expression did not significantly change, and IL-36 receptor antagonist (IL-36Ra) was found to be increased.	Imiquimod	18-27	interleukin 36 receptor antagonist	Mus musculus	391-398
34884834-12	2021	Our results show that the commensal ATCC12228EVs have a greater protective/attenuating effect on the murine imiquimod-induced psoriasis by inducing IL-36Ra expression in comparison with EVs from a clinical isolate of S. epidermidis.	Imiquimod	108-117	interleukin 36 receptor antagonist	Mus musculus	148-155
34097921-5	2021	We showed that CAR and its target genes were induced in the lesions from psoriasis patients and imiquimod (IMQ)-treated mice.	Imiquimod	96-105	nuclear receptor subfamily 1 group I member 3	Homo sapiens	15-18
34494306-0	2021	Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis.	Imiquimod	59-68	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	21-26
34494306-0	2021	Differential role of TNFR1 and TNFR2 in the development of imiquimod-induced mouse psoriasis.	Imiquimod	59-68	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	31-36
34097921-5	2021	We showed that CAR and its target genes were induced in the lesions from psoriasis patients and imiquimod (IMQ)-treated mice.	Imiquimod	107-110	nuclear receptor subfamily 1 group I member 3	Homo sapiens	15-18
34494306-5	2021	In this study, it is shown that in imiquimod-induced mouse psoriasis model, TNF receptor type 1 (TNFR1) deficiency inhibited the development of skin diseases.	Imiquimod	35-44	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	97-102
34494306-7	2021	Importantly, adoptive transfer of WT Tregs was able to attenuate inflammatory responses in imiquimod-treated TNFR2-/- mice, suggestive of a role of malfunctioned Tregs in mice deficient in TNFR2.	Imiquimod	91-100	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	109-114
34097921-9	2021	In addition, we showed that topical application of TCPOBOP, a selective agonist for mouse CAR, exacerbated the IMQ-induced psoriasis lesions with increased expressions of proliferative and inflammatory markers.	Imiquimod	111-114	nuclear receptor subfamily 1, group I, member 3	Mus musculus	90-93
34780714-5	2022	Although mRNA levels of inflammatory cytokines in skin after topical application of 12-O-tetradecanoylphorbol-13-acetate or imiquimod were comparable between kCYC+/- and wild-type mice, protein levels of inflammatory cytokines such as interleukin (IL)-17A, IL-22, and IL-23 were significantly upregulated in kCYC+/- mice in both models.	Imiquimod	124-133	interleukin 17A	Mus musculus	235-255
34597998-0	2021	IL-30 ameliorates imiquimod and K14-VEGF induced psoriasis-like disease by inhibiting both innate and adaptive immunity disorders.	Imiquimod	18-27	interleukin 27	Homo sapiens	0-5
34597998-5	2021	In vivo, IL-30 inhibited the development of skin disease in two animal models: Krt14-Vegfa and imiquimod (IMQ)-induced psoriasis-like skin disease.	Imiquimod	95-104	interleukin 27	Homo sapiens	9-14
34597998-5	2021	In vivo, IL-30 inhibited the development of skin disease in two animal models: Krt14-Vegfa and imiquimod (IMQ)-induced psoriasis-like skin disease.	Imiquimod	106-109	interleukin 27	Homo sapiens	9-14
34780714-5	2022	Although mRNA levels of inflammatory cytokines in skin after topical application of 12-O-tetradecanoylphorbol-13-acetate or imiquimod were comparable between kCYC+/- and wild-type mice, protein levels of inflammatory cytokines such as interleukin (IL)-17A, IL-22, and IL-23 were significantly upregulated in kCYC+/- mice in both models.	Imiquimod	124-133	interleukin 22	Mus musculus	257-262
34780714-5	2022	Although mRNA levels of inflammatory cytokines in skin after topical application of 12-O-tetradecanoylphorbol-13-acetate or imiquimod were comparable between kCYC+/- and wild-type mice, protein levels of inflammatory cytokines such as interleukin (IL)-17A, IL-22, and IL-23 were significantly upregulated in kCYC+/- mice in both models.	Imiquimod	124-133	interleukin 23, alpha subunit p19	Mus musculus	268-273
34774872-0	2022	NF-kappaB1 contributes to imiquimod-induced psoriasis-like skin inflammation by inducing Vgamma4+Vdelta4+gammadeltaT17 cells.	Imiquimod	26-35	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	0-10
34723528-5	2021	In animal studies, oral administration of compound d3 showed a robust and dose-dependent inhibition of the IL-17A cytokine expression in a mouse imiquimod-induced skin inflammation model.	Imiquimod	145-154	interleukin 17A	Mus musculus	107-113
34774872-5	2022	The numbers of Vgamma4+Vdelta4+gammadeltaT17 cells, which cause skin inflammation in this model, were significantly reduced in the skin and draining lymph nodes in IMQ-treated NF-kappaB1-/- mice.	Imiquimod	164-167	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	176-186
34774872-10	2022	These results suggest that NF-kappaB1 plays a crucial role in the pathogenesis of IMQ-induced psoriasis-like skin inflammation by promoting the proliferation of Vgamma4+Vdelta4+gammadeltaT17 cells.	Imiquimod	82-85	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	27-37
34687744-5	2022	Rescuing CTRP3 level with glucagon-like peptide-1 receptor agonist, exendin-4, in diet-induced obese mice could alleviate its severer psoriatic symptoms in imiquimod (IMQ)-induced mouse model.	Imiquimod	156-165	C1q and tumor necrosis factor related protein 3	Mus musculus	9-14
34726306-0	2022	The 5-HT1A receptor agonist, 8-OH-DPAT, Attenuates Long-Lasting Pain in Imiquimod-Induced Psoriasis in Mice.	Imiquimod	72-81	5-hydroxytryptamine (serotonin) receptor 1A	Mus musculus	4-19
34537997-6	2021	Besides, we found that imiquimod upregulated the expression of OX40 on CD4+ T cells and thus enhanced the effectiveness of OX40 agonist.	Imiquimod	23-32	tumor necrosis factor receptor superfamily, member 4	Mus musculus	63-67
34537997-6	2021	Besides, we found that imiquimod upregulated the expression of OX40 on CD4+ T cells and thus enhanced the effectiveness of OX40 agonist.	Imiquimod	23-32	CD4 antigen	Mus musculus	71-74
34537997-6	2021	Besides, we found that imiquimod upregulated the expression of OX40 on CD4+ T cells and thus enhanced the effectiveness of OX40 agonist.	Imiquimod	23-32	tumor necrosis factor receptor superfamily, member 4	Mus musculus	123-127
34547680-0	2021	Nintedanib ameliorates imiquimod-induced psoriasis in mice by inhibiting NF-kappaB and VEGFR2 signaling.	Imiquimod	23-32	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	73-82
34432872-6	2021	Imiquimod alleviates anaemia by promoting haematopoietic stem and progenitor cell expansion and erythroid differentiation, the mechanism of which is dependent on TLR7 ligation and Myd88.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	162-166
34432872-6	2021	Imiquimod alleviates anaemia by promoting haematopoietic stem and progenitor cell expansion and erythroid differentiation, the mechanism of which is dependent on TLR7 ligation and Myd88.	Imiquimod	0-9	MYD88 innate immune signal transduction adaptor	Homo sapiens	180-185
34674702-9	2021	RESULTS: BRD4 expression was upregulated in injured skin on the back of imiquimod-induced mice and (+)-JQ1 relieved the skin injury by suppressing the inflammation and promoting apoptosis of keratinocytes.	Imiquimod	72-81	bromodomain containing 4	Mus musculus	9-13
34734243-8	2022	In vivo studies indicated that MafB is involved in resistance against imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	70-79	MAF bZIP transcription factor B	Homo sapiens	31-35
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	110-119	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	68-99
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	110-119	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	101-105
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	110-119	interleukin 23, alpha subunit p19	Mus musculus	148-153
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	121-124	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	68-99
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	121-124	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	101-105
34745116-2	2021	This study reveals the essential role of the sensory neuron-derived calcitonin gene-related peptide (CGRP) in imiquimod (IMQ)-induced expression of IL-23.	Imiquimod	121-124	interleukin 23, alpha subunit p19	Mus musculus	148-153
34745116-5	2021	In addition, IMQ exposure induced a transient increase in CGRP expression in the dorsal root ganglion.	Imiquimod	13-16	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	58-62
34687744-5	2022	Rescuing CTRP3 level with glucagon-like peptide-1 receptor agonist, exendin-4, in diet-induced obese mice could alleviate its severer psoriatic symptoms in imiquimod (IMQ)-induced mouse model.	Imiquimod	156-165	glucagon-like peptide 1 receptor	Mus musculus	26-58
34687744-5	2022	Rescuing CTRP3 level with glucagon-like peptide-1 receptor agonist, exendin-4, in diet-induced obese mice could alleviate its severer psoriatic symptoms in imiquimod (IMQ)-induced mouse model.	Imiquimod	167-170	C1q and tumor necrosis factor related protein 3	Mus musculus	9-14
34687744-5	2022	Rescuing CTRP3 level with glucagon-like peptide-1 receptor agonist, exendin-4, in diet-induced obese mice could alleviate its severer psoriatic symptoms in imiquimod (IMQ)-induced mouse model.	Imiquimod	167-170	glucagon-like peptide 1 receptor	Mus musculus	26-58
34687744-6	2022	Topical application of CTRP3 also exerted a protective effect on IMQ-induced normal diet mice.	Imiquimod	65-68	C1q and tumor necrosis factor related protein 3	Mus musculus	23-28
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	interleukin 6	Homo sapiens	54-58
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	C-X-C motif chemokine ligand 8	Homo sapiens	63-67
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	ATP binding cassette subfamily C member 4	Homo sapiens	90-95
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	phosphodiesterase 4A	Homo sapiens	100-104
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	ATP binding cassette subfamily C member 4	Homo sapiens	140-145
34666750-10	2021	LABA/GCS attenuation of Poly I:C or imiquimod-induced IL-6 and IL-8 were potentiated with ABCC4 and PDE4 inhibition, which was greater when ABCC4 and PDE4 inhibition was combined.	Imiquimod	36-45	phosphodiesterase 4A	Homo sapiens	150-154
34733164-6	2021	Mice lacking PKM2 specifically in keratinocytes, pharmacological inhibition of PKM2 or glycolysis inhibited keratinocyte proliferation and showed obvious remission in an imiquimod-induced psoriatic mouse model.	Imiquimod	170-179	pyruvate kinase, muscle	Mus musculus	79-83
34639115-9	2021	In conclusion, we demonstrated that LPAR1/3 antagonist alleviates IMQ-induced psoriasis-like symptoms in mice, and in particular, LPAR1 signaling is involved in cell cycle progression via ROCK2/PI3K/AKT pathways in keratinocytes.	Imiquimod	66-69	lysophosphatidic acid receptor 1	Mus musculus	36-43
34428436-5	2021	Furthermore, curcumin treatment (50 mg/kg and 200 mg/kg, intragastrically) for 21 consecutive days suppressed the IMQ exposure-induced increase in PGRN expression.	Imiquimod	114-117	granulin	Mus musculus	147-151
34639115-0	2021	Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1/ROCK2/PI3K/AKT Signaling Pathway.	Imiquimod	31-40	lysophosphatidic acid receptor 1	Mus musculus	121-126
34639115-9	2021	In conclusion, we demonstrated that LPAR1/3 antagonist alleviates IMQ-induced psoriasis-like symptoms in mice, and in particular, LPAR1 signaling is involved in cell cycle progression via ROCK2/PI3K/AKT pathways in keratinocytes.	Imiquimod	66-69	lysophosphatidic acid receptor 1	Mus musculus	130-135
34639115-0	2021	Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1/ROCK2/PI3K/AKT Signaling Pathway.	Imiquimod	31-40	Rho-associated coiled-coil containing protein kinase 2	Mus musculus	127-132
34582699-9	2021	RNA-seq results showed that histamine decarboxylase (HDC) mRNA levels were significantly upregulated after IMQ treatment.	Imiquimod	107-110	histidine decarboxylase	Mus musculus	28-51
34639115-0	2021	Lysophosphatidic Acid Mediates Imiquimod-Induced Psoriasis-like Symptoms by Promoting Keratinocyte Proliferation through LPAR1/ROCK2/PI3K/AKT Signaling Pathway.	Imiquimod	31-40	thymoma viral proto-oncogene 1	Mus musculus	138-141
34639115-5	2021	Treatment with the LPAR1/3 antagonist, ki16425, alleviated skin symptoms in IMQ-induced psoriasis-like mouse models and decreased keratinocyte proliferation in the lesion.	Imiquimod	76-79	lysophosphatidic acid receptor 1	Mus musculus	19-26
34685616-8	2021	It is worth mentioning that PI3Kdelta inhibition by seletalisib attenuates the severity of psoriasiform phenotype induced in the Imiquimod-induced mouse model of psoriasis by restoring the physiological proliferation and differentiation programs in epidermal keratinocytes and contrasting the cutaneous inflammatory responses.	Imiquimod	129-138	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Mus musculus	28-37
34582699-9	2021	RNA-seq results showed that histamine decarboxylase (HDC) mRNA levels were significantly upregulated after IMQ treatment.	Imiquimod	107-110	histidine decarboxylase	Mus musculus	53-56
34582699-10	2021	Targeted inhibition of histamine biosynthesis process using HDC-specific inhibitor, pinocembrin (PINO), significantly alleviated epidermal thickness, downregulated the expression of interleukin (IL)-17A and IL-23, and inhibited the infiltration of immune cells during IMQ-induced psoriasis-like skin inflammation.	Imiquimod	268-271	histidine decarboxylase	Mus musculus	60-63
34233233-11	2021	Taxifolin significantly reduced p-cPLA2 and increased PPAR-gamma protein level in keratinocytes and lesions induced by IL-17 and imiquimod respectively.	Imiquimod	129-138	phospholipase A2, group IVA (cytosolic, calcium-dependent)	Mus musculus	34-39
34233233-11	2021	Taxifolin significantly reduced p-cPLA2 and increased PPAR-gamma protein level in keratinocytes and lesions induced by IL-17 and imiquimod respectively.	Imiquimod	129-138	peroxisome proliferator activated receptor gamma	Mus musculus	54-64
34638757-6	2021	A transcriptomic assay of macrophages revealed that the expressions of pro-inflammatory mediators and GDAP1L1 were largely increased after an IMQ intervention.	Imiquimod	142-145	ganglioside-induced differentiation-associated protein 1-like 1	Mus musculus	102-109
34548208-6	2021	RESULTS: Apremilast alleviated IMQ-induced psoriasiform dermatitis clinically and pathologically on days 3-6 by reducing infiltration of antigen-presenting cells and interleukin (IL)-17A-positive cells and increasing infiltration of Foxp3-postive cells into the skin on day 6, although a significant increase in IL-10 mRNA level was not observed on day 2.	Imiquimod	31-34	interleukin 17A	Mus musculus	166-186
34638757-9	2021	Besides GDAP1L1, another mitochondrial fission factor, Drp1, translocated from the cytosol to mitochondria after IMQ stimulation, followed by the mitochondrial fragmentation according to the immunofluorescence imaging.	Imiquimod	113-116	ganglioside-induced differentiation-associated protein 1-like 1	Mus musculus	8-15
34638757-9	2021	Besides GDAP1L1, another mitochondrial fission factor, Drp1, translocated from the cytosol to mitochondria after IMQ stimulation, followed by the mitochondrial fragmentation according to the immunofluorescence imaging.	Imiquimod	113-116	collapsin response mediator protein 1	Mus musculus	55-59
34638757-13	2021	The silencing of GDAP1L1 in IMQ-treated animals reduced the psoriasiform severity score from 8 to 2.	Imiquimod	28-31	ganglioside-induced differentiation-associated protein 1-like 1	Mus musculus	17-24
34328106-9	2021	The results showed that capsaicin administration obstructed the activation of IL-23/IL-17 pathway induced by imiquimod, presenting with significantly reduced psoriasiform dermatitis both in gross appearance and microscopic features.	Imiquimod	109-118	interleukin 23, alpha subunit p19	Mus musculus	78-83
34488805-12	2021	In vivo results indicated microglial influences on neuroinflammation were agonist specific, with responses to TLR7 agonist IMQ more dysregulated in mice with reduced microglia.	Imiquimod	123-126	toll-like receptor 7	Mus musculus	110-114
34243099-0	2021	Tuhuaiyin alleviates imiquimod-induced psoriasis via inhibiting the properties of IL-17-producing cells and remodels the gut microbiota.	Imiquimod	21-30	interleukin 17A	Mus musculus	82-87
34685526-4	2021	Here, we showed the upregulation of miR-21-3p in an IMQ-induced psoriasiform mouse model.	Imiquimod	52-55	microRNA 181a-1	Mus musculus	36-45
34328106-9	2021	The results showed that capsaicin administration obstructed the activation of IL-23/IL-17 pathway induced by imiquimod, presenting with significantly reduced psoriasiform dermatitis both in gross appearance and microscopic features.	Imiquimod	109-118	interleukin 17A	Mus musculus	84-89
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	myeloperoxidase	Mus musculus	6-21
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	immunoglobulin heavy variable V1-9	Mus musculus	23-28
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interleukin 1 alpha	Mus musculus	30-38
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interleukin 6	Mus musculus	40-44
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interleukin 17A	Mus musculus	46-51
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	tumor necrosis factor	Mus musculus	57-66
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interferon gamma	Mus musculus	82-91
34153674-10	2021	Serum myeloperoxidase, IgG2a, IL-1beta, IL-6, IL-17, and TNF-alpha and spleen CD4+IFN-gamma+IL-17+ T lymphocytes were reduced after PD1 treatment in IMQ-induced psoriasiform mouse models.	Imiquimod	149-152	interleukin 17A	Mus musculus	92-97
34511969-8	2021	In imiquimod (IMQ)-induced psoriasis-like inflammation, Lin28a overexpressing transgenic (TG) mice exhibited more severe symptoms of psoriasis.	Imiquimod	3-12	lin-28 homolog A	Mus musculus	56-62
34176198-0	2021	The potential role for topical imiquimod in the treatment of Chronic mucocutaneous candidiasis caused by gain-of-function mutation in STAT1: a case-report.	Imiquimod	31-40	signal transducer and activator of transcription 1	Homo sapiens	134-139
34155928-4	2021	This study aims to investigate the therapeutic effect of HGF overexpressed dental pulp stem cells (DPSCs; HGF-DPSCs) on imiquimod (IMQ) induced psoriasis.	Imiquimod	120-129	hepatocyte growth factor	Mus musculus	57-60
34155928-4	2021	This study aims to investigate the therapeutic effect of HGF overexpressed dental pulp stem cells (DPSCs; HGF-DPSCs) on imiquimod (IMQ) induced psoriasis.	Imiquimod	131-134	hepatocyte growth factor	Mus musculus	57-60
34097550-8	2021	In contrast, cytokine concentrations were unaffected or slightly reduced by IFNAR blockade, but macrophages died at a greater rate when imiquimod was the stimulus.	Imiquimod	136-145	interferon alpha and beta receptor subunit 1	Homo sapiens	76-81
34511969-8	2021	In imiquimod (IMQ)-induced psoriasis-like inflammation, Lin28a overexpressing transgenic (TG) mice exhibited more severe symptoms of psoriasis.	Imiquimod	14-17	lin-28 homolog A	Mus musculus	56-62
34461129-5	2022	Furthermore, we provide functional evidence that elevated Il33 expression reduces, whereas persistent accumulation and epidermal migration of neutrophils exacerbates, disease severity in imiquimod-treated Ovol1-deficient mice.	Imiquimod	187-196	ovo like zinc finger 1	Mus musculus	205-210
34062352-9	2021	Also, imiquimod (IMQ)-induced lupus mice had the same NPSLE cognitive dysfunction, brain damage, and overexpressed hippocampal microglia CD40 as MRL/lpr mice.	Imiquimod	6-15	CD40 antigen	Mus musculus	137-141
34062352-9	2021	Also, imiquimod (IMQ)-induced lupus mice had the same NPSLE cognitive dysfunction, brain damage, and overexpressed hippocampal microglia CD40 as MRL/lpr mice.	Imiquimod	17-20	CD40 antigen	Mus musculus	137-141
34367187-10	2021	Functional testing of this variant revealed decreased type I and II interferon responses in peripheral mononuclear blood cells upon stimulation with the TLR7 agonist imiquimod, confirming a loss-of-function effect.	Imiquimod	166-175	toll like receptor 7	Homo sapiens	153-157
34456715-8	2021	FZHFZY ameliorated symptoms of psoriasis, regulated epidermal differentiation and inhibited phosphorylation of the Akt/mTORC1/S6K1 pathway in the skin of mice with imiquimod-induced psoriasis.	Imiquimod	164-173	thymoma viral proto-oncogene 1	Mus musculus	115-118
34456715-8	2021	FZHFZY ameliorated symptoms of psoriasis, regulated epidermal differentiation and inhibited phosphorylation of the Akt/mTORC1/S6K1 pathway in the skin of mice with imiquimod-induced psoriasis.	Imiquimod	164-173	CREB regulated transcription coactivator 1	Mus musculus	119-125
34456715-8	2021	FZHFZY ameliorated symptoms of psoriasis, regulated epidermal differentiation and inhibited phosphorylation of the Akt/mTORC1/S6K1 pathway in the skin of mice with imiquimod-induced psoriasis.	Imiquimod	164-173	ribosomal protein S6 kinase, polypeptide 1	Mus musculus	126-130
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	20-29	complement component 1, q subcomponent binding protein	Mus musculus	138-141
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	20-29	complement component 1, q subcomponent binding protein	Mus musculus	142-147
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	31-34	complement component 1, q subcomponent binding protein	Mus musculus	138-141
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	31-34	complement component 1, q subcomponent binding protein	Mus musculus	142-147
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	231-234	complement component 1, q subcomponent binding protein	Mus musculus	138-141
34421919-3	2021	In a mouse model of imiquimod (IMQ)-induced psoriasiform skin inflammation, we found that hematopoietic cell-specific genetic deletion of p32/C1qbp, a regulator of mitochondrial protein synthesis and metabolism, protects mice from IMQ-induced psoriatic inflammation.	Imiquimod	231-234	complement component 1, q subcomponent binding protein	Mus musculus	142-147
34421919-4	2021	Additionally, we demonstrate that p32/C1qbp is an important regulator of IMQ-induced DC activation, both in vivo and in vitro.	Imiquimod	73-76	complement component 1, q subcomponent binding protein	Mus musculus	34-37
34421919-4	2021	Additionally, we demonstrate that p32/C1qbp is an important regulator of IMQ-induced DC activation, both in vivo and in vitro.	Imiquimod	73-76	complement component 1, q subcomponent binding protein	Mus musculus	38-43
34421919-5	2021	We also found that p32/C1qbp-deficient DCs exhibited impaired production of IL-1beta, IL-23, and mitochondrial reactive oxygen species (mtROS) after IMQ stimulation.	Imiquimod	149-152	complement component 1, q subcomponent binding protein	Mus musculus	19-22
34421919-5	2021	We also found that p32/C1qbp-deficient DCs exhibited impaired production of IL-1beta, IL-23, and mitochondrial reactive oxygen species (mtROS) after IMQ stimulation.	Imiquimod	149-152	complement component 1, q subcomponent binding protein	Mus musculus	23-28
34421919-5	2021	We also found that p32/C1qbp-deficient DCs exhibited impaired production of IL-1beta, IL-23, and mitochondrial reactive oxygen species (mtROS) after IMQ stimulation.	Imiquimod	149-152	interleukin 1 alpha	Mus musculus	76-84
34421919-5	2021	We also found that p32/C1qbp-deficient DCs exhibited impaired production of IL-1beta, IL-23, and mitochondrial reactive oxygen species (mtROS) after IMQ stimulation.	Imiquimod	149-152	interleukin 23, alpha subunit p19	Mus musculus	86-91
34421919-6	2021	Because the inhibition of mtROS suppressed IMQ-induced DC activation and psoriatic inflammation, we presume that p32/C1qbp and mtROS can serve as therapeutic targets in psoriasis.	Imiquimod	43-46	complement component 1, q subcomponent binding protein	Mus musculus	113-116
34421919-6	2021	Because the inhibition of mtROS suppressed IMQ-induced DC activation and psoriatic inflammation, we presume that p32/C1qbp and mtROS can serve as therapeutic targets in psoriasis.	Imiquimod	43-46	complement component 1, q subcomponent binding protein	Mus musculus	117-122
34444829-2	2021	We treated eight-week-old BALB/cByJRj mice without (Ctrl) or with the agonist of TLR-7 Imiquimod (IMQ) for 8 weeks.	Imiquimod	87-96	toll-like receptor 7	Mus musculus	81-86
34444829-2	2021	We treated eight-week-old BALB/cByJRj mice without (Ctrl) or with the agonist of TLR-7 Imiquimod (IMQ) for 8 weeks.	Imiquimod	98-101	toll-like receptor 7	Mus musculus	81-86
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	tumor necrosis factor	Mus musculus	335-343
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 23, alpha subunit p19	Mus musculus	345-350
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 17A	Mus musculus	352-358
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 6	Mus musculus	360-364
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 1 alpha	Mus musculus	366-374
34171426-8	2021	Importantly, compared to MTX oral administration, topical application of MTX/NIC cerosomes on imiquimod (IMQ)-induced psoriatic mouse model exhibited a superior performance in ameliorating skin lesions, reducing spleen index and epidermal thickness, and downregulating the mRNA expression levels of proinflammatory cytokines including TNFalpha, IL-23, IL-17A, IL-6, IL-1beta, and IL-22.	Imiquimod	105-108	interleukin 22	Mus musculus	380-385
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	0-3	interferon gamma	Mus musculus	16-43
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	0-3	recombination activating 1	Mus musculus	158-162
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	0-3	interferon gamma	Mus musculus	182-191
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	0-3	interferon gamma	Mus musculus	224-233
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	286-289	interferon gamma	Mus musculus	16-43
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	286-289	recombination activating 1	Mus musculus	158-162
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	286-289	interferon gamma	Mus musculus	182-191
34439104-5	2021	IMQ upregulated interferon gamma (IFN-gamma) expression in CD8+ T cells in both the lymph nodes and the tumor, and the antitumor effect was abolished in both Rag1-deficient mice and IFN-gamma-deficient mice, indicating that IFN-gamma produced by CD8+ T cells play a crucial role in the IMQ-induced antitumor effect.	Imiquimod	286-289	interferon gamma	Mus musculus	224-233
34439104-6	2021	IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling.	Imiquimod	0-3	CD274 molecule	Sus scrofa	59-64
34439104-6	2021	IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling.	Imiquimod	0-3	programmed cell death 1 ligand 2	Sus scrofa	65-70
34439104-6	2021	IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling.	Imiquimod	116-119	CD274 molecule	Sus scrofa	59-64
34439104-6	2021	IMQ also upregulated PD-1 expression in T cells as well as PD-L1/PD-L2 expression in myeloid cells, suggesting that IMQ induces not only T-cell activation but also T-cell exhaustion by enhanced PD-1 inhibitory signaling.	Imiquimod	116-119	programmed cell death 1 ligand 2	Sus scrofa	65-70
34082258-4	2021	We previously showed that porcine TLR8 (pTLR8) exhibited species specificity for recognition of the hTLR7 agonist imiquimod (R837).	Imiquimod	114-123	toll like receptor 8	Homo sapiens	34-38
34082258-4	2021	We previously showed that porcine TLR8 (pTLR8) exhibited species specificity for recognition of the hTLR7 agonist imiquimod (R837).	Imiquimod	114-123	toll like receptor 7	Homo sapiens	100-105
34381369-6	2021	Furthermore, L-THE inhibited the production of IL-23 in dendritic cells (DCs) after IMQ treatment, and decreased the levels of chemokines in keratinocytes treated with IL-17A by downregulating the expression of IL-17RA.	Imiquimod	84-87	interleukin 23, alpha subunit p19	Mus musculus	47-52
34281197-0	2021	Anoctamin1 Induces Hyperproliferation of HaCaT Keratinocytes and Triggers Imiquimod-Induced Psoriasis-Like Skin Injury in Mice.	Imiquimod	74-83	anoctamin 1, calcium activated chloride channel	Mus musculus	0-10
34215755-6	2021	This enhanced intradermal IL-6 may alleviate imiquimod-induced skin inflammation.	Imiquimod	45-54	interleukin 6	Mus musculus	26-30
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 22	Mus musculus	54-59
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 23, alpha subunit p19	Mus musculus	61-66
34356516-0	2021	TLR7 Activation of Macrophages by Imiquimod Inhibits HIV Infection through Modulation of Viral Entry Cellular Factors.	Imiquimod	34-43	toll like receptor 7	Homo sapiens	0-4
34356516-2	2021	Imiquimod, a synthetic ligand for TLR7, has been successfully used for the topical treatment of genital/perianal warts in immunocompetent individuals.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	34-38
34356516-8	2021	These findings provide experimental evidence to support the notion that TLR7 participates in the intracellular immunity against HIV in macrophages, suggesting the further clinical evaluation of imiquimod for its additional benefit of treating genital/perianal warts in people infected with HIV.	Imiquimod	194-203	toll like receptor 7	Homo sapiens	72-76
34162135-0	2021	Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation in BALB/c mice via down regulating NF-kappaB and activation of Nrf2 signaling pathways.	Imiquimod	21-30	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	107-116
34162135-0	2021	Galangin ameliorates Imiquimod-Induced psoriasis-like skin inflammation in BALB/c mice via down regulating NF-kappaB and activation of Nrf2 signaling pathways.	Imiquimod	21-30	nuclear factor, erythroid derived 2, like 2	Mus musculus	135-139
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 6	Mus musculus	68-72
34281197-8	2021	Coapplication of IMQ and T16Ainh-A01 on ears of mice reduced not only symptoms of IMQ-induced psoriasis such as thickening and erythema, but also expression of ANO1 and pERK1/2 compared to that of application of IMQ alone.	Imiquimod	17-20	anoctamin 1, calcium activated chloride channel	Mus musculus	160-164
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 1 alpha	Mus musculus	74-82
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	tumor necrosis factor	Mus musculus	88-97
34281197-8	2021	Coapplication of IMQ and T16Ainh-A01 on ears of mice reduced not only symptoms of IMQ-induced psoriasis such as thickening and erythema, but also expression of ANO1 and pERK1/2 compared to that of application of IMQ alone.	Imiquimod	212-215	anoctamin 1, calcium activated chloride channel	Mus musculus	160-164
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 17A	Mus musculus	38-44
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 17F	Mus musculus	46-52
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 22	Mus musculus	54-59
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 23, alpha subunit p19	Mus musculus	61-66
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 6	Mus musculus	68-72
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	interleukin 1 alpha	Mus musculus	74-82
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	123-126	tumor necrosis factor	Mus musculus	88-97
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 17A	Mus musculus	38-44
34281197-9	2021	In addition, the expression levels of IL-17A, IL-17F, IL-22, IL-23, IL-6, IL-1beta, and TNF-alpha increased after applying IMQ and were significantly reduced by coapplying IMQ and T16Ainh-A01.	Imiquimod	172-175	interleukin 17F	Mus musculus	46-52
34211367-6	2021	Intrathecal application of Imiquimod (TLR7 ligand) or CpG oligonucleotide (TLR9 ligand) into CNS of otherwise unmanipulated mice induced IFNbeta expression, with greater magnitude in response to CpG.	Imiquimod	27-36	toll-like receptor 7	Mus musculus	38-42
34172768-10	2021	Consistently, tazarotene treatment or NB-UVB irradiation attenuated imiquimod-induced psoriasis-like dermatitis and decreased MMP13 expression in a mouse model.	Imiquimod	68-77	matrix metallopeptidase 13	Mus musculus	126-131
34220863-6	2021	Results: We showed that RPL22 expression was significantly increased in the skin lesions of psoriasis patients and IMQ-treated psoriatic-like mice.	Imiquimod	115-118	ribosomal protein L22	Homo sapiens	24-29
34220863-9	2021	Finally, we demonstrated that RPL22 overexpression promoted psoriasiform phenotypes in IMQ-induced mouse skins.	Imiquimod	87-90	ribosomal protein L22	Mus musculus	30-35
34211367-6	2021	Intrathecal application of Imiquimod (TLR7 ligand) or CpG oligonucleotide (TLR9 ligand) into CNS of otherwise unmanipulated mice induced IFNbeta expression, with greater magnitude in response to CpG.	Imiquimod	27-36	interferon alpha	Mus musculus	137-144
35576719-7	2022	Inhibition of Lck signaling led to amelioration of clinical features of psoriasis through attenuation of Th1/Th17 immune responses and upregulation of Treg cells in IMQ-treated mice.	Imiquimod	165-168	lymphocyte protein tyrosine kinase	Mus musculus	14-17
34124307-3	2021	Defined monocyte subsets are isolated from the bone marrow of donor mice by cell sorting and adoptively transferred into the systemic circulation of congenic hosts, with or without concurrent activation of TLR7 via the topical application of the small molecule agonist, imiquimod, in a cream formulation that induces a systemic inflammatory response.	Imiquimod	270-279	toll-like receptor 7	Mus musculus	206-210
34088889-9	2021	Compared with IMQ-treated and PBS-treated mice, pGP3- and PGP3M-treated mice had less inflammatory cell infiltration in skin tissues and had significantly reduced IL-17A, IFN-gamma, and IL-22 levels in serum.	Imiquimod	14-17	interferon gamma	Mus musculus	171-180
34088889-9	2021	Compared with IMQ-treated and PBS-treated mice, pGP3- and PGP3M-treated mice had less inflammatory cell infiltration in skin tissues and had significantly reduced IL-17A, IFN-gamma, and IL-22 levels in serum.	Imiquimod	14-17	interleukin 22	Mus musculus	186-191
34805481-11	2021	We then subjected the final results to molecular dynamics simulation and compared our compounds with imiquimod (an FDA-approved TLR7 agonist) and compound 1 (the most active compound against TLR7 in vitro, EC50 = 0.2 nM).	Imiquimod	101-110	toll like receptor 7	Homo sapiens	128-132
35582997-12	2022	In vitro study from 5% IMQ-induced mouse splenic mononuclear cells presented that high dose of LY294002 exerted more obviously regulatory effect on Notch1/Hes1-PTEN/AKT/IL-17A feedback loop.	Imiquimod	23-26	notch 1	Mus musculus	148-154
35582997-12	2022	In vitro study from 5% IMQ-induced mouse splenic mononuclear cells presented that high dose of LY294002 exerted more obviously regulatory effect on Notch1/Hes1-PTEN/AKT/IL-17A feedback loop.	Imiquimod	23-26	hes family bHLH transcription factor 1	Mus musculus	155-159
35543945-20	2022	CONCLUSION: Fire needling therapy improves skin lesion severity in imiquimod induced psoriasis-like lesion of the mice, which is probably related to the inhibition of STAT3 pathway activation and the decrease of Th17 inflammatory factors expression.	Imiquimod	67-76	signal transducer and activator of transcription 3	Mus musculus	167-172
35436657-6	2022	Intra-tumoral injection of Imiquimod, a TLR7/8 ligand, reduced the tumor burden; the anti-tumor effect was reversed upon IL-27 and IL-27R silencing by intra-tumorally administered, lentivirally expressed IL-27 and IL-27R shRNA.	Imiquimod	27-36	interleukin 27	Mus musculus	121-126
35436657-6	2022	Intra-tumoral injection of Imiquimod, a TLR7/8 ligand, reduced the tumor burden; the anti-tumor effect was reversed upon IL-27 and IL-27R silencing by intra-tumorally administered, lentivirally expressed IL-27 and IL-27R shRNA.	Imiquimod	27-36	interleukin 27 receptor, alpha	Mus musculus	131-137
35436657-6	2022	Intra-tumoral injection of Imiquimod, a TLR7/8 ligand, reduced the tumor burden; the anti-tumor effect was reversed upon IL-27 and IL-27R silencing by intra-tumorally administered, lentivirally expressed IL-27 and IL-27R shRNA.	Imiquimod	27-36	interleukin 27	Mus musculus	204-209
35436657-6	2022	Intra-tumoral injection of Imiquimod, a TLR7/8 ligand, reduced the tumor burden; the anti-tumor effect was reversed upon IL-27 and IL-27R silencing by intra-tumorally administered, lentivirally expressed IL-27 and IL-27R shRNA.	Imiquimod	27-36	interleukin 27 receptor, alpha	Mus musculus	214-220
35253588-11	2022	Furthermore, asiatic acid (high-dose) suppressed the imiquimod-induced increase in serum levels of IL-17A and IL-23.Conclusion: These results indicate that asiatic acid showed an anti-psoriatic effect in the imiquimod-induced psoriasis model via mediating IL-17A and IL-23 pathways.	Imiquimod	53-62	interleukin 17A	Mus musculus	99-105
35253588-11	2022	Furthermore, asiatic acid (high-dose) suppressed the imiquimod-induced increase in serum levels of IL-17A and IL-23.Conclusion: These results indicate that asiatic acid showed an anti-psoriatic effect in the imiquimod-induced psoriasis model via mediating IL-17A and IL-23 pathways.	Imiquimod	53-62	interleukin 23, alpha subunit p19	Mus musculus	110-115
35588658-7	2022	In both in vitro and in vivo studies, protein levels of nuclear factor erythroid 2-related factor 2 (Nrf2) were elevated following imiquimod and olive oil administration.	Imiquimod	131-140	nuclear factor, erythroid derived 2, like 2	Mus musculus	101-105
35588658-8	2022	Inhibition of Nrf2 abolished the increased proliferation of keratinocytes treated with imiquimod and olive oil, demonstrating the role of Nrf2 in olive oil-mediated exacerbation of psoriasiform skin inflammation.	Imiquimod	87-96	nuclear factor, erythroid derived 2, like 2	Mus musculus	14-18
35588658-8	2022	Inhibition of Nrf2 abolished the increased proliferation of keratinocytes treated with imiquimod and olive oil, demonstrating the role of Nrf2 in olive oil-mediated exacerbation of psoriasiform skin inflammation.	Imiquimod	87-96	nuclear factor, erythroid derived 2, like 2	Mus musculus	138-142
35543945-0	2022	(Effect of fire needling on imiquimod induced psoriasis-like lesion and STAT3 pathway in mice).	Imiquimod	28-37	signal transducer and activator of transcription 3	Mus musculus	72-77
35563616-0	2022	The Protective Role of pVHL in Imiquimod-Induced Psoriasis-like Skin Inflammation.	Imiquimod	31-40	von Hippel-Lindau tumor suppressor	Homo sapiens	23-27
35563616-7	2022	We used the imiquimod-induced psoriasis-like mouse model as an adenoviral vector that allowed us to express pVHL in the skin.	Imiquimod	12-21	von Hippel-Lindau tumor suppressor	Mus musculus	108-112
35478358-5	2022	Genetic deletion of cPLA2 epsilon exacerbated IMQ-induced ear swelling and psoriatic marker expression, with a dramatic reduction of NAE-related lipids in IMQ-treated, and even normal, skin.	Imiquimod	46-49	phospholipase A2 group IVA	Homo sapiens	20-25
35545140-2	2022	Here we show that TGM3 expression was increased in skin lesions of psoriasis patients and a mouse model of imiquimod (IMQ)-induced psoriatic dermatitis.	Imiquimod	107-116	transglutaminase 3	Homo sapiens	18-22
35545140-2	2022	Here we show that TGM3 expression was increased in skin lesions of psoriasis patients and a mouse model of imiquimod (IMQ)-induced psoriatic dermatitis.	Imiquimod	118-121	transglutaminase 3	Homo sapiens	18-22
35545140-6	2022	Moreover, topical application of Tgm3-specific siRNA or the pan-TGM inhibitor cysteamine exacerbated skin inflammation in mice with IMQ-induced psoriatic dermatitis.	Imiquimod	132-135	transglutaminase 3, E polypeptide	Mus musculus	33-37
35513071-4	2022	Analysis in psoriatic tissues and imiquimod (IMQ)-induced mouse models showed that Chrna5 was highly expressed in psoriatic lesional skin.	Imiquimod	34-43	cholinergic receptor, nicotinic, alpha polypeptide 5	Mus musculus	83-89
35513071-4	2022	Analysis in psoriatic tissues and imiquimod (IMQ)-induced mouse models showed that Chrna5 was highly expressed in psoriatic lesional skin.	Imiquimod	45-48	cholinergic receptor, nicotinic, alpha polypeptide 5	Mus musculus	83-89
35347767-8	2022	Additionally, MBL-deficient (MBL-/- ) mice exhibited decreased accumulation of pDC in lymph nodes, spleens, and skin lesions with reduced secretion of pDC-related cytokines compared with wild-type (WT) mice in the preliminary stage of psoriasis induced by imiquimod.	Imiquimod	256-265	mannose-binding lectin (protein C) 2	Mus musculus	29-32
35470561-0	2022	The Toll-like receptor 7 agonist imiquimod increases ethanol self-administration and induces expression of Toll-like receptor related genes.	Imiquimod	33-42	toll-like receptor 7	Rattus norvegicus	4-24
35429062-5	2022	C3aR showed protective roles in mouse models of imiquimod (IMQ)- and interleukin-23-induced psoriasis.	Imiquimod	48-57	complement component 3a receptor 1	Mus musculus	0-4
35429062-5	2022	C3aR showed protective roles in mouse models of imiquimod (IMQ)- and interleukin-23-induced psoriasis.	Imiquimod	59-62	complement component 3a receptor 1	Mus musculus	0-4
35429062-7	2022	Pharmacological treatment with a C3aR agonist ameliorated IMQ-induced psoriasiform lesions in mice and decreased the expression of K6, K16, and K17.	Imiquimod	58-61	complement component 3a receptor 1	Mus musculus	33-37
35218026-10	2022	In this paper, the detection of skin histopathological analysis, CCK-8, flow cytometry, western blot, and ELISA analysis shows that ginsenoside Rg1 has preventive effect on psoriasis caused by imiquimod or M5 cocktail through inhibiting NLRP3 inflammasome, which helps in the development of novel nutraceutical/functional food against psoriasis and thus could improve the quality of life in psoriasis patients.	Imiquimod	193-202	protein phosphatase 1 regulatory subunit 3A	Homo sapiens	144-147
35478358-5	2022	Genetic deletion of cPLA2 epsilon exacerbated IMQ-induced ear swelling and psoriatic marker expression, with a dramatic reduction of NAE-related lipids in IMQ-treated, and even normal, skin.	Imiquimod	155-158	phospholipase A2 group IVA	Homo sapiens	20-25
35358680-0	2022	The miR-145-MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance.	Imiquimod	50-59	microRNA 145	Homo sapiens	4-11
35358680-0	2022	The miR-145-MMP1 axis is a critical regulator for imiquimod-induced cancer stemness and chemoresistance.	Imiquimod	50-59	matrix metallopeptidase 1	Homo sapiens	12-16
35358680-3	2022	Here, we report that imiquimod (IMQ) facilitates the acquisition of stem-cell-like properties and chemoresistance via the upregulation of matrix metalloproteinase 1 (MMP1) and downregulation of microRNA-145 (miR-145).	Imiquimod	21-30	matrix metallopeptidase 1	Homo sapiens	138-164
35358680-3	2022	Here, we report that imiquimod (IMQ) facilitates the acquisition of stem-cell-like properties and chemoresistance via the upregulation of matrix metalloproteinase 1 (MMP1) and downregulation of microRNA-145 (miR-145).	Imiquimod	21-30	matrix metallopeptidase 1	Homo sapiens	166-170
35358680-3	2022	Here, we report that imiquimod (IMQ) facilitates the acquisition of stem-cell-like properties and chemoresistance via the upregulation of matrix metalloproteinase 1 (MMP1) and downregulation of microRNA-145 (miR-145).	Imiquimod	21-30	microRNA 145	Homo sapiens	194-206
35358680-3	2022	Here, we report that imiquimod (IMQ) facilitates the acquisition of stem-cell-like properties and chemoresistance via the upregulation of matrix metalloproteinase 1 (MMP1) and downregulation of microRNA-145 (miR-145).	Imiquimod	21-30	microRNA 145	Homo sapiens	208-215
35358680-4	2022	MiR-145-5p was found to suppress MMP1 expression through direct binding, and miR-145-mediated downregulation of MMP1 reversed the effects of IMQ.	Imiquimod	141-144	matrix metallopeptidase 1	Homo sapiens	33-37
35358680-4	2022	MiR-145-5p was found to suppress MMP1 expression through direct binding, and miR-145-mediated downregulation of MMP1 reversed the effects of IMQ.	Imiquimod	141-144	microRNA 145	Homo sapiens	77-84
35358680-4	2022	MiR-145-5p was found to suppress MMP1 expression through direct binding, and miR-145-mediated downregulation of MMP1 reversed the effects of IMQ.	Imiquimod	141-144	matrix metallopeptidase 1	Homo sapiens	112-116
35358680-6	2022	DNA methyltransferase inhibitors limited IMQ-induced MMP1 expression, stemness, and chemoresistance.	Imiquimod	41-44	matrix metallopeptidase 1	Homo sapiens	53-57
35392911-5	2022	After loading with R837 (imiquimod, a toll-like receptor-7 agonist), MPSNs@R837 will elicit high-efficiency immunogenic cell death via PDT and PTT, and promote dendritic cell maturation after the PH-responsive release of R837, thereby, inducing tumor-specific immune responses.	Imiquimod	19-23	toll like receptor 7	Homo sapiens	38-58
35631342-6	2022	ME1 with 1% IMQ (bicontinuous ME with Bingham rheology) delivered similar IMQ quantities to the human epidermis ex vivo as the commercial product while having a 5-fold lower IMQ dose.	Imiquimod	74-77	malic enzyme 1	Homo sapiens	0-3
35631342-6	2022	ME1 with 1% IMQ (bicontinuous ME with Bingham rheology) delivered similar IMQ quantities to the human epidermis ex vivo as the commercial product while having a 5-fold lower IMQ dose.	Imiquimod	174-177	malic enzyme 1	Homo sapiens	0-3
35491357-0	2022	Therapeutic effects of the extract of Sancao Formula, a Chinese herbal compound, on imiquimod-induced psoriasis via cysteine-rich protein 61.	Imiquimod	84-93	cellular communication network factor 1	Mus musculus	116-140
35562873-6	2022	Imiquimod-induced psoriasis-like skin lesions, which present as erythematous papules and plaques with silver scaling, as well as markedly elevated IL-17/IL-23 cytokine levels in skin tissues, were significantly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice.	Imiquimod	0-9	interleukin 17A	Mus musculus	147-152
35562873-6	2022	Imiquimod-induced psoriasis-like skin lesions, which present as erythematous papules and plaques with silver scaling, as well as markedly elevated IL-17/IL-23 cytokine levels in skin tissues, were significantly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice.	Imiquimod	0-9	interleukin 23, alpha subunit p19	Mus musculus	153-158
35562873-7	2022	Enlarged lymph nodes and spleens, as well as imiquimod-induced, elevated IL-17/IL-23 cytokine levels, were also strongly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice.	Imiquimod	45-54	interleukin 17A	Mus musculus	73-78
35562873-7	2022	Enlarged lymph nodes and spleens, as well as imiquimod-induced, elevated IL-17/IL-23 cytokine levels, were also strongly suppressed by Compound A in FFA4 WT mice, but not in FFA4 KO mice.	Imiquimod	45-54	interleukin 23, alpha subunit p19	Mus musculus	79-84
35562873-8	2022	Imiquimod-induced increases in the CD4+IL-17A+ T cell population in lymph nodes and spleens were suppressed by Compound A treatment in FFA4 WT mice; however, this was not seen in FFA4 KO mice.	Imiquimod	0-9	CD4 antigen	Mus musculus	35-38
35562873-8	2022	Imiquimod-induced increases in the CD4+IL-17A+ T cell population in lymph nodes and spleens were suppressed by Compound A treatment in FFA4 WT mice; however, this was not seen in FFA4 KO mice.	Imiquimod	0-9	interleukin 17A	Mus musculus	39-45
35392911-5	2022	After loading with R837 (imiquimod, a toll-like receptor-7 agonist), MPSNs@R837 will elicit high-efficiency immunogenic cell death via PDT and PTT, and promote dendritic cell maturation after the PH-responsive release of R837, thereby, inducing tumor-specific immune responses.	Imiquimod	25-34	toll like receptor 7	Homo sapiens	38-58
35331618-6	2022	Imiquimod-induced psoriasis-like skin inflammation was induced in wild-type (WT) and adiponectin-deficient (Adipoq-/-) mice.	Imiquimod	0-9	adiponectin, C1Q and collagen domain containing	Mus musculus	85-96
35464441-6	2022	Consequently, TET nanoemulsion potently inhibited IL-17-expressing cells in the spleen and lymph nodes of imiquimod-treated WT mice, accompanied by decreased serum levels of IL-17A, INF-gamma, and TNF and their mRNA levels in the flamed lesion.	Imiquimod	106-115	interleukin 17A	Mus musculus	50-55
35464441-6	2022	Consequently, TET nanoemulsion potently inhibited IL-17-expressing cells in the spleen and lymph nodes of imiquimod-treated WT mice, accompanied by decreased serum levels of IL-17A, INF-gamma, and TNF and their mRNA levels in the flamed lesion.	Imiquimod	106-115	interleukin 17A	Mus musculus	174-180
35464441-6	2022	Consequently, TET nanoemulsion potently inhibited IL-17-expressing cells in the spleen and lymph nodes of imiquimod-treated WT mice, accompanied by decreased serum levels of IL-17A, INF-gamma, and TNF and their mRNA levels in the flamed lesion.	Imiquimod	106-115	tumor necrosis factor	Mus musculus	197-200
35174638-3	2022	In this study, we investigated the activation of the STING-IRF3 pathway in human immortalized keratinocytes (HaCaT) cells treated with palmitic acid (PA) and imiquimod (IMQ).	Imiquimod	158-167	interferon regulatory factor 3	Homo sapiens	59-63
35174638-3	2022	In this study, we investigated the activation of the STING-IRF3 pathway in human immortalized keratinocytes (HaCaT) cells treated with palmitic acid (PA) and imiquimod (IMQ).	Imiquimod	169-172	interferon regulatory factor 3	Homo sapiens	59-63
35174638-4	2022	Additionally, we detected the STING-IRF3 pathway in diabetic mice with imiquimod (IMQ)-induced psoriasis and assessed the potential of STING inhibitor C-176.	Imiquimod	71-80	interferon regulatory factor 3	Mus musculus	36-40
35174638-4	2022	Additionally, we detected the STING-IRF3 pathway in diabetic mice with imiquimod (IMQ)-induced psoriasis and assessed the potential of STING inhibitor C-176.	Imiquimod	82-85	interferon regulatory factor 3	Mus musculus	36-40
35331618-6	2022	Imiquimod-induced psoriasis-like skin inflammation was induced in wild-type (WT) and adiponectin-deficient (Adipoq-/-) mice.	Imiquimod	0-9	adiponectin, C1Q and collagen domain containing	Mus musculus	108-114
35324153-5	2022	The toll-like receptors 7 (TLR7) agonist imiquimod could be released from these microparticles in the cytoplasm to reprogram M2-like TAMs.	Imiquimod	41-50	toll like receptor 7	Homo sapiens	4-25
35324153-5	2022	The toll-like receptors 7 (TLR7) agonist imiquimod could be released from these microparticles in the cytoplasm to reprogram M2-like TAMs.	Imiquimod	41-50	toll like receptor 7	Homo sapiens	27-31
35281792-4	2022	The deficiency of SHP2 in neutrophils significantly alleviated psoriasis-like phenotype in an imiquimod-induced murine model.	Imiquimod	94-103	protein tyrosine phosphatase, non-receptor type 11	Mus musculus	18-22
35279880-8	2022	RESULTS: We show that mice lacking SLPI had exaggerated skin alterations that extended beyond the treatment site in an imiquimod-induced psoriasis.	Imiquimod	119-128	secretory leukocyte peptidase inhibitor	Mus musculus	35-39
35279880-9	2022	The spatiotemporally distinct skin responses in SLPI deficient mice, compared to their wild-type littermates, resulted from a compromised skin barrier function that manifested itself in heightened transepidermal water loss through the larger skin area surrounding the imiquimod challenged skin.	Imiquimod	268-277	secretory leukocyte peptidase inhibitor	Mus musculus	48-52
35371102-3	2022	An imiquimod (IMQ)-induced lupus model was used to analyze the lupus mechanism related to the aberrant TLR7 signals.	Imiquimod	3-12	toll-like receptor 7	Mus musculus	103-107
35371102-3	2022	An imiquimod (IMQ)-induced lupus model was used to analyze the lupus mechanism related to the aberrant TLR7 signals.	Imiquimod	14-17	toll-like receptor 7	Mus musculus	103-107
35371102-5	2022	Monocytes expressed intermediate to high levels of TLR7, and the long-term application of IMQ increased Ly6Clo monocytes in the peripheral blood and Ly6Clo monocyte-like cells in the lymph nodes and kidneys, whereas Ly6Chi monocyte-like cell numbers were increased in lymph nodes.	Imiquimod	90-93	toll-like receptor 7	Mus musculus	51-55
35371102-11	2022	However, MF in IMQ-induced lupus mice were characterized by their high expression of Cxcl13.	Imiquimod	15-18	chemokine (C-X-C motif) ligand 13	Mus musculus	85-91
35051865-12	2022	In IMQ-induced psoriatic dermatitis, Cel gel reduced the secretion of interleukin (IL)- 23 by Langerhans cells, suppressed the interaction between Langerhans cells and gammadeltaT cells, and decreased the number of activated gammadeltaT cells and related IL-17 secretion, alleviating psoriasis-like inflammation.	Imiquimod	3-6	interleukin 23, alpha subunit p19	Mus musculus	70-90
34998030-7	2022	Moreover, the results further indicated that YJS could inhibit TLR4 activation and NF-kappaB p65 nuclear transfer by suppressing HSP70 secretion to attenuate the inflammatory response in IMQ-induced mice, which provided a theoretical basis for the clinical use of YJS in the treatment of psoriasis.	Imiquimod	187-190	heat shock protein 1B	Mus musculus	129-134
35582636-7	2022	In an Imiquimod (IMQ)-induced psoriasis model, the topical treatment of psoriasis lesions with CHALT effectively attenuated the STAT3 hyperactivation within keratinocytes and ameliorated the symptoms of psoriasis.	Imiquimod	6-15	signal transducer and activator of transcription 3	Homo sapiens	128-133
35582636-7	2022	In an Imiquimod (IMQ)-induced psoriasis model, the topical treatment of psoriasis lesions with CHALT effectively attenuated the STAT3 hyperactivation within keratinocytes and ameliorated the symptoms of psoriasis.	Imiquimod	17-20	signal transducer and activator of transcription 3	Homo sapiens	128-133
35143820-6	2022	Furthermore, in mice with imiquimod-induced psoriasis-like dermatitis, topical application of AhR small-interfering RNA substantially exacerbated the disease severity with increased NLRP3 inflammasome activation.	Imiquimod	26-35	aryl-hydrocarbon receptor	Mus musculus	94-97
35250276-4	2022	We hypothesized that mice lacking the IDO1 gene would exhibit a hyperactive immune response and an exacerbation of skin lesions in the imiquimod-induced mouse model of psoriasis.	Imiquimod	135-144	indoleamine 2,3-dioxygenase 1	Mus musculus	38-42
35250276-7	2022	Imiquimod increased ear edema, PASI scores, and epidermal thickness in both WT and IDO1 knockout mice; however, there were no differences observed between the 2 genotypes.	Imiquimod	0-9	indoleamine 2,3-dioxygenase 1	Mus musculus	83-87
35273606-10	2022	Lipopolysaccharide-induced expression of Il1b and Il6 was less in 2610528A11Rik deficient mouse keratinocytes than in wild-type, and imiquimod-induced psoriatic dermatitis was blunted in 2610528A11Rik deficient mice.	Imiquimod	133-142	interleukin 6	Mus musculus	50-53
35121555-4	2022	Further studies were performed to establish mouse psoriasis model induced by Imiquimod (IMQ), and the preliminary mechanism indicated that compound 8A2 may alleviate mouse psoriasis through obstructed the JAK1/2-STAT1/3 pathway.	Imiquimod	77-86	signal transducer and activator of transcription 1	Mus musculus	212-219
35214117-2	2022	In this study, we collected basic information to help elucidate the mechanism responsible for the transcutaneous adjuvant activity of imiquimod (IMQ), which is a ligand of toll-like receptor (TLR) 7.	Imiquimod	134-143	toll-like receptor 7	Mus musculus	172-198
35214117-2	2022	In this study, we collected basic information to help elucidate the mechanism responsible for the transcutaneous adjuvant activity of imiquimod (IMQ), which is a ligand of toll-like receptor (TLR) 7.	Imiquimod	145-148	toll-like receptor 7	Mus musculus	172-198
35214117-3	2022	In mouse groups administered ovalbumin (OVA), the OVA-specific IgG antibody titer of the IMQ-adjuvanted group was higher than that of the group administered OVA alone.	Imiquimod	89-92	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	29-38
35214117-3	2022	In mouse groups administered ovalbumin (OVA), the OVA-specific IgG antibody titer of the IMQ-adjuvanted group was higher than that of the group administered OVA alone.	Imiquimod	89-92	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	40-43
35214117-3	2022	In mouse groups administered ovalbumin (OVA), the OVA-specific IgG antibody titer of the IMQ-adjuvanted group was higher than that of the group administered OVA alone.	Imiquimod	89-92	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	50-53
35214117-3	2022	In mouse groups administered ovalbumin (OVA), the OVA-specific IgG antibody titer of the IMQ-adjuvanted group was higher than that of the group administered OVA alone.	Imiquimod	89-92	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	157-160
35214117-6	2022	Transcutaneously administered IMQ did not affect the direction of CD4+ T cell differentiation, while promoted B cell activation and germinal center (GC) B cell differentiation.	Imiquimod	30-33	natriuretic peptide receptor 2	Mus musculus	132-154
35214117-9	2022	In addition, our results suggested that the administration of IMQ enhanced B cell differentiation into plasma cells and GC B cells in the dLNs and spleen.	Imiquimod	62-65	natriuretic peptide receptor 2	Mus musculus	120-124
35143820-6	2022	Furthermore, in mice with imiquimod-induced psoriasis-like dermatitis, topical application of AhR small-interfering RNA substantially exacerbated the disease severity with increased NLRP3 inflammasome activation.	Imiquimod	26-35	NLR family, pyrin domain containing 3	Mus musculus	182-187
35120997-4	2022	Silencing 24p3R alleviated hyperkeratosis, inflammatory cell infiltration, and overexpression of inflammatory mediators in an imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	126-135	solute carrier family 22 member 17	Homo sapiens	10-15
35260898-0	2022	Exposure of female NZBWF1 mice to imiquimod-induced lupus nephritis at an early age via a unique mechanism that differed from spontaneous onset.	Imiquimod	34-43	WD repeat and FYVE domain containing 3	Mus musculus	19-25
35260898-5	2022	Female and male NZBWF1 (BWF1) mice were treated from 20 weeks of age with a TLR7 agonist, imiquimod (IMQ), 3 times weekly for up to 12 weeks.	Imiquimod	90-99	WD repeat and FYVE domain containing 3	Mus musculus	16-22
35120997-4	2022	Silencing 24p3R alleviated hyperkeratosis, inflammatory cell infiltration, and overexpression of inflammatory mediators in an imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	137-140	solute carrier family 22 member 17	Homo sapiens	10-15
35260898-5	2022	Female and male NZBWF1 (BWF1) mice were treated from 20 weeks of age with a TLR7 agonist, imiquimod (IMQ), 3 times weekly for up to 12 weeks.	Imiquimod	90-99	toll-like receptor 7	Mus musculus	76-80
35173615-0	2022	CB2R Deficiency Exacerbates Imiquimod-Induced Psoriasiform Dermatitis and Itch Through the Neuro-Immune Pathway.	Imiquimod	28-37	cannabinoid receptor 2 (macrophage)	Mus musculus	0-4
35260898-6	2022	IMQ-exposed female BWF1 mice showed worsened lupus nephritis.	Imiquimod	0-3	WD repeat and FYVE domain containing 3	Mus musculus	19-23
35260898-9	2022	In IMQ-exposed BWF1 mice, neutralization of IFN-gamma suppressed early-phase lupus nephritis.	Imiquimod	3-6	WD repeat and FYVE domain containing 3	Mus musculus	15-19
35260898-9	2022	In IMQ-exposed BWF1 mice, neutralization of IFN-gamma suppressed early-phase lupus nephritis.	Imiquimod	3-6	interferon gamma	Mus musculus	44-53
35260898-10	2022	Additionally, in male BWF1 mice IMQ exposure induced minor aggravation of lupus nephritis.	Imiquimod	32-35	WD repeat and FYVE domain containing 3	Mus musculus	22-26
35065421-0	2022	SIDT1 plays a key role in type I IFN responses to nucleic acids in plasmacytoid dendritic cells and mediates the pathogenesis of an imiquimod-induced psoriasis model.	Imiquimod	132-141	SID1 transmembrane family member 1	Homo sapiens	0-5
35173615-2	2022	However, the role of CB2R in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) and itch is poorly understood.	Imiquimod	29-38	cannabinoid receptor 2 (macrophage)	Mus musculus	21-25
35173615-2	2022	However, the role of CB2R in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) and itch is poorly understood.	Imiquimod	29-38	itchy, E3 ubiquitin protein ligase	Mus musculus	87-91
35173615-2	2022	However, the role of CB2R in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) and itch is poorly understood.	Imiquimod	40-43	cannabinoid receptor 2 (macrophage)	Mus musculus	21-25
35173615-2	2022	However, the role of CB2R in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) and itch is poorly understood.	Imiquimod	40-43	itchy, E3 ubiquitin protein ligase	Mus musculus	87-91
35173615-9	2022	Compared with WT mice, CB2R deficiency exacerbated IMQ-induced PsD and scratching bouts and upregulated the expression of proinflammatory cytokines by increasing the infiltration of CD4+ T cells and the Th17/Treg ratio.	Imiquimod	51-54	cannabinoid receptor 2 (macrophage)	Mus musculus	23-27
35173615-9	2022	Compared with WT mice, CB2R deficiency exacerbated IMQ-induced PsD and scratching bouts and upregulated the expression of proinflammatory cytokines by increasing the infiltration of CD4+ T cells and the Th17/Treg ratio.	Imiquimod	51-54	CD4 antigen	Mus musculus	182-185
35153762-0	2021	P. granatum Peel Polysaccharides Ameliorate Imiquimod-Induced Psoriasis-Like Dermatitis in Mice via Suppression of NF-kappaB and STAT3 Pathways.	Imiquimod	44-53	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	115-124
35153762-0	2021	P. granatum Peel Polysaccharides Ameliorate Imiquimod-Induced Psoriasis-Like Dermatitis in Mice via Suppression of NF-kappaB and STAT3 Pathways.	Imiquimod	44-53	signal transducer and activator of transcription 3	Mus musculus	129-134
35032503-5	2022	IMQ application elicited aberrant cutaneous nerve outgrowth and excessive generation of neuropeptide calcitonin gene-related peptide (CGRP) from dorsal root ganglion (DRG) neurons, both of which were inhibited by epidural lidocaine treatment.	Imiquimod	0-3	calcitonin related polypeptide alpha	Homo sapiens	101-132
35145520-7	2022	Imiquimod, LPS and CpG strongly induced CD86 expression in IgD+CD27- naive and IgD-CD27+ memory B cells in the young group.	Imiquimod	0-9	CD86 molecule	Homo sapiens	40-44
35145520-7	2022	Imiquimod, LPS and CpG strongly induced CD86 expression in IgD+CD27- naive and IgD-CD27+ memory B cells in the young group.	Imiquimod	0-9	CD27 molecule	Homo sapiens	63-67
35145520-7	2022	Imiquimod, LPS and CpG strongly induced CD86 expression in IgD+CD27- naive and IgD-CD27+ memory B cells in the young group.	Imiquimod	0-9	CD27 molecule	Homo sapiens	83-87
35126161-11	2022	In IMQ-induced psoriasis-like mice, sulforaphane reduced the proportions of Th1 and Th17 cells and increased the expression of antioxidant gene Prdx1.	Imiquimod	3-6	peroxiredoxin 1	Mus musculus	144-149
35032503-5	2022	IMQ application elicited aberrant cutaneous nerve outgrowth and excessive generation of neuropeptide calcitonin gene-related peptide (CGRP) from dorsal root ganglion (DRG) neurons, both of which were inhibited by epidural lidocaine treatment.	Imiquimod	0-3	calcitonin related polypeptide alpha	Homo sapiens	134-138
35041513-4	2022	We found that subcutaneous injection of human umbilical cord MSCs-Exo (hucMSCs-Exo) significantly suppressed the proliferation of epidermis and reduced Psoriasis Area and Severity Index (PASI) scores in imiquimod (IMQ)-induced mice.	Imiquimod	203-212	5'-3' exoribonuclease 1	Mus musculus	66-69
35069008-0	2022	Topical Treatment of Colquhounia Root Relieves Skin Inflammation and Itch in Imiquimod-Induced Psoriasiform Dermatitis in Mice.	Imiquimod	77-86	itchy, E3 ubiquitin protein ligase	Mus musculus	69-73
35041513-4	2022	We found that subcutaneous injection of human umbilical cord MSCs-Exo (hucMSCs-Exo) significantly suppressed the proliferation of epidermis and reduced Psoriasis Area and Severity Index (PASI) scores in imiquimod (IMQ)-induced mice.	Imiquimod	203-212	5'-3' exoribonuclease 1	Mus musculus	79-82
35041513-4	2022	We found that subcutaneous injection of human umbilical cord MSCs-Exo (hucMSCs-Exo) significantly suppressed the proliferation of epidermis and reduced Psoriasis Area and Severity Index (PASI) scores in imiquimod (IMQ)-induced mice.	Imiquimod	214-217	5'-3' exoribonuclease 1	Mus musculus	66-69
35041513-4	2022	We found that subcutaneous injection of human umbilical cord MSCs-Exo (hucMSCs-Exo) significantly suppressed the proliferation of epidermis and reduced Psoriasis Area and Severity Index (PASI) scores in imiquimod (IMQ)-induced mice.	Imiquimod	214-217	5'-3' exoribonuclease 1	Mus musculus	79-82
35041513-5	2022	hucMSCs-Exo also reduced the expression of interleukin (IL)-17, IL-23, and chemokine C-C-motif ligand 20 (CCL20) and inhibited phosphorylation of signal transducer and activator of transcription 3 (STAT3) in the skin of IMQ-induced mice and in human keratinocyte (HaCaT) cells.	Imiquimod	220-223	5'-3' exoribonuclease 1	Mus musculus	8-11
34028144-4	2021	IMQ induced psoriatic symptoms such as erythema and scaling and also upregulated interleukin (IL)-17, a key effector cytokine of psoriasis, in the skin.	Imiquimod	0-3	interleukin 17A	Mus musculus	81-100
33333123-5	2021	Furthermore, we provide evidence for excessive full-length IL-1alpha signaling in the microenvironment of IMQ-treated Ovol1-deficient skin that functionally contributes to immune cell infiltration and epidermal hyperplasia.	Imiquimod	106-109	ovo like transcriptional repressor 1	Homo sapiens	118-123
33333123-3	2021	Here we show that the expression of Ovol1 (encoding Ovo-like 1 transcription factor) is upregulated in psoriatic skin, and its deletion results in aggravated psoriasis-like skin symptoms following stimulation with imiquimod (IMQ).	Imiquimod	214-223	ovo like transcriptional repressor 1	Homo sapiens	36-41
33333123-3	2021	Here we show that the expression of Ovol1 (encoding Ovo-like 1 transcription factor) is upregulated in psoriatic skin, and its deletion results in aggravated psoriasis-like skin symptoms following stimulation with imiquimod (IMQ).	Imiquimod	225-228	ovo like transcriptional repressor 1	Homo sapiens	36-41
33333123-5	2021	Furthermore, we provide evidence for excessive full-length IL-1alpha signaling in the microenvironment of IMQ-treated Ovol1-deficient skin that functionally contributes to immune cell infiltration and epidermal hyperplasia.	Imiquimod	106-109	interleukin 1 alpha	Homo sapiens	59-68
34058746-8	2021	Furthermore, we demonstrated that imiquimod, a TLR7 agonist, inhibited cytokine and chemokine production induced by a TLR8 agonist, TL8-506.	Imiquimod	34-43	toll like receptor 7	Homo sapiens	47-51
34058746-8	2021	Furthermore, we demonstrated that imiquimod, a TLR7 agonist, inhibited cytokine and chemokine production induced by a TLR8 agonist, TL8-506.	Imiquimod	34-43	toll like receptor 8	Homo sapiens	118-122
34039637-3	2021	In this study, using the TLR7 agonist, imiquimod-induced SLE model, we observed that loss of miR-21 in Sle1b mice prevented the formation of plasma cells and autoantibody-producing Ab-forming cells (AFCs) without a significant effect on the magnitude of the germinal center (GC) response.	Imiquimod	39-48	microRNA 21a	Mus musculus	93-99
34004188-3	2021	Meanwhile, genetic or pharmacological inhibition of CDK7 ameliorated the severity of psoriasis in imiquimod-induced psoriasis-like mouse model and suppressed CD4+ T cell activation as well as Th17/Th1 cell differentiation in vivo and in vitro.	Imiquimod	98-107	cyclin-dependent kinase 7	Mus musculus	52-56
34008239-0	2021	Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.	Imiquimod	35-44	interleukin 23, alpha subunit p19	Mus musculus	99-104
34008239-0	2021	Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.	Imiquimod	35-44	Janus kinase 2	Mus musculus	130-134
34008239-0	2021	Rosmarinic acid protects mice from imiquimod induced psoriasis-like skin lesions by inhibiting the IL-23/Th17 axis via regulating Jak2/Stat3 signaling pathway.	Imiquimod	35-44	signal transducer and activator of transcription 3	Mus musculus	135-140
33990689-0	2021	2"-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice.	Imiquimod	37-46	pyruvate kinase, muscle	Mus musculus	94-98
33990547-4	2021	N4BP1-deficient mice exhibited normal grossly, but developed severe and prolonged IMQ-induced psoriasis-like disease comparing to controls.	Imiquimod	82-85	NEDD4 binding protein 1	Mus musculus	0-5
33990689-0	2021	2"-Hydroxycinnamaldehyde ameliorates imiquimod-induced psoriasiform inflammation by targeting PKM2-STAT3 signaling in mice.	Imiquimod	37-46	signal transducer and activator of transcription 3	Mus musculus	99-104
33964283-9	2021	In addition, imiquimod-induced psoriasis-like symptoms, including epidermal hyperplasia, desquamation with scaling, neutrophil skin infiltration, and transepidermal water loss were significantly reduced by both RAB and TA.	Imiquimod	13-22	ArfGAP with FG repeats 1	Homo sapiens	211-214
33992648-0	2021	A targetable, non-canonical STAT3 activation induced by the tyrosine-less region of IL-22R orchestrates imiquimod-induced psoriasis-like dermatitis in mice.	Imiquimod	104-113	signal transducer and activator of transcription 3	Mus musculus	28-33
33992648-0	2021	A targetable, non-canonical STAT3 activation induced by the tyrosine-less region of IL-22R orchestrates imiquimod-induced psoriasis-like dermatitis in mice.	Imiquimod	104-113	interleukin 22 receptor, alpha 1	Mus musculus	84-90
34015449-4	2021	Here, we showed that LLDT-8 significantly attenuated symptoms of psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7 agonist) by reducing the Psoriasis Area and Severity Index (PASI) score and inflammatory parameters.	Imiquimod	102-111	toll-like receptor 7	Mus musculus	120-124
34015449-4	2021	Here, we showed that LLDT-8 significantly attenuated symptoms of psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7 agonist) by reducing the Psoriasis Area and Severity Index (PASI) score and inflammatory parameters.	Imiquimod	113-116	toll-like receptor 7	Mus musculus	120-124
34015449-7	2021	In conclusion, LLDT-8 notably alleviated IMQ-induced psoriasis-like skin inflammation via suppressing the IL-36alpha signaling pathway, suggesting LLDT-8 might be a potential drug for the treatment of psoriasis.	Imiquimod	41-44	interleukin 36A	Mus musculus	106-116
34025679-9	2021	Additionally, it alleviated the progression in the TLR7-agonist imiquimod-mediated lupus mice and spontaneous lupus MRL/lpr mice.	Imiquimod	64-73	toll-like receptor 7	Mus musculus	51-55
33096083-3	2021	In our previous studies, we showed that Trim32 null mice developed Th2 biased skin inflammation in response to imiquimod and associated low level of TRIM32 with AD.	Imiquimod	111-120	tripartite motif-containing 32	Mus musculus	40-46
33759666-16	2021	In IL-22/LPS-stimulated HaCaT cells and skin of imiquimod-induced mice, we found that lower NORAD resulted in an increase of miR-26a and a decrease of CDC6, further decreased levels of keratinocyte proliferation-related proteins (K6, K16, and K17).	Imiquimod	48-57	non-coding RNA activated by DNA damage	Homo sapiens	92-97
33759666-16	2021	In IL-22/LPS-stimulated HaCaT cells and skin of imiquimod-induced mice, we found that lower NORAD resulted in an increase of miR-26a and a decrease of CDC6, further decreased levels of keratinocyte proliferation-related proteins (K6, K16, and K17).	Imiquimod	48-57	microRNA 26a-1	Mus musculus	125-132
33759666-16	2021	In IL-22/LPS-stimulated HaCaT cells and skin of imiquimod-induced mice, we found that lower NORAD resulted in an increase of miR-26a and a decrease of CDC6, further decreased levels of keratinocyte proliferation-related proteins (K6, K16, and K17).	Imiquimod	48-57	cell division cycle 6	Mus musculus	151-155
33759666-16	2021	In IL-22/LPS-stimulated HaCaT cells and skin of imiquimod-induced mice, we found that lower NORAD resulted in an increase of miR-26a and a decrease of CDC6, further decreased levels of keratinocyte proliferation-related proteins (K6, K16, and K17).	Imiquimod	48-57	keratin 16	Mus musculus	234-237
33759666-16	2021	In IL-22/LPS-stimulated HaCaT cells and skin of imiquimod-induced mice, we found that lower NORAD resulted in an increase of miR-26a and a decrease of CDC6, further decreased levels of keratinocyte proliferation-related proteins (K6, K16, and K17).	Imiquimod	48-57	keratin 17	Mus musculus	243-246
34025642-9	2021	Hyperforin also suppressed the typical psoriasis-like inflammatory responses and the infiltration of IL-17A+ cells in dermal gammadelta T cells of IMQ treated Tcrd -/- mice transferred with gammadelta T cells.	Imiquimod	147-150	interleukin 17A	Mus musculus	101-107
34025642-9	2021	Hyperforin also suppressed the typical psoriasis-like inflammatory responses and the infiltration of IL-17A+ cells in dermal gammadelta T cells of IMQ treated Tcrd -/- mice transferred with gammadelta T cells.	Imiquimod	147-150	T cell receptor delta chain	Mus musculus	159-163
34025642-11	2021	In conclusion, hyperforin alleviates IMQ-induced inflammation in psoriasis through suppressing the immune responses exerted by IL-17 A-producing gammadelta T cells and related cytokines by modulating MAPK/STAT3 pathways.	Imiquimod	37-40	interleukin 17A	Mus musculus	127-134
33896047-11	2021	These results suggest that preliminary histological evaluation of FE may be useful to predict the efficacy of imiquimod for AK.	Imiquimod	110-119	general transcription factor IIE subunit 1	Homo sapiens	66-68
33596715-11	2021	CONCLUSION: This study is the first to demonstrate early fecal calprotectin increase and liver activation of TLR4- NFkappaB pathway in wild-type murine imiquimod-induced lupus.	Imiquimod	152-161	toll-like receptor 4	Mus musculus	109-113
34016718-0	2021	Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model.	Imiquimod	142-151	suppressor of cytokine signaling 3	Mus musculus	0-35
34016718-0	2021	Suppressor of cytokine signalling 3 (SOCS3) expressed in podocytes attenuates glomerulonephritis and suppresses autoantibody production in an imiquimod-induced lupus model.	Imiquimod	142-151	suppressor of cytokine signaling 3	Mus musculus	37-42
34016718-4	2021	METHODS: We investigated the expression of SOCS family members in glomeruli in murine lupus model induced by repeated epicutaneous administration of the TLR7/8 agonist imiquimod.	Imiquimod	168-177	cytokine inducible SH2-containing protein	Mus musculus	43-47
34016718-4	2021	METHODS: We investigated the expression of SOCS family members in glomeruli in murine lupus model induced by repeated epicutaneous administration of the TLR7/8 agonist imiquimod.	Imiquimod	168-177	toll-like receptor 7	Mus musculus	153-159
34016718-7	2021	RESULTS: qPCR analysis revealed that among SOCS family members, SOCS3 was preferentially induced in glomeruli on epicutaneous administration of imiquimod and that interleukin 6 (IL-6) induced SOCS3 expression in podocyte cell lines.	Imiquimod	144-153	cytokine inducible SH2-containing protein	Mus musculus	43-47
34016718-7	2021	RESULTS: qPCR analysis revealed that among SOCS family members, SOCS3 was preferentially induced in glomeruli on epicutaneous administration of imiquimod and that interleukin 6 (IL-6) induced SOCS3 expression in podocyte cell lines.	Imiquimod	144-153	suppressor of cytokine signaling 3	Mus musculus	64-69
34016718-12	2021	CONCLUSION: SOCS3 expressed in podocytes plays protective roles for the development of glomerulonephritis and inhibits autoantibody production in the imiquimod-induced lupus model presumably by suppressing IL-6 production of podocytes.	Imiquimod	150-159	suppressor of cytokine signaling 3	Mus musculus	12-17
34016718-12	2021	CONCLUSION: SOCS3 expressed in podocytes plays protective roles for the development of glomerulonephritis and inhibits autoantibody production in the imiquimod-induced lupus model presumably by suppressing IL-6 production of podocytes.	Imiquimod	150-159	interleukin 6	Mus musculus	206-210
33995349-7	2021	We found that IMQ treatment increased CD3+ T cells in skin from both OFA and SD, being higher in desmoglein-4-deficient rats.	Imiquimod	14-17	desmoglein 4	Rattus norvegicus	97-109
33888401-12	2021	CONCLUSION: Our results demonstrated that fingolimod showed effectiveness for IMQ-induced psoriasiform dermatitis by hindering the emigration of IL-17A-producing gammadelta T cells from the lymph nodes to the skin, and suggest that fingolimod is a promising candidate for the treatment of psoriasis.	Imiquimod	78-81	interleukin 17A	Mus musculus	145-151
33648938-4	2021	Following topical treatment with IMQ, serum levels of LRG and its expression in the liver were abruptly elevated.	Imiquimod	33-36	leucine-rich alpha-2-glycoprotein 1	Mus musculus	54-57
33851477-0	2021	Antibiotics and Imiquimod for CTCL in Veterans: A Patient Population with Agent Orange Exposure.	Imiquimod	16-25	TSPY like 2	Homo sapiens	30-34
33851477-2	2021	This trial of antibiotic therapy followed by imiquimod in early stage CTCL was not completed due to difficulties with patient accrual.	Imiquimod	45-54	TSPY like 2	Homo sapiens	70-74
33851477-17	2021	CONCLUSION: Antibiotics and imiquimod have reported activity as single agents in CTCL; we did not enroll enough patients to assess value in the sequence of antibiotic therapy followed by imiquimod.	Imiquimod	28-37	TSPY like 2	Homo sapiens	81-85
33921372-8	2021	In conclusion, we demonstrated that rapamycin alleviates TCDD-induced aggravated dermatitis in mice with imiquimod-induced psoriasis-like dermatitis through AHR and autophagy modulation.	Imiquimod	105-114	aryl-hydrocarbon receptor	Mus musculus	157-160
33836731-8	2021	CONCLUSION: Our study suggests that the anti-inflammatory effects of MabE on the activation of the macrophage cell line RAW246.7 by TLRs and IMQ-induced ear edema are through the inhibition of NF-kappaB activation and IL-17A-producing gammadeltaT cells, respectively.	Imiquimod	141-144	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	193-202
33836731-8	2021	CONCLUSION: Our study suggests that the anti-inflammatory effects of MabE on the activation of the macrophage cell line RAW246.7 by TLRs and IMQ-induced ear edema are through the inhibition of NF-kappaB activation and IL-17A-producing gammadeltaT cells, respectively.	Imiquimod	141-144	interleukin 17A	Mus musculus	218-224
33473072-0	2021	Topical Application of BMS-509744, a Selective Inhibitor of Interleukin-2-inducible T cell Kinase, Ameliorates Imiquimod-induced Skin Inflammation in Mice.	Imiquimod	111-120	IL2 inducible T cell kinase	Mus musculus	60-97
32888954-7	2021	Correspondingly, an MMP-9 inhibitor significantly reduced cutaneous vasodilation, vascular permeability, and psoriatic symptoms in an imiquimod- or IL-23-induced psoriasiform mouse model.	Imiquimod	134-143	matrix metallopeptidase 9	Mus musculus	20-25
33039402-3	2021	RNA sequencing analysis of mouse spinal cord in chronic itch models induced by squaric acid dibutylester and imiquimod showed that extracellular signal-regulated kinase 1/2 (ERK1/2) cascade is the most significantly up-regulated gene cluster in both models.	Imiquimod	109-118	itchy, E3 ubiquitin protein ligase	Mus musculus	56-60
33039402-3	2021	RNA sequencing analysis of mouse spinal cord in chronic itch models induced by squaric acid dibutylester and imiquimod showed that extracellular signal-regulated kinase 1/2 (ERK1/2) cascade is the most significantly up-regulated gene cluster in both models.	Imiquimod	109-118	mitogen-activated protein kinase 3	Mus musculus	131-172
33039402-3	2021	RNA sequencing analysis of mouse spinal cord in chronic itch models induced by squaric acid dibutylester and imiquimod showed that extracellular signal-regulated kinase 1/2 (ERK1/2) cascade is the most significantly up-regulated gene cluster in both models.	Imiquimod	109-118	mitogen-activated protein kinase 3	Mus musculus	174-180
33648938-6	2021	LRG-KO mice showed less skin inflammation in the IMQ model than wild-type mice.	Imiquimod	49-52	leucine-rich alpha-2-glycoprotein 1	Mus musculus	0-3
33744296-6	2021	Moreover, imiquimod-induced lysosomal adaptation occurred through lysosomal Ca2+ release and activation of the calcineurin/TFEB axis to promote lysosome biogenesis.	Imiquimod	10-19	transcription factor EB	Homo sapiens	123-127
33785385-11	2022	The IHC analysis showed a higher level of Interferon gamma in the resected specimens of patients responding to imiquimod (p = 0.04).	Imiquimod	111-120	interferon gamma	Homo sapiens	42-58
33744296-7	2021	Finally, depletion of TFEB sensitized skin cancer cells to imiquimod-induced apoptosis in vitro and in vivo.	Imiquimod	59-68	transcription factor EB	Homo sapiens	22-26
33747624-0	2021	Usefulness of Topical Imiquimod 3.75% in Cytokeratin 7 Positive Extramammary Paget Disease of the Vulva: Towards Personalized Therapy.	Imiquimod	22-31	keratin 7	Homo sapiens	41-54
33549905-3	2021	Molecular docking studies and structure-activity relationship studies led to the identification of 9-fluorobenzo[f]pyrido[4,3-b][1,4]oxazepin-10-one derivative 43, which exhibited potent BRD4 inhibitory activity with excellent potency in imiquimod-induced psoriasis model mice.	Imiquimod	238-247	bromodomain containing 4	Mus musculus	187-191
33676948-5	2021	Using the Imiquimod (IMQ) psoriasis mouse model, we found that MTH1 inhibition diminished psoriatic histological characteristics and normalized the levels of neutrophils and T cells in skin and skin-draining lymph nodes.	Imiquimod	10-19	nudix (nucleoside diphosphate linked moiety X)-type motif 1	Mus musculus	63-67
33705829-13	2021	The in vivo relevance of this pathway is supported by decreased miR-149 expression in psoriasis keratinocytes, as well as the protective effect of synthetic miR-149 in the imiquimod-induced mouse model of psoriasis.	Imiquimod	172-181	microRNA 149	Mus musculus	157-164
33676948-5	2021	Using the Imiquimod (IMQ) psoriasis mouse model, we found that MTH1 inhibition diminished psoriatic histological characteristics and normalized the levels of neutrophils and T cells in skin and skin-draining lymph nodes.	Imiquimod	21-24	nudix (nucleoside diphosphate linked moiety X)-type motif 1	Mus musculus	63-67
33708208-2	2021	Here, we evaluated the role of Hsp70 as a treatment target in the imiquimod-induced, psoriasis-like skin inflammation mouse model and related in vitro assays.	Imiquimod	66-75	heat shock protein 1B	Mus musculus	31-36
32853659-6	2021	IL-33 specific deficiency in keratinocytes ameliorated IMQ-induced psoriatic dermatitis.	Imiquimod	55-58	interleukin 33	Homo sapiens	0-5
33419765-4	2021	Selective inactivation of keratinocyte-specific MALT1 proteolytic activity strongly ameliorated the Card14 E138A/+- and Card14 DeltaQ136/+-induced skin disease, which was reproduced by using the imiquimod-induced mouse model.	Imiquimod	195-204	MALT1 paracaspase	Mus musculus	48-53
33419765-4	2021	Selective inactivation of keratinocyte-specific MALT1 proteolytic activity strongly ameliorated the Card14 E138A/+- and Card14 DeltaQ136/+-induced skin disease, which was reproduced by using the imiquimod-induced mouse model.	Imiquimod	195-204	caspase recruitment domain family, member 14	Mus musculus	100-106
33419765-4	2021	Selective inactivation of keratinocyte-specific MALT1 proteolytic activity strongly ameliorated the Card14 E138A/+- and Card14 DeltaQ136/+-induced skin disease, which was reproduced by using the imiquimod-induced mouse model.	Imiquimod	195-204	caspase recruitment domain family, member 14	Mus musculus	120-126
32531088-7	2021	Within IMQ-induced psoriasis-like dermatitis in mice, CTNNBIP1 silence further aggravated psoriatic phenotypes.	Imiquimod	7-10	catenin beta interacting protein 1	Mus musculus	54-62
33613525-0	2020	JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara -Induced Skin Inflammation.	Imiquimod	61-67	mitogen-activated protein kinase 8	Homo sapiens	0-4
33613525-0	2020	JNK1 Signaling Downstream of the EGFR Pathway Contributes to Aldara -Induced Skin Inflammation.	Imiquimod	61-67	epidermal growth factor receptor	Homo sapiens	33-37
33613525-2	2020	Herein, we studied the role of JNK1 in the context of Aldara -induced skin inflammation.	Imiquimod	54-60	mitogen-activated protein kinase 8	Homo sapiens	31-35
33613525-3	2020	We observed that constitutive ablation of JNK1 reduced Aldara -induced acanthosis and expression of inflammatory markers.	Imiquimod	55-61	mitogen-activated protein kinase 8	Homo sapiens	42-46
33613525-8	2020	Finally, we show that inhibition of the EGFR pathway reduced Aldara -induced acanthosis.	Imiquimod	61-67	epidermal growth factor receptor	Homo sapiens	40-44
33643287-6	2020	We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha.	Imiquimod	53-62	interleukin 1 alpha	Mus musculus	167-190
33643287-6	2020	We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha.	Imiquimod	53-62	interleukin 6	Mus musculus	192-196
33643287-6	2020	We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha.	Imiquimod	53-62	interleukin 17A	Mus musculus	198-204
33643287-6	2020	We now confirm that induction of S100-alarmins in an imiquimod-induced murine model of psoriasis-like skin inflammation was associated with an increased expression of interleukin (IL)-1alpha, IL-6, IL-17A, or TNFalpha.	Imiquimod	53-62	tumor necrosis factor	Mus musculus	209-217
33488612-8	2020	We found that imiquimod induced plasmacytoid dendritic cell (pDC) accumulation in psoriatic skin, spleen, and draining lymph nodes (DLN) were drastically decreased in Zdhhc2 deficient mice, and the expression of pDC activation marker CD80 also exhibited significantly inhibited in psoriatic skin.	Imiquimod	14-23	zinc finger, DHHC domain containing 2	Mus musculus	167-173
32679047-5	2021	Sirt2 KO mice and WT littermates had psoriatic dermatitis induced by topical treatment of imiquimod or intradermal injection of recombinant IL-23.	Imiquimod	90-99	sirtuin 2	Mus musculus	0-5
33509093-0	2021	Application of imiquimod-induced murine psoriasis model in evaluating interleukin-17A antagonist.	Imiquimod	15-24	interleukin 17A	Mus musculus	70-85
33509093-5	2021	Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment.	Imiquimod	180-183	interleukin 17A	Mus musculus	52-57
33509093-5	2021	Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment.	Imiquimod	180-183	interleukin 17A	Mus musculus	132-137
33509093-5	2021	Meanwhile, we validated the detailed involvement of IL17A signaling in disease progression, confirmed that the expression levels of IL17A and its related cytokines were induced by IMQ application, and its downstream cytokines can be inhibited by IL17A antagonist treatment.	Imiquimod	180-183	interleukin 17A	Mus musculus	132-137
33509093-6	2021	In further study, we revealed that IL17A was transient induced by IMQ and directly caused downstream signaling activation.	Imiquimod	66-69	interleukin 17A	Mus musculus	35-40
33509093-8	2021	CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.	Imiquimod	228-231	interleukin 17A	Mus musculus	121-126
33509093-8	2021	CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.	Imiquimod	228-231	interleukin 17A	Mus musculus	193-198
33509093-8	2021	CONCLUSIONS: Our work presents the application of a convenient psoriatic animal model in the research and development of IL17A antagonists, meanwhile providing extra evidence for understanding IL17A"s role in the progression of IMQ-induced psoriasis model, which manifest the research and development of IL17A antagonists.	Imiquimod	228-231	interleukin 17A	Mus musculus	193-198
33495490-6	2021	Epidermal hyperplasia, induced using imiquimod, was more severe in C6st-1-knockout mice than in C6st-1 wild-type mice.	Imiquimod	37-46	carbohydrate sulfotransferase 3	Mus musculus	67-73
33450859-6	2021	Nevertheless, topically applied MSC exosomes in a mouse model of imiquimod (IMQ) psoriasis significantly reduced IL-17 and terminal complement activation complex C5b-9 in the mouse skin.	Imiquimod	65-74	interleukin 17A	Mus musculus	113-118
33450859-6	2021	Nevertheless, topically applied MSC exosomes in a mouse model of imiquimod (IMQ) psoriasis significantly reduced IL-17 and terminal complement activation complex C5b-9 in the mouse skin.	Imiquimod	76-79	interleukin 17A	Mus musculus	113-118
33361205-0	2021	Deletion of S100a8 and S100a9 Enhances Skin Hyperplasia and Promotes the Th17 Response in Imiquimod-Induced Psoriasis.	Imiquimod	90-99	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	12-18
33361205-0	2021	Deletion of S100a8 and S100a9 Enhances Skin Hyperplasia and Promotes the Th17 Response in Imiquimod-Induced Psoriasis.	Imiquimod	90-99	S100 calcium binding protein A9 (calgranulin B)	Mus musculus	23-29
33532507-11	2021	The proteins related to the PI3K/Akt pathway and beta-catenin expression and the nuclear entry of beta-catenin were reduced in IMQ-induced PA mice treated with YXJD.	Imiquimod	127-130	thymoma viral proto-oncogene 1	Mus musculus	33-36
33532507-11	2021	The proteins related to the PI3K/Akt pathway and beta-catenin expression and the nuclear entry of beta-catenin were reduced in IMQ-induced PA mice treated with YXJD.	Imiquimod	127-130	catenin (cadherin associated protein), beta 1	Mus musculus	49-61
33532507-11	2021	The proteins related to the PI3K/Akt pathway and beta-catenin expression and the nuclear entry of beta-catenin were reduced in IMQ-induced PA mice treated with YXJD.	Imiquimod	127-130	catenin (cadherin associated protein), beta 1	Mus musculus	98-110
33548169-8	2021	Strain effect on oxidative stress induced by IMQ was evaluated by estimating antioxidant factors, superoxide dismutase (SOD), catalase, and glutathione (GSH).	Imiquimod	45-48	catalase	Mus musculus	126-134
33548169-12	2021	Decreased cellular enzyme activity in SOD, Catalase, and levels of GSH was observed in IMQ challenged mice, indicating the participation of the redox system in the genesis of the disease that was comparable among the strains.	Imiquimod	87-90	catalase	Mus musculus	43-51
33488612-8	2020	We found that imiquimod induced plasmacytoid dendritic cell (pDC) accumulation in psoriatic skin, spleen, and draining lymph nodes (DLN) were drastically decreased in Zdhhc2 deficient mice, and the expression of pDC activation marker CD80 also exhibited significantly inhibited in psoriatic skin.	Imiquimod	14-23	CD80 antigen	Mus musculus	234-238
32232831-11	2021	Finally, both in vitro and in vivo experiments verified that topical application of Trim21-specific small interfering RNA (siRNA) markedly ameliorated imiquimod (IMQ)-induced psoriasis-like lesions.	Imiquimod	151-160	tripartite motif containing 21	Homo sapiens	84-90
32232831-11	2021	Finally, both in vitro and in vivo experiments verified that topical application of Trim21-specific small interfering RNA (siRNA) markedly ameliorated imiquimod (IMQ)-induced psoriasis-like lesions.	Imiquimod	162-165	tripartite motif containing 21	Homo sapiens	84-90
33176965-10	2021	Additionally, CGRP antagonist also suppressed the development of IMQ-induced psoriasis-like dermatitis in mice.	Imiquimod	65-68	calcitonin/calcitonin-related polypeptide, alpha	Mus musculus	14-18
32990395-3	2021	As a toll-like receptor 7/8 (TLR7/8) agonist imiquimod induces a local inflammatory response through increased production of cytokines, co-stimulatory molecules and by activation of Nk-cells and antigen-specific T-cells.	Imiquimod	45-54	toll like receptor 7	Homo sapiens	5-27
32990395-3	2021	As a toll-like receptor 7/8 (TLR7/8) agonist imiquimod induces a local inflammatory response through increased production of cytokines, co-stimulatory molecules and by activation of Nk-cells and antigen-specific T-cells.	Imiquimod	45-54	toll like receptor 7	Homo sapiens	29-35
33443029-3	2020	Humanized DITRA-like mice displayed increased skin inflammation in a preclinical model of psoriasis, and in vivo blockade of IL-36R pathway using anti-human IL-36R antibody ameliorated imiquimod-induced skin pathology as both prophylactic and therapeutic treatments.	Imiquimod	185-194	interleukin 1 receptor like 2	Homo sapiens	157-163
33023784-0	2020	Imiquimod-induced dermatitis impairs thymic tolerance of autoreactive CD4+ T cells to desmoglein 3.	Imiquimod	0-9	CD4 antigen	Mus musculus	70-73
32692482-8	2020	RESULTS: Unexpectedly, GSDMD-/- mice developed enhanced mortality, more severe renal and pulmonary inflammation, and exacerbated autoantibody production in response to imiquimod.	Imiquimod	168-177	gasdermin D	Mus musculus	23-28
33007409-0	2020	Inhibition of interleukin-2-inducible T-cell kinase causes reduction in imiquimod-induced psoriasiform inflammation through reduction of Th17 cells and enhancement of Treg cells in mice.	Imiquimod	72-81	IL2 inducible T cell kinase	Mus musculus	14-51
33007409-6	2020	Effect of ITK inhibitor in imiquimod (IMQ)-induced psoriasiform inflammation remains to be explored.	Imiquimod	27-36	IL2 inducible T cell kinase	Mus musculus	10-13
33007409-6	2020	Effect of ITK inhibitor in imiquimod (IMQ)-induced psoriasiform inflammation remains to be explored.	Imiquimod	38-41	IL2 inducible T cell kinase	Mus musculus	10-13
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	IL2 inducible T cell kinase	Mus musculus	22-25
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	IL2 inducible T cell kinase	Mus musculus	120-123
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	125-131
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	signal transducer and activator of transcription 3	Mus musculus	146-151
33007409-8	2020	Our data display that ITK signaling is involved in IMQ-induced psoriatic inflammation as paralleled by enhancement of p-ITK, NFATc1, p-NFkB and p-STAT3 in CD4+ T cells.	Imiquimod	51-54	CD4 antigen	Mus musculus	155-158
33443029-3	2020	Humanized DITRA-like mice displayed increased skin inflammation in a preclinical model of psoriasis, and in vivo blockade of IL-36R pathway using anti-human IL-36R antibody ameliorated imiquimod-induced skin pathology as both prophylactic and therapeutic treatments.	Imiquimod	185-194	interleukin 1 receptor like 2	Homo sapiens	125-131
33911791-6	2020	Methods: We examined the expression of KDM2A using a well established imiquimod-induced psoriasiform dermatitis model.	Imiquimod	70-79	lysine demethylase 2A	Homo sapiens	39-44
33911791-7	2020	Results: Immunohistochemistry analysis showed that expression of KDM2A was increased in imiquimod-induced psoriasiform dermatitis.	Imiquimod	88-97	lysine demethylase 2A	Homo sapiens	65-70
32828805-0	2020	A dual and conflicting role for imiquimod in inflammation: a TLR7 agonist and a cAMP phosphodiesterase inhibitor.	Imiquimod	32-41	toll like receptor 7	Homo sapiens	61-65
32828805-1	2020	The Toll-like receptor 7 (TLR7) agonist imiquimod is an antitumor and antiviral drug used for the treatment of skin indications such as basal cell carcinoma, squamous cell carcinoma, and genital warts caused by the human papilloma virus.	Imiquimod	40-49	toll like receptor 7	Homo sapiens	4-24
32828805-1	2020	The Toll-like receptor 7 (TLR7) agonist imiquimod is an antitumor and antiviral drug used for the treatment of skin indications such as basal cell carcinoma, squamous cell carcinoma, and genital warts caused by the human papilloma virus.	Imiquimod	40-49	toll like receptor 7	Homo sapiens	26-30
32828805-2	2020	We show that imiquimod has TLR7-independent activity in which it directly inhibits phosphodiesterase (PDE), leading to cAMP increase, PKA-mediated CREB phosphorylation and subsequent CRE-dependent reporter transcription.	Imiquimod	13-22	toll like receptor 7	Homo sapiens	27-31
32828805-2	2020	We show that imiquimod has TLR7-independent activity in which it directly inhibits phosphodiesterase (PDE), leading to cAMP increase, PKA-mediated CREB phosphorylation and subsequent CRE-dependent reporter transcription.	Imiquimod	13-22	cAMP responsive element binding protein 1	Homo sapiens	147-151
32828805-5	2020	Moreover, molecular docking simulated the binding of imiquimod in the active site of PDE4B, enabled by the high molecular similarity between imiquimod and the adenine moiety of cAMP.	Imiquimod	53-62	phosphodiesterase 4B	Homo sapiens	85-90
32828805-5	2020	Moreover, molecular docking simulated the binding of imiquimod in the active site of PDE4B, enabled by the high molecular similarity between imiquimod and the adenine moiety of cAMP.	Imiquimod	141-150	phosphodiesterase 4B	Homo sapiens	85-90
32828805-7	2020	To conclude, our results indicate that the widely used inflammatory drug, imiquimod, is not only a TLR7 agonist, but also harbors a novel anti-inflammatory function as a PDE inhibitor.	Imiquimod	74-83	toll like receptor 7	Homo sapiens	99-103
33023784-0	2020	Imiquimod-induced dermatitis impairs thymic tolerance of autoreactive CD4+ T cells to desmoglein 3.	Imiquimod	0-9	desmoglein 3	Mus musculus	86-98
33023784-5	2020	OBJECTIVE: We investigated whether imiquimod-induced dermatitis causes ATI and impairs thymic immune tolerance against desmoglein 3 (Dsg3), an epidermal autoantigen of pemphigus vulgaris.	Imiquimod	35-44	desmoglein 3	Mus musculus	119-131
33023784-5	2020	OBJECTIVE: We investigated whether imiquimod-induced dermatitis causes ATI and impairs thymic immune tolerance against desmoglein 3 (Dsg3), an epidermal autoantigen of pemphigus vulgaris.	Imiquimod	35-44	desmoglein 3	Mus musculus	133-137
33023784-11	2020	Accordingly, the number of Dsg3-experssing UEA-1+keratin 5+mTEC decreased in the thymus during imiquimod-induced dermatitis.	Imiquimod	95-104	desmoglein 3	Mus musculus	27-31
33023784-11	2020	Accordingly, the number of Dsg3-experssing UEA-1+keratin 5+mTEC decreased in the thymus during imiquimod-induced dermatitis.	Imiquimod	95-104	keratin 5	Mus musculus	43-58
33023784-12	2020	Although Dsg3-sepcific transgenic thymocytes was usually deleted in the thymus under physiological condition by central tolerance, Dsg3-sepcific transgenic CD4+CD8- thymocytes significantly increased in number under imiquimod-induced dermatitis.	Imiquimod	216-225	desmoglein 3	Mus musculus	131-135
33023784-12	2020	Although Dsg3-sepcific transgenic thymocytes was usually deleted in the thymus under physiological condition by central tolerance, Dsg3-sepcific transgenic CD4+CD8- thymocytes significantly increased in number under imiquimod-induced dermatitis.	Imiquimod	216-225	CD4 antigen	Mus musculus	156-159
33239358-6	2020	Intradermal injection with recombinant human IL-37 into imiquimod-induced psoriasis skin of C57BL/6J mice demonstrated a trend toward a protective effect, however NS.	Imiquimod	56-65	interleukin 37	Homo sapiens	45-50
33237695-6	2020	This study aimed to investigate the therapeutic effect of K17-specific small interfering RNA (siRNA) on mice with imiquimod (IMQ)-induced psoriasis-like dermatitis.	Imiquimod	114-123	keratin 17	Mus musculus	58-61
33237695-6	2020	This study aimed to investigate the therapeutic effect of K17-specific small interfering RNA (siRNA) on mice with imiquimod (IMQ)-induced psoriasis-like dermatitis.	Imiquimod	125-128	keratin 17	Mus musculus	58-61
33237695-14	2020	CONCLUSIONS: Inhibition of K17 expression by its specific siRNA significantly alleviated inflammation in mice with IMQ-induced psoriasis-like dermatitis.	Imiquimod	115-118	keratin 17	Mus musculus	27-30
32739587-0	2020	HPV11E7 inhibits IMQ-induced chemokine and colony-stimulating factor production in keratinocytes.	Imiquimod	17-20	colony-stimulating factor	None	43-68
33214582-4	2020	We evaluated the severity of psoriasis-like lesions induced by imiquimod cream treatment in Il36rn-/- mice.	Imiquimod	63-72	interleukin 36 receptor antagonist	Mus musculus	92-98
32574376-7	2020	Our data show that the immune microenvironment of complete responders (CR) to imiquimod resembled the coordinated infiltration with type 1 CD4+ and CD8+ T cells and CD14+ inflammatory myeloid cells also found in healthy vulva.	Imiquimod	78-87	CD4 molecule	Homo sapiens	139-142
32574376-7	2020	Our data show that the immune microenvironment of complete responders (CR) to imiquimod resembled the coordinated infiltration with type 1 CD4+ and CD8+ T cells and CD14+ inflammatory myeloid cells also found in healthy vulva.	Imiquimod	78-87	CD8a molecule	Homo sapiens	148-151
33011750-9	2020	In vivo, the inhibitor of EZH2, GSK126 could ameliorate the imiquimod-induced psoriasiform lesion.	Imiquimod	60-69	enhancer of zeste 2 polycomb repressive complex 2 subunit	Homo sapiens	26-30
32574376-7	2020	Our data show that the immune microenvironment of complete responders (CR) to imiquimod resembled the coordinated infiltration with type 1 CD4+ and CD8+ T cells and CD14+ inflammatory myeloid cells also found in healthy vulva.	Imiquimod	78-87	CD14 molecule	Homo sapiens	165-169
32574376-10	2020	Importantly, complete responses after imiquimod or therapeutic vaccination showed the same dependency on a pre-existing coordinated type 1 T cell and CD14+ myeloid cell infiltration.	Imiquimod	38-47	CD14 molecule	Homo sapiens	150-154
33202847-0	2020	TLR2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation through Decrease in Regulatory T Cells and Impaired IL-10 Production.	Imiquimod	28-37	interleukin 10	Mus musculus	131-136
33202847-2	2020	In this study, we investigated the role of TLR2 in psoriasis using imiquimod-induced psoriasis-like dermatitis.	Imiquimod	67-76	toll-like receptor 2	Mus musculus	43-47
33202847-7	2020	Finally, adoptive transfer of Tregs from wild-type mice reduced imiquimod-induced skin inflammation in TLR2 KO mice.	Imiquimod	64-73	toll-like receptor 2	Mus musculus	103-107
33202847-8	2020	Taken together, our results suggest that TLR2 signaling directly enhances Treg proliferation and IL-10 production by Tregs and DCs, suppressing imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	144-153	toll-like receptor 2	Mus musculus	41-45
33202847-8	2020	Taken together, our results suggest that TLR2 signaling directly enhances Treg proliferation and IL-10 production by Tregs and DCs, suppressing imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	144-153	interleukin 10	Mus musculus	97-102
32289348-6	2020	We also showed that silencing TRPC4 in DRG and its inhibition by intradermal injections were also effective in decreasing psoriatic itch after repeated applications of imiquimod (IMQ), a preclinical model of psoriasis.	Imiquimod	168-177	transient receptor potential cation channel, subfamily C, member 4	Mus musculus	30-35
32289348-6	2020	We also showed that silencing TRPC4 in DRG and its inhibition by intradermal injections were also effective in decreasing psoriatic itch after repeated applications of imiquimod (IMQ), a preclinical model of psoriasis.	Imiquimod	179-182	transient receptor potential cation channel, subfamily C, member 4	Mus musculus	30-35
32911323-4	2020	In the present study, we revealed that apoptotic cells accumulate in the spleen, macrophage efferocytosis is impaired, and uPAR is increased in the spleen and peritoneal macrophages of the TLR7 agonist imiquimod (IMQ)-induced SLE mouse model.	Imiquimod	202-211	plasminogen activator, urokinase receptor	Mus musculus	123-127
32911323-4	2020	In the present study, we revealed that apoptotic cells accumulate in the spleen, macrophage efferocytosis is impaired, and uPAR is increased in the spleen and peritoneal macrophages of the TLR7 agonist imiquimod (IMQ)-induced SLE mouse model.	Imiquimod	202-211	toll-like receptor 7	Mus musculus	189-193
32911323-4	2020	In the present study, we revealed that apoptotic cells accumulate in the spleen, macrophage efferocytosis is impaired, and uPAR is increased in the spleen and peritoneal macrophages of the TLR7 agonist imiquimod (IMQ)-induced SLE mouse model.	Imiquimod	213-216	plasminogen activator, urokinase receptor	Mus musculus	123-127
32911323-4	2020	In the present study, we revealed that apoptotic cells accumulate in the spleen, macrophage efferocytosis is impaired, and uPAR is increased in the spleen and peritoneal macrophages of the TLR7 agonist imiquimod (IMQ)-induced SLE mouse model.	Imiquimod	213-216	toll-like receptor 7	Mus musculus	189-193
33081840-20	2020	Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice.	Imiquimod	31-34	interleukin 6	Mus musculus	92-96
33081840-20	2020	Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice.	Imiquimod	31-34	interleukin 23, alpha subunit p19	Mus musculus	98-104
33081840-20	2020	Daphnetin treatment attenuated IMQ-induced upregulation of inflammatory cytokines including IL-6, IL-23A and IL-17A in skin lesion of mice.	Imiquimod	31-34	interleukin 17A	Mus musculus	109-115
33060784-3	2020	By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6.	Imiquimod	27-36	CD8a molecule	Homo sapiens	172-175
33060784-3	2020	By using a murine model of imiquimod-induced psoriasis-like dermatitis, we further demonstrated that PD-1 deficiency accelerates skin inflammation with activated cytotoxic CD8 T cells into the epidermis, which engage in pathogenic cross-talk with keratinocytes resulting in production of IL-6.	Imiquimod	27-36	interleukin 6	Mus musculus	288-292
33171607-0	2020	A Novel Selective Sphingosine Kinase 2 Inhibitor, HWG-35D, Ameliorates the Severity of Imiquimod-Induced Psoriasis Model by Blocking Th17 Differentiation of Naive CD4 T Lymphocytes.	Imiquimod	87-96	sphingosine kinase 2	Mus musculus	18-38
33171607-6	2020	Topical application of HWG-35D ameliorated IMQ-induced skin lesions and normalized the serum interleukin-17A levels elevated by IMQ.	Imiquimod	128-131	interleukin 17A	Mus musculus	93-108
33146282-0	2020	4"-O-beta-D-glucosyl-5-O-methylvisamminol ameliorates imiquimod-induced psoriasis-like dermatitis and inhibits inflammatory cytokines production by suppressing the NF-kappaB and MAPK signaling pathways.	Imiquimod	54-63	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	164-173
32835761-0	2020	Oxymatrine ameliorates imiquimod-induced psoriasis pruritus and inflammation through inhibiting heat shock protein 90 and heat shock protein 60 expression in keratinocytes.	Imiquimod	23-32	heat shock protein 1 (chaperonin)	Mus musculus	122-143
32569862-4	2020	Here, imiquimod (R837), a TLR 7 agonist, was loaded into mesoporous polydopamine (MPDA) nanocarriers with high efficiency.	Imiquimod	6-15	toll like receptor 7	Homo sapiens	26-31
30610201-5	2020	Prenatal TLR7 activation via administration of the selective agonist imiquimod (5.0 mg/kg) induces a phenotype in offspring characterized by reduced anxiety-like behavior, fragmented social behavior, and altered ultrasonic vocalization patterns at 6-12 weeks of age.	Imiquimod	69-78	toll-like receptor 7	Mus musculus	9-13
32679548-0	2020	Hispidulin alleviates imiquimod-induced psoriasis-like skin inflammation by inhibiting splenic Th1/Th17 cell population and keratinocyte activation.	Imiquimod	22-31	negative elongation factor complex member C/D, Th1l	Mus musculus	95-98
32368827-0	2020	Estrogen receptor alpha activation aggravates imiquimod-induced psoriasis-like dermatitis in mice by enhancing dendritic cell interleukin-23 secretion.	Imiquimod	46-55	estrogen receptor 1 (alpha)	Mus musculus	0-23
32368827-11	2020	Our findings indicate that the activation of ERalpha, but not ERbeta, is directly associated with inflammatory and pruritic responses in a mouse model of the imiquimod-induced psoriasis by enhancing the secretion of IL-23 by dendritic cells.	Imiquimod	158-167	estrogen receptor 1 (alpha)	Mus musculus	45-52
32368827-11	2020	Our findings indicate that the activation of ERalpha, but not ERbeta, is directly associated with inflammatory and pruritic responses in a mouse model of the imiquimod-induced psoriasis by enhancing the secretion of IL-23 by dendritic cells.	Imiquimod	158-167	interleukin 23, alpha subunit p19	Mus musculus	216-221
32294231-5	2020	Additionally, leptin levels also correlate with severity of psoriasis, and knocking out leptin suppresses imiquimod-induced psoriatic inflammation in mice.	Imiquimod	106-115	leptin	Mus musculus	88-94
33205009-6	2020	In contrast, imiquimod broadly upregulates Il17/Il22 and Ccl4/Ccl5.	Imiquimod	13-22	interleukin 17A	Mus musculus	43-47
33205009-6	2020	In contrast, imiquimod broadly upregulates Il17/Il22 and Ccl4/Ccl5.	Imiquimod	13-22	interleukin 22	Mus musculus	48-52
33205009-6	2020	In contrast, imiquimod broadly upregulates Il17/Il22 and Ccl4/Ccl5.	Imiquimod	13-22	chemokine (C-C motif) ligand 4	Mus musculus	57-61
33205009-6	2020	In contrast, imiquimod broadly upregulates Il17/Il22 and Ccl4/Ccl5.	Imiquimod	13-22	chemokine (C-C motif) ligand 5	Mus musculus	62-66
32881074-3	2021	The expression of miR-215-5p was found to be down-regulated in proinflammatory factor-stimulated HaCaT cells and imiquimod (IMQ)-treated skin tissues.	Imiquimod	113-122	microRNA 215	Homo sapiens	18-25
32949628-0	2020	The effect of anti IL-2/IL-2 complex versus stand-alone low dose of IL-2 on Imiquimod induced psoriasis like skin inflammation model.	Imiquimod	76-85	interleukin 2	Mus musculus	24-28
32949628-0	2020	The effect of anti IL-2/IL-2 complex versus stand-alone low dose of IL-2 on Imiquimod induced psoriasis like skin inflammation model.	Imiquimod	76-85	interleukin 2	Mus musculus	24-28
32949628-3	2020	AIM OF THE WORK: The aim of the work is to assess the effect of anti IL2/IL-2 complex versus low dose of IL2 on psoriasis like skin inflammation induced by imiquimod in mouse model and its effect on Treg cells.	Imiquimod	156-165	interleukin 2	Mus musculus	69-72
32949628-3	2020	AIM OF THE WORK: The aim of the work is to assess the effect of anti IL2/IL-2 complex versus low dose of IL2 on psoriasis like skin inflammation induced by imiquimod in mouse model and its effect on Treg cells.	Imiquimod	156-165	interleukin 2	Mus musculus	73-77
32949628-3	2020	AIM OF THE WORK: The aim of the work is to assess the effect of anti IL2/IL-2 complex versus low dose of IL2 on psoriasis like skin inflammation induced by imiquimod in mouse model and its effect on Treg cells.	Imiquimod	156-165	interleukin 2	Mus musculus	105-108
33015527-13	2020	After tumor genomic profiling, a patient who was initially treated with multiple resections and imiquimod was found to have a PIK3CA p.E542K mutation.	Imiquimod	96-105	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha	Homo sapiens	126-132
32887440-3	2020	Here, we report the significance of the mouse antimicrobial cathelicidin, mouse cathelicidin-related antimicrobial peptide (mCRAMP) (an orthologue of LL37 in humans), on the modulation of platelet reactivity during psoriasis using Imiquimod-induced psoriasis in mice as an inflammatory disease model for psoriasis vulgaris in humans.	Imiquimod	231-240	cathelicidin antimicrobial peptide	Mus musculus	124-130
32881074-3	2021	The expression of miR-215-5p was found to be down-regulated in proinflammatory factor-stimulated HaCaT cells and imiquimod (IMQ)-treated skin tissues.	Imiquimod	124-127	microRNA 215	Homo sapiens	18-25
32881074-5	2021	Further, miR-215-5p agomir alleviated the disease severity, pathological features, and Ki67 positive cells in IMQ-treated mice.	Imiquimod	110-113	microRNA 215	Mus musculus	9-16
32881074-5	2021	Further, miR-215-5p agomir alleviated the disease severity, pathological features, and Ki67 positive cells in IMQ-treated mice.	Imiquimod	110-113	antigen identified by monoclonal antibody Ki 67	Mus musculus	87-91
32634696-5	2020	In imiquimod (IMQ)-induced mice, gavage with SSA markedly decreased Psoriasis Area and Severity Index (PASI) score and ameliorated epidermal hyperplasia through inhibition of NF-kappaB and NLRP3 signaling pathway.	Imiquimod	14-17	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	175-184
32524263-3	2020	After treatment with poly(I:C)-LMW, poly (I:C)-LMW/LyoVec, and Imiquimod, the replication of IBV was significantly suppressed after 24 h. However, treatment with TLR3 pathway inhibitors such as Pepinh-TRIF, celastrol, chloroquine, and BX795 resulted in increased replication of IBV after 36 h. These results also showed that chloroquine and celastrol were most effective inhibitors of the antiviral response at 48 hpi.	Imiquimod	63-72	toll like receptor 3	Homo sapiens	162-166
32891181-2	2020	Given its unique attributes, this study was designed to characterize inflammatory skin reactions of this animal to topical application of imiquimod, a toll-like receptor 7 and 8 agonist that triggers psoriasis-like skin reaction.	Imiquimod	138-147	toll-like receptor 7	Heterocephalus glaber	151-177
32846644-4	2020	Imiquimod is an immune-stimulator that activates TLR 7 and can be used to enhance the innate and adaptive immunity.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	49-54
32584520-7	2020	The mRNA expression levels of GRP and GRPR were upregulated in the cervical spinal dorsal horn (SDH) on days 7 and 10 after IMQ application.	Imiquimod	124-127	gastrin releasing peptide receptor	Mus musculus	38-42
32705251-9	2020	Moreover, low levels of CEBPD in the imiquimod-induced mouse model of psoriasis were restored by shikonin treatment, which ameliorated excessive keratinocyte proliferation.	Imiquimod	37-46	CCAAT/enhancer binding protein (C/EBP), delta	Mus musculus	24-29
32584520-8	2020	Either chemogenetic silencing of GRP+ neurons by Gi-DREADD or ablation of GRPR+ neurons significantly attenuated IMQ-induced scratching behaviors.	Imiquimod	113-116	gastrin releasing peptide receptor	Mus musculus	74-78
32584520-3	2020	In this study, we aimed to determine whether itch-responsive GRPR+ neurons contribute to the spinal transmission of imiquimod (IMQ)-induced psoriatic itch.	Imiquimod	116-125	gastrin releasing peptide receptor	Mus musculus	61-65
32584520-3	2020	In this study, we aimed to determine whether itch-responsive GRPR+ neurons contribute to the spinal transmission of imiquimod (IMQ)-induced psoriatic itch.	Imiquimod	127-130	gastrin releasing peptide receptor	Mus musculus	61-65
32298200-4	2020	Indeed, in silico molecular modeling studies predicted that BBIQ had a higher TLR7 docking score and binding free energy than imiquimod, the gold standard TLR7 agonist.	Imiquimod	126-135	toll-like receptor 7	Mus musculus	155-159
32584520-7	2020	The mRNA expression levels of GRP and GRPR were upregulated in the cervical spinal dorsal horn (SDH) on days 7 and 10 after IMQ application.	Imiquimod	124-127	gastrin releasing peptide	Mus musculus	30-33
32954049-7	2021	The results obtained from in vivo tests indicate that these hydrogels could alleviate the symptoms of psoriasis caused by Imiquimod (IMQ) in mice by reducing the inflammatory factor in STAT3 pathway and therefore reduce the immune stimulation of the spleen.	Imiquimod	122-131	signal transducer and activator of transcription 3	Mus musculus	185-190
32954049-7	2021	The results obtained from in vivo tests indicate that these hydrogels could alleviate the symptoms of psoriasis caused by Imiquimod (IMQ) in mice by reducing the inflammatory factor in STAT3 pathway and therefore reduce the immune stimulation of the spleen.	Imiquimod	133-136	signal transducer and activator of transcription 3	Mus musculus	185-190
32706371-18	2020	The production of IFN-gamma, a type II IFN, was decreased in patients in response to stimulation with imiquimod.	Imiquimod	102-111	interferon gamma	Homo sapiens	18-27
32908937-0	2020	The Protective Effects of 18beta-Glycyrrhetinic Acid on Imiquimod-Induced Psoriasis in Mice via Suppression of mTOR/STAT3 Signaling.	Imiquimod	56-65	olfactory receptor family 7 subfamily D member 10	Mus musculus	26-32
32929361-5	2020	Methods: In the present study, the right ear and shaved back skin of wild type and Vsir-/- mice were treated with IMQ for 5 consecutive days to induce psoriasis-like dermatitis.	Imiquimod	114-117	V-set immunoregulatory receptor	Mus musculus	83-87
32535539-0	2020	Complement component 3 prevents imiquimod-induced psoriatic skin inflammation by inhibiting apoptosis in mice.	Imiquimod	32-41	complement component 3	Mus musculus	0-22
32557852-0	2020	C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from gammadelta-T cells.	Imiquimod	19-22	hemolytic complement	Mus musculus	0-3
32557852-0	2020	C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from gammadelta-T cells.	Imiquimod	19-22	complement component 5a receptor 1	Mus musculus	4-9
32557852-0	2020	C5a/C5aR1 mediates IMQ-induced psoriasiform skin inflammation by promoting IL-17A production from gammadelta-T cells.	Imiquimod	19-22	interleukin 17A	Mus musculus	75-81
32557852-11	2020	Consistently, C5aR1 deficiency clearly ameliorated IMQ-induced chronic psoriasiform dermatitis, with a significant decrease in IL-17A expression.	Imiquimod	51-54	complement component 5a receptor 1	Mus musculus	14-19
32306382-11	2020	Subcutaneous injection of IL-33 alleviated the IMQ-induced psoriatic inflammation in mice, reduced tumor necrosis factor (TNF)-alpha and IL-23 expression, and decreased the proportion of T helper (Th)17 cells in the skin-draining lymph nodes in the mice.	Imiquimod	47-50	interleukin 33	Mus musculus	26-31
32598088-3	2020	We have shown that inhibition of Beclin 1, a key activator in the initiation phase of autophagy, attenuates imiquimod (IMQ)-induced epidermal hyperplasia in adult mice as well as naturally occurring hyperproliferation in neonatal mouse epidermis.	Imiquimod	108-117	beclin 1, autophagy related	Mus musculus	33-41
32598088-3	2020	We have shown that inhibition of Beclin 1, a key activator in the initiation phase of autophagy, attenuates imiquimod (IMQ)-induced epidermal hyperplasia in adult mice as well as naturally occurring hyperproliferation in neonatal mouse epidermis.	Imiquimod	119-122	beclin 1, autophagy related	Mus musculus	33-41
32544868-0	2020	2"-fucosyllactose inhibits imiquimod-induced psoriasis in mice by regulating Th17 cell response via the STAT3 signaling pathway.	Imiquimod	27-36	signal transducer and activator of transcription 3	Mus musculus	104-109
32544868-6	2020	Furthermore, we have demonstrated that 2"-FL reduced the phosphorylation of STAT3 in the skin tissue from mice with IMQ stimulation, which could account for the decreasing recruitment of Th17 cells.	Imiquimod	116-119	signal transducer and activator of transcription 3	Mus musculus	76-81
32544868-8	2020	Our results indicate that 2"-FL ameliorates IMQ-induced psoriasis by inhibiting Th17 cell immune response and Th17-related cytokine secretion via modulation of the STAT3 signaling pathway.	Imiquimod	44-47	signal transducer and activator of transcription 3	Mus musculus	164-169
32468061-0	2020	Recombinant programmed cell death 1 inhibits psoriatic inflammation in imiquimod-treated mice.	Imiquimod	71-80	programmed cell death 1	Mus musculus	12-35
32468061-6	2020	PD-1-fragment crystallizable (PD-1-Fc) treatment inhibited psoriatic inflammation and exhibited additive effects with anti-tumor necrosis factor alpha therapy in imiquimod-induced mouse psoriasis, suggesting that PD-1-Fc treatment may serve as a new therapeutic strategy for psoriasis.	Imiquimod	162-171	programmed cell death 1	Mus musculus	0-4
32535539-6	2020	Moreover, blocking apoptosis with Z-VAD-FMK, a broad caspase inhibitor, markedly attenuated imiquimod-induced psoriasis-like skin inflammation and IFN-gamma+ T cell responses in C3-deficient mice.	Imiquimod	92-101	interferon gamma	Mus musculus	147-156
32468061-6	2020	PD-1-fragment crystallizable (PD-1-Fc) treatment inhibited psoriatic inflammation and exhibited additive effects with anti-tumor necrosis factor alpha therapy in imiquimod-induced mouse psoriasis, suggesting that PD-1-Fc treatment may serve as a new therapeutic strategy for psoriasis.	Imiquimod	162-171	programmed cell death 1	Mus musculus	30-34
32468061-6	2020	PD-1-fragment crystallizable (PD-1-Fc) treatment inhibited psoriatic inflammation and exhibited additive effects with anti-tumor necrosis factor alpha therapy in imiquimod-induced mouse psoriasis, suggesting that PD-1-Fc treatment may serve as a new therapeutic strategy for psoriasis.	Imiquimod	162-171	tumor necrosis factor	Mus musculus	123-150
32535539-7	2020	Collectively, our results suggest that C3 prevents imiquimod-induced psoriasis-like skin inflammation by inhibiting apoptosis.	Imiquimod	51-60	complement component 3	Mus musculus	39-41
32468061-6	2020	PD-1-fragment crystallizable (PD-1-Fc) treatment inhibited psoriatic inflammation and exhibited additive effects with anti-tumor necrosis factor alpha therapy in imiquimod-induced mouse psoriasis, suggesting that PD-1-Fc treatment may serve as a new therapeutic strategy for psoriasis.	Imiquimod	162-171	programmed cell death 1	Mus musculus	30-34
32525225-7	2020	In vivo, miR-205-5p significantly alleviated imiquimod (IMQ)-induced psoriasis in mice, and deactivated mitogen-activated protein kinase (MAPK) and Wnt/beta-catenin pathways.	Imiquimod	45-54	microRNA 205	Mus musculus	9-16
32525225-7	2020	In vivo, miR-205-5p significantly alleviated imiquimod (IMQ)-induced psoriasis in mice, and deactivated mitogen-activated protein kinase (MAPK) and Wnt/beta-catenin pathways.	Imiquimod	56-59	microRNA 205	Mus musculus	9-16
32752186-0	2020	Indoleamine 2,3-Dioxygenase 2 Deficiency Exacerbates Imiquimod-Induced Psoriasis-Like Skin Inflammation.	Imiquimod	53-62	indoleamine 2,3-dioxygenase 2	Mus musculus	0-29
32752186-5	2020	In this study, to elucidate the role of IDO2 in psoriasis, we assessed imiquimod (IMQ)-induced psoriasis-like dermatitis in IDO2 knockout (KO) mice.	Imiquimod	71-80	indoleamine 2,3-dioxygenase 2	Mus musculus	124-128
32752186-9	2020	These results suggest that IDO2 might decrease IL-17 expression, thereby resulting in the suppression of skin inflammation in IMQ-induced psoriasis-like dermatitis.	Imiquimod	126-129	indoleamine 2,3-dioxygenase 2	Mus musculus	27-31
32752186-9	2020	These results suggest that IDO2 might decrease IL-17 expression, thereby resulting in the suppression of skin inflammation in IMQ-induced psoriasis-like dermatitis.	Imiquimod	126-129	interleukin 17A	Mus musculus	47-52
32525225-8	2020	In summary, we demonstrated that miR-205-5p alleviated IMQ-induced psoriasis in mice by restraining epidermal hyperproliferation and excessive neovascularization.	Imiquimod	55-58	microRNA 205	Mus musculus	33-40
32707926-0	2020	Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages.	Imiquimod	48-57	lysophosphatidic acid receptor 5	Mus musculus	0-32
32584352-8	2020	STAT3-dependent IL-22 signalling and effects in keratinocytes are negatively regulated by the 310 nm UV-LED, which significantly ameliorated IMQ-induced psoriasis-like dermatitis development and reduced Th17 cytokine levels (IL-17A, IL-22) in serum and dorsal skin.	Imiquimod	141-144	signal transducer and activator of transcription 3	Mus musculus	0-5
32584352-8	2020	STAT3-dependent IL-22 signalling and effects in keratinocytes are negatively regulated by the 310 nm UV-LED, which significantly ameliorated IMQ-induced psoriasis-like dermatitis development and reduced Th17 cytokine levels (IL-17A, IL-22) in serum and dorsal skin.	Imiquimod	141-144	interleukin 22	Mus musculus	16-21
32584352-8	2020	STAT3-dependent IL-22 signalling and effects in keratinocytes are negatively regulated by the 310 nm UV-LED, which significantly ameliorated IMQ-induced psoriasis-like dermatitis development and reduced Th17 cytokine levels (IL-17A, IL-22) in serum and dorsal skin.	Imiquimod	141-144	interleukin 17A	Mus musculus	225-231
32584352-8	2020	STAT3-dependent IL-22 signalling and effects in keratinocytes are negatively regulated by the 310 nm UV-LED, which significantly ameliorated IMQ-induced psoriasis-like dermatitis development and reduced Th17 cytokine levels (IL-17A, IL-22) in serum and dorsal skin.	Imiquimod	141-144	interleukin 22	Mus musculus	233-238
32710000-12	2021	In p16+ patients receiving treatment with imiquimod alone or with surgery, response rates were 100% vs 54% without imiquimod (n = 56; p = 0.017).	Imiquimod	42-51	cyclin dependent kinase inhibitor 2A	Homo sapiens	3-6
32710000-13	2021	In p16- patients receiving treatment with imiquimod alone or with surgery, response rates were 100% vs 56% without imiquimod (n = 17; p = 0.99).	Imiquimod	42-51	cyclin dependent kinase inhibitor 2A	Homo sapiens	3-6
32512223-12	2020	In vitro, resveratrol and its derivatives had comparable ability to inhibit IMQ-induced IL-1beta, IL-6, and CXCL8 secretion in activated keratinocytes.	Imiquimod	76-79	interleukin 1 alpha	Mus musculus	88-96
32512223-12	2020	In vitro, resveratrol and its derivatives had comparable ability to inhibit IMQ-induced IL-1beta, IL-6, and CXCL8 secretion in activated keratinocytes.	Imiquimod	76-79	interleukin 6	Mus musculus	98-102
32707926-0	2020	Lysophosphatidic Acid Receptor 5 Contributes to Imiquimod-Induced Psoriasis-Like Lesions through NLRP3 Inflammasome Activation in Macrophages.	Imiquimod	48-57	NLR family, pyrin domain containing 3	Mus musculus	97-102
32707926-2	2020	Here, we identified lysophosphatidic acid (LPA) receptor 5 (LPA5)-mediated signaling as a novel pathogenic factor in psoriasis using an imiquimod-induced psoriasis mouse model.	Imiquimod	136-145	lysophosphatidic acid receptor 5	Mus musculus	20-58
32707926-2	2020	Here, we identified lysophosphatidic acid (LPA) receptor 5 (LPA5)-mediated signaling as a novel pathogenic factor in psoriasis using an imiquimod-induced psoriasis mouse model.	Imiquimod	136-145	lysophosphatidic acid receptor 5	Mus musculus	60-64
32707926-6	2020	Notably, TCLPA5 administration attenuated the upregulation of macrophage NLRP3 in injured skin of mice with imiquimod-induced psoriasis.	Imiquimod	108-117	NLR family, pyrin domain containing 3	Mus musculus	73-78
32708987-4	2020	The nanohydrogel restored the normal distribution of TJs proteins ZO1 and occludin and reduced the expression of TNF-alpha and inducible nitric oxide synthetase (iNOS) compared to the untreated IMQ group.	Imiquimod	194-197	nitric oxide synthase 2, inducible	Mus musculus	127-160
32708987-4	2020	The nanohydrogel restored the normal distribution of TJs proteins ZO1 and occludin and reduced the expression of TNF-alpha and inducible nitric oxide synthetase (iNOS) compared to the untreated IMQ group.	Imiquimod	194-197	nitric oxide synthase 2, inducible	Mus musculus	162-166
32387475-4	2020	Imiquimod is known as a TLR7 agonist, but additionally acts as an antagonist for adenosine receptors.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	24-28
32708790-10	2020	Primary macrophages responded to imiquimod with increased secretion of IL-10 while isolated VICs did not respond.	Imiquimod	33-42	interleukin 10	Homo sapiens	71-76
32515468-0	2020	Cimifugin ameliorates imiquimod-induced psoriasis by inhibiting oxidative stress and inflammation via NF-kappaB/MAPK pathway.	Imiquimod	22-31	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	102-111
32421901-4	2020	To address this question, we established an emotional stress mouse model induced by empty bottle stimulation, and applied imiquimod (IMQ), a ligand of TLR7/8 and effective potent immune activator, on the dorsal skin to induce psoriasis-like lesions.	Imiquimod	122-131	toll-like receptor 7	Mus musculus	151-157
32421901-4	2020	To address this question, we established an emotional stress mouse model induced by empty bottle stimulation, and applied imiquimod (IMQ), a ligand of TLR7/8 and effective potent immune activator, on the dorsal skin to induce psoriasis-like lesions.	Imiquimod	133-136	toll-like receptor 7	Mus musculus	151-157
32586038-6	2020	Herein, we assessed the therapeutic efficacy of the ABP dendrimer in the preclinical mouse model of psoriasis induced by imiquimod.	Imiquimod	121-130	amine oxidase, copper-containing 1	Mus musculus	52-55
32612613-0	2020	Activation of TLR7 and Innate Immunity as an Efficient Method Against COVID-19 Pandemic: Imiquimod as a Potential Therapy.	Imiquimod	89-98	toll like receptor 7	Homo sapiens	14-18
32655553-9	2020	Adoptively transferred Padi4 KO neutrophils showed decreased migration to the kidneys of IMQ-treated WT mice, and adhesion to ICAM-1 was impaired in Padi4 KO neutrophils.	Imiquimod	89-92	peptidyl arginine deiminase, type IV	Mus musculus	23-28
32655553-12	2020	Neutrophils from heterozygous Jlp KO mice showed impaired adhesion to ICAM-1 and decreased migration to the kidneys of IMQ-treated WT mice.	Imiquimod	119-122	sperm associated antigen 9	Mus musculus	30-33
32556176-0	2021	A double-blind randomized phase 2 controlled trial of intradermal hepatitis B vaccination with a topical Toll-like receptor 7 agonist imiquimod, in patients on dialysis.	Imiquimod	134-143	toll like receptor 7	Homo sapiens	105-125
32556176-11	2021	CONCLUSIONS: Pretreatment with topical imiquimod (TLR7 agonist) before ID HBVv Sci-B-Vac  was safe with favorable seroprotection and as such potentially improved prevention against HBV infection in dialysis patients.	Imiquimod	39-48	toll like receptor 7	Homo sapiens	50-54
32234429-7	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in oxidative stress in neutrophils, and CD11c + DCs in skin/periphery.	Imiquimod	22-25	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	58-61
32234429-7	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in oxidative stress in neutrophils, and CD11c + DCs in skin/periphery.	Imiquimod	22-25	integrin alpha X	Mus musculus	145-150
32234429-8	2020	Therapeutic treatment with Ibrutinib caused attenuation of IMQ-induced oxidative stress in CD11c + DCs and neutrophils.	Imiquimod	59-62	integrin alpha X	Mus musculus	91-96
32234429-9	2020	Further there were dysregulations in antioxidants enzymes (SOD/GPx/GR) in the skin of IMQ-treated mice, which were corrected by Ibrutinib.	Imiquimod	86-89	glutathione reductase	Mus musculus	67-69
32556081-0	2020	Curcumin against imiquimod-induced psoriasis of mice through IL-6/STAT3 signaling pathway.	Imiquimod	17-26	interleukin 6	Mus musculus	61-65
32556081-0	2020	Curcumin against imiquimod-induced psoriasis of mice through IL-6/STAT3 signaling pathway.	Imiquimod	17-26	signal transducer and activator of transcription 3	Mus musculus	66-71
32577560-3	2020	Objective: To screen the effectiveness of a novel IFN-alpha/beta signalling inhibitor in the development reduction of skin lesions in IMQ and TPA mice models of psoriasis.	Imiquimod	134-137	interferon alpha	Mus musculus	50-59
32395072-0	2020	Salvianolic acid B ameliorates psoriatic changes in imiquimod-induced psoriasis on BALB/c mice by inhibiting inflammatory and keratin markers via altering phosphatidylinositol-3-kinase/protein kinase B signaling pathway.	Imiquimod	52-61	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	155-184
32528072-8	2020	Topical application of selective endothelin A receptor (ETAR) antagonist ambrisentan significantly attenuated the development of IMQ-induced psoriasiform dermatitis and also significantly inhibited the histological inflammation and cytokine expression (TNF-alpha, IL-12p40, IL-12 p19, and IL-17) in the lesional skin of the mouse model.	Imiquimod	129-132	endothelin receptor type A	Mus musculus	33-54
32528072-8	2020	Topical application of selective endothelin A receptor (ETAR) antagonist ambrisentan significantly attenuated the development of IMQ-induced psoriasiform dermatitis and also significantly inhibited the histological inflammation and cytokine expression (TNF-alpha, IL-12p40, IL-12 p19, and IL-17) in the lesional skin of the mouse model.	Imiquimod	129-132	endothelin receptor type A	Mus musculus	56-60
32456211-0	2020	Exacerbated Imiquimod-Induced Psoriasis-Like Skin Inflammation in IRF5-Deficient Mice.	Imiquimod	12-21	interferon regulatory factor 5	Mus musculus	66-70
32456211-3	2020	In this study, we investigated the role of IRF5 in psoriasis using imiquimod-induced psoriasis-like dermatitis.	Imiquimod	67-76	interferon regulatory factor 5	Mus musculus	43-47
32456211-8	2020	Taken together, our results suggest that IRF5 deficiency induces the upregulation of IRF4 in DCs followed by augmented IL-23 production, resulting in the amplification of Th17 responses and the exacerbation of imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	210-219	interferon regulatory factor 5	Mus musculus	41-45
32456211-8	2020	Taken together, our results suggest that IRF5 deficiency induces the upregulation of IRF4 in DCs followed by augmented IL-23 production, resulting in the amplification of Th17 responses and the exacerbation of imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	210-219	interferon regulatory factor 4	Mus musculus	85-89
32392912-0	2020	Salvianolic acid B ameliorates psoriatic changes in imiquimod-induced psoriasis on BALB/c mice by inhibiting inflammatory and keratin markers via altering phosphatidylinositol-3-kinase/protein kinase B signaling pathway.	Imiquimod	52-61	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	155-184
32392912-6	2020	Moreover, the protein expression of keratin markers (K16 and K17) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signaling proteins (pAkt/Akt and pPI3K/PI3K) were significantly downregulated after administration with SAB and MTX as compared with IMQ induced mice.	Imiquimod	263-266	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	70-99
32376151-3	2020	IMQ also induces apoptotic and autophagic cell death in various cancers through a TLR7-independent pathway.	Imiquimod	0-3	toll like receptor 7	Homo sapiens	82-86
32376151-12	2020	Pretreatment with the antioxidant NAC reduced IMQ-induced ROS production and attenuated IMQ-induced mitochondrial fission and mitophagy in skin cancer cells.	Imiquimod	46-49	X-linked Kx blood group	Homo sapiens	34-37
32376151-12	2020	Pretreatment with the antioxidant NAC reduced IMQ-induced ROS production and attenuated IMQ-induced mitochondrial fission and mitophagy in skin cancer cells.	Imiquimod	88-91	X-linked Kx blood group	Homo sapiens	34-37
32220586-10	2020	In the cell-based study, IL-1beta inhibition in imiquimod (IMQ)-stimulated keratinocytes was increased following the increase in compound lipophilicity.	Imiquimod	48-57	interleukin 1 alpha	Mus musculus	25-33
32220586-10	2020	In the cell-based study, IL-1beta inhibition in imiquimod (IMQ)-stimulated keratinocytes was increased following the increase in compound lipophilicity.	Imiquimod	59-62	interleukin 1 alpha	Mus musculus	25-33
32395072-6	2020	Moreover, the protein expression of keratin markers (K16 and K17) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (Akt) signaling proteins (pAkt/Akt and pPI3K/PI3K) were significantly downregulated after administration with SAB and MTX as compared with IMQ induced mice.	Imiquimod	263-266	phosphoinositide-3-kinase regulatory subunit 1	Mus musculus	70-99
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	cell division cycle 25A	Mus musculus	54-60
32355189-6	2020	In keratinocytes, IMQ treatment activated TG2, which in turn activated NF-kappaB signaling, leading to the upregulation of IL-6, CCL20, and CXCL8 and increased leukocyte migration, in vitro.	Imiquimod	18-21	interleukin 6	Mus musculus	123-127
32355189-6	2020	In keratinocytes, IMQ treatment activated TG2, which in turn activated NF-kappaB signaling, leading to the upregulation of IL-6, CCL20, and CXCL8 and increased leukocyte migration, in vitro.	Imiquimod	18-21	chemokine (C-C motif) ligand 20	Mus musculus	129-134
32355189-7	2020	Consequently, TG2-deficient mice showed markedly decreased CCR6+ gammadeltaT-cell and neutrophil infiltration in IMQ-treated skin.	Imiquimod	113-116	transglutaminase 2, C polypeptide	Mus musculus	14-17
32355189-4	2020	TG2-deficient mice exhibited reduced psoriatic inflammation in skin treated with IMQ but showed systemic immune responses similar to wild-type mice.	Imiquimod	81-84	transglutaminase 2, C polypeptide	Mus musculus	0-3
32355189-6	2020	In keratinocytes, IMQ treatment activated TG2, which in turn activated NF-kappaB signaling, leading to the upregulation of IL-6, CCL20, and CXCL8 and increased leukocyte migration, in vitro.	Imiquimod	18-21	transglutaminase 2, C polypeptide	Mus musculus	42-45
32355189-6	2020	In keratinocytes, IMQ treatment activated TG2, which in turn activated NF-kappaB signaling, leading to the upregulation of IL-6, CCL20, and CXCL8 and increased leukocyte migration, in vitro.	Imiquimod	18-21	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	71-80
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	134-137
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	172-181
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	cell division cycle 25C	Mus musculus	54-59
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	263-266
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	eukaryotic translation initiation factor 2-alpha kinase 2	Mus musculus	277-286
32236445-10	2020	This phenomenon was accompanied by down-regulation of CDC25A, a phosphatase regulating progression of cell cycle through S phase, and PKR-dependenthyper-phosphorylation of eIF2alpha, an inhibitor of CDC25 translation.In Aldara-treated mice, albendazole activated PKR, enhanced eIF2alpha phosphorylation and reduced CDC25A expression.	Imiquimod	220-226	cell division cycle 25A	Mus musculus	315-321
32398953-6	2020	High-throughput sequencing confirmed that IMQ-induced activation of toll-like receptor 2 (TLR2)/ nuclear factor-kappaB (NF-kappaB) signaling pathway was significantly suppressed in psoriasis-like lesions after topical ozone treatment.	Imiquimod	42-45	toll-like receptor 2	Mus musculus	68-88
32398953-6	2020	High-throughput sequencing confirmed that IMQ-induced activation of toll-like receptor 2 (TLR2)/ nuclear factor-kappaB (NF-kappaB) signaling pathway was significantly suppressed in psoriasis-like lesions after topical ozone treatment.	Imiquimod	42-45	toll-like receptor 2	Mus musculus	90-94
32398953-6	2020	High-throughput sequencing confirmed that IMQ-induced activation of toll-like receptor 2 (TLR2)/ nuclear factor-kappaB (NF-kappaB) signaling pathway was significantly suppressed in psoriasis-like lesions after topical ozone treatment.	Imiquimod	42-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	120-129
32398953-6	2020	High-throughput sequencing confirmed that IMQ-induced activation of toll-like receptor 2 (TLR2)/ nuclear factor-kappaB (NF-kappaB) signaling pathway was significantly suppressed in psoriasis-like lesions after topical ozone treatment.	Imiquimod	42-45	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	97-118
31702822-8	2020	Their effector cell function could be restored by additional peritumoral treatment with the TLR7 agonist imiquimod, a clinically approved agent for nonmelanoma skin cancer.	Imiquimod	105-114	toll-like receptor 7	Mus musculus	92-96
32398957-7	2020	Consistently, in rat ONFH models induced by methylprednisolone (MPSL) and imiquimod (IMI), significant bone loss in the femoral head was observed, attributable to increased numbers of TRAP positive osteoclasts.	Imiquimod	74-83	acid phosphatase 5, tartrate resistant	Rattus norvegicus	184-188
32398957-7	2020	Consistently, in rat ONFH models induced by methylprednisolone (MPSL) and imiquimod (IMI), significant bone loss in the femoral head was observed, attributable to increased numbers of TRAP positive osteoclasts.	Imiquimod	85-88	acid phosphatase 5, tartrate resistant	Rattus norvegicus	184-188
31953037-5	2020	By using the imiquimod-induced cutaneous inflammation model, an exaggerated inflammatory response and impaired epidermal differentiation in Nrf2-/- mice was detected.	Imiquimod	13-22	nuclear factor, erythroid derived 2, like 2	Mus musculus	140-144
31932497-8	2020	No intracellular effect of icIL-1Ra1 could be detected in isolated keratinocytes using RNA-sequencing analysis; however, Aldara treatment led to caspase 1/11-, caspase 8-, and RIPK3-independent keratinocyte cell death accompanied by the release of both icIL-1Ra1 and IL-1alpha.	Imiquimod	121-127	receptor-interacting serine-threonine kinase 3	Mus musculus	176-181
31982823-0	2020	Bruton"s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.	Imiquimod	46-55	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	0-24
31982823-0	2020	Bruton"s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.	Imiquimod	46-55	interleukin 23, alpha subunit p19	Mus musculus	122-127
31982823-0	2020	Bruton"s tyrosine kinase inhibitor suppresses imiquimod-induced psoriasis-like inflammation in mice through regulation of IL-23/IL-17A in innate immune cells.	Imiquimod	46-55	interleukin 17A	Mus musculus	128-134
31982823-6	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in inflammatory cytokines (IL-23, TNF-alpha) in CD11c + DCs in the skin.	Imiquimod	22-25	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	58-61
31982823-6	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in inflammatory cytokines (IL-23, TNF-alpha) in CD11c + DCs in the skin.	Imiquimod	22-25	interleukin 23, alpha subunit p19	Mus musculus	132-137
31982823-6	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in inflammatory cytokines (IL-23, TNF-alpha) in CD11c + DCs in the skin.	Imiquimod	22-25	tumor necrosis factor	Mus musculus	139-148
31982823-6	2020	Our results show that IMQ treatment led to induction of p-BTK expression along with concomitant increase in inflammatory cytokines (IL-23, TNF-alpha) in CD11c + DCs in the skin.	Imiquimod	22-25	integrin alpha X	Mus musculus	153-158
31982823-7	2020	Preventive treatment with BTK inhibitor led to significant reversal in IMQ-induced inflammatory changes in CD11c + DCs of skin.	Imiquimod	71-74	Bruton agammaglobulinemia tyrosine kinase	Mus musculus	26-29
31982823-7	2020	Preventive treatment with BTK inhibitor led to significant reversal in IMQ-induced inflammatory changes in CD11c + DCs of skin.	Imiquimod	71-74	integrin alpha X	Mus musculus	107-112
30897993-8	2020	Topical application of CYC liposomal gels on imiquimod induced psoriatic plaque model reduced the symptoms of psoriasis and levels of key psoriatic cytokines such as tumour necrosis factor-alpha, IL-17, and IL-22.	Imiquimod	45-54	interleukin 22	Homo sapiens	207-212
32106600-0	2020	Transglutaminase 3 Reduces the Severity of Psoriasis in Imiquimod-Treated Mouse Skin.	Imiquimod	56-65	transglutaminase 3, E polypeptide	Mus musculus	0-18
31932497-8	2020	No intracellular effect of icIL-1Ra1 could be detected in isolated keratinocytes using RNA-sequencing analysis; however, Aldara treatment led to caspase 1/11-, caspase 8-, and RIPK3-independent keratinocyte cell death accompanied by the release of both icIL-1Ra1 and IL-1alpha.	Imiquimod	121-127	interleukin 1 alpha	Mus musculus	267-276
31932497-9	2020	Furthermore, blocking IL-1alpha attenuated the clinical severity of Aldara-induced ear thickening in icIL-1Ra1-/- mice.	Imiquimod	68-74	interleukin 1 alpha	Mus musculus	22-31
32059361-0	2020	PDRN, a Bioactive Natural Compound, Ameliorates Imiquimod-Induced Psoriasis through NF-kappaB Pathway Inhibition and Wnt/beta-Catenin Signaling Modulation.	Imiquimod	48-57	nuclear factor kappa B subunit 1	Homo sapiens	84-93
33350987-2	2020	In the present study, we assessed whether intranasal challenge with the TLR7 agonist R-837 additionally activated neurons in the central nervous system.	Imiquimod	85-90	toll like receptor 7	Homo sapiens	72-76
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	158-161	CD4 antigen	Mus musculus	140-143
31773789-5	2020	We found that topical treatment with NG-anti-miR-210 significantly decreased the expression of miR-210 in both the skin lesions and splenic CD4+ T cells from IMQ-induced psoriasis-like mouse models and ameliorated the dermatitis in terms of the erythema, scales, acanthosis and dermal inflammatory cell infiltration in IMQ-induced mice.	Imiquimod	319-322	CD4 antigen	Mus musculus	140-143
31773789-6	2020	In addition, the proportion of T-helper (Th)1 and Th17 cells in dermal and splenic cells of IMQ-treated mice were decreased by application of NG-anti-miR-210, accompanied by decreased interleukin-17A and gamma-interferon mRNA levels.	Imiquimod	92-95	interleukin 17A	Mus musculus	184-199
31773789-6	2020	In addition, the proportion of T-helper (Th)1 and Th17 cells in dermal and splenic cells of IMQ-treated mice were decreased by application of NG-anti-miR-210, accompanied by decreased interleukin-17A and gamma-interferon mRNA levels.	Imiquimod	92-95	interferon gamma	Mus musculus	204-220
31863918-10	2020	In IMQ + acitretin group, the skin lesion severity was slightly relieved, however, immunohistochemistry showed IL-36beta and IL-36gamma expression in keratinocytes significantly declined in comparison with IMQ group.	Imiquimod	3-6	interleukin 36 alpha	Homo sapiens	111-120
33350987-3	2020	Within one hour, R-837 induced activation of the nucleus of the solitary tract, as well as a small increase in nasal IL-6, but otherwise in the absence of an overt inflammatory response.	Imiquimod	17-22	interleukin 6	Homo sapiens	117-121
31407330-12	2019	Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice.	Imiquimod	96-99	interleukin 17A	Mus musculus	42-48
31252033-8	2020	In this study, we demonstrate that signaling via IL-20 receptors, including in response to IL-19, delimited aspects of imiquimod-induced psoriatic inflammation.	Imiquimod	119-128	interleukin 20	Mus musculus	49-54
31252033-8	2020	In this study, we demonstrate that signaling via IL-20 receptors, including in response to IL-19, delimited aspects of imiquimod-induced psoriatic inflammation.	Imiquimod	119-128	interleukin 19	Mus musculus	91-96
31678366-5	2020	Compared to controls, IMQ-treated neutropenic mice had significantly lower levels of macrophages in tissue samples (P < .05) and displayed significantly lower numbers of CD4+ T-cells (P < .05).	Imiquimod	22-25	CD4 antigen	Mus musculus	170-173
31407330-12	2019	Kaempferol also lowered the percentage of IL-17A+ CD4+ T cells in the spleen and lymph nodes of IMQ-induced psoriatic mice.	Imiquimod	96-99	CD4 antigen	Mus musculus	50-53
31393597-2	2019	Employing T-cell epitopes and the TLR7 agonist imiquimod onto intact skin mounts strong primary, but limited memory CTL responses.	Imiquimod	47-56	toll-like receptor 7	Mus musculus	34-38
31599020-3	2019	We experienced a case of eruptive squamous cell carcinoma (SCC) in a patient treated concomitantly with pembrolizumab and imiquimod, a TLR7 agonist.	Imiquimod	122-131	toll like receptor 7	Homo sapiens	135-139
31393597-3	2019	To overcome this limitation, we developed a novel imiquimod-containing vaccination platform (IMI-Sol) rendering superior primary CD8+ and CD4+ T-cell responses.	Imiquimod	50-59	CD4 antigen	Mus musculus	138-141
31502279-1	2019	This animal experiment was framed to evaluate the beneficial effect of ginsenoside Rg1 (GRg1) against imiquimod (IMQ)-induced psoriasis-like dermatitis model to reveal the underpinning mechanism.	Imiquimod	113-116	protein phosphatase 1, regulatory subunit 3A	Mus musculus	83-86
31502279-6	2019	Collectively, GRg1 or DXM treatment significantly abolishes IMQ-induced psoriasis-like dermatitis by lowering PASI score, inflammation through downregulating NF-kappaB signaling pathway.	Imiquimod	60-63	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	158-167
31502279-7	2019	PRACTICAL APPLICATIONS: This is the very first study to explore the efficacy of ginsenoside Rg1 (GRg1) against IMQ-induced psoriasis in the mice model to reveal the underpinning mechanism.	Imiquimod	111-114	protein phosphatase 1, regulatory subunit 3A	Mus musculus	92-95
31401494-10	2019	In mice with IMQ-induced psoriasis, PSORI-CM02 relieved psoriasis symptoms, induced autophagy and inhibited the phosphorylation of the PI3K/AKT/mTOR pathway in the skin.	Imiquimod	13-16	thymoma viral proto-oncogene 1	Mus musculus	140-143
31401494-10	2019	In mice with IMQ-induced psoriasis, PSORI-CM02 relieved psoriasis symptoms, induced autophagy and inhibited the phosphorylation of the PI3K/AKT/mTOR pathway in the skin.	Imiquimod	13-16	mechanistic target of rapamycin kinase	Mus musculus	144-148
31446161-3	2019	However, whether ART functions in psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7/8 agonist) is currently unkown.	Imiquimod	71-80	toll-like receptor 7	Mus musculus	89-95
31288049-10	2019	CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F.	Imiquimod	36-45	negative elongation factor complex member C/D, Th1l	Mus musculus	157-160
31288049-10	2019	CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F.	Imiquimod	36-45	interleukin 23, alpha subunit p19	Mus musculus	271-276
31288049-10	2019	CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F.	Imiquimod	36-45	interleukin 17A	Mus musculus	278-284
31288049-10	2019	CONCLUSION: WBR is effective in the imiquimod-induced psoriasis-like inflammation mouse model with the efficacy arising from its proliferation inhibition of Th1/Th17 cells and epidermal keratinocytes via the down-regulation of the relevant inflammatory cytokines such as IL-23, IL-17A, and IL-17F.	Imiquimod	36-45	interleukin 17F	Mus musculus	290-296
31659208-9	2019	These results indicated that MHP1-AcN could decrease imiquimod-induced IL-6, IL-23 and IL-17A production.	Imiquimod	53-62	interleukin 6	Mus musculus	71-75
31659208-9	2019	These results indicated that MHP1-AcN could decrease imiquimod-induced IL-6, IL-23 and IL-17A production.	Imiquimod	53-62	interleukin 23, alpha subunit p19	Mus musculus	77-82
31659208-9	2019	These results indicated that MHP1-AcN could decrease imiquimod-induced IL-6, IL-23 and IL-17A production.	Imiquimod	53-62	interleukin 17A	Mus musculus	87-93
31446161-3	2019	However, whether ART functions in psoriasis-like dermatitis induced by imiquimod (IMQ, a TLR7/8 agonist) is currently unkown.	Imiquimod	82-85	toll-like receptor 7	Mus musculus	89-95
31362906-8	2019	Anti-IL-17A or IL-23p19 antibody-treated imiquimod-applied mice showed a significant increase in the number of Foxp3+ IL-10+ Tregs.	Imiquimod	41-50	forkhead box P3	Mus musculus	111-116
31260126-4	2019	In this study, we investigated the function of MBL on the course of experimental murine imiquimod (IMQ)-induced psoriasis.	Imiquimod	88-97	mannose-binding lectin (protein C) 2	Mus musculus	47-50
31260126-4	2019	In this study, we investigated the function of MBL on the course of experimental murine imiquimod (IMQ)-induced psoriasis.	Imiquimod	99-102	mannose-binding lectin (protein C) 2	Mus musculus	47-50
31260126-5	2019	Our data showed that MBL-deficient (MBL-/- ) mice exhibited attenuated skin damage characterized by greatly decreased erythema compared with wild-type control mice during the early stages of IMQ-induced psoriasis-like skin inflammation.	Imiquimod	191-194	mannose-binding lectin (protein C) 2	Mus musculus	21-24
31260126-7	2019	Furthermore, we have determined that MBL deficiency limited the chemokine CXCL1 production from skin keratinocytes upon IMQ stimulation, which might be responsible for the impaired skin recruitment of neutrophils.	Imiquimod	120-123	chemokine (C-X-C motif) ligand 1	Mus musculus	74-79
31203155-0	2019	Inhibition of NLRP3 inflammasome-mediated pyroptosis in macrophage by cycloastragenol contributes to amelioration of imiquimod-induced psoriasis-like skin inflammation in mice.	Imiquimod	117-126	NLR family, pyrin domain containing 3	Mus musculus	14-19
31203155-9	2019	Taken together, the results show that CAG selectively modulates macrophage function by inhibiting NLRP3 inflammasome-mediated pyroptosis to ameliorate IMQ-induced psoriasis-like skin inflammation in mice.	Imiquimod	151-154	NLR family, pyrin domain containing 3	Mus musculus	98-103
31362906-0	2019	Anti-IL-17A and IL-23p19 antibodies but not anti-TNFalpha antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.	Imiquimod	155-164	interleukin 17A	Mus musculus	5-11
31362906-0	2019	Anti-IL-17A and IL-23p19 antibodies but not anti-TNFalpha antibody induce expansion of regulatory T cells and restoration of their suppressive function in imiquimod-induced psoriasiform dermatitis.	Imiquimod	155-164	interleukin 23, alpha subunit p19	Mus musculus	16-24
31362906-8	2019	Anti-IL-17A or IL-23p19 antibody-treated imiquimod-applied mice showed a significant increase in the number of Foxp3+ IL-10+ Tregs.	Imiquimod	41-50	interleukin 10	Mus musculus	118-123
31362906-8	2019	Anti-IL-17A or IL-23p19 antibody-treated imiquimod-applied mice showed a significant increase in the number of Foxp3+ IL-10+ Tregs.	Imiquimod	41-50	interleukin 17A	Mus musculus	5-11
31362906-10	2019	Anti-IL-17A or IL-23p19 antibody-induced Tregs significantly increased the number of Foxp3+ cells and IL-10 expression in imiquimod-induced psoriasiform dermatitis in recipient mice but anti-TNFalpha antibody-induced Tregs did not.	Imiquimod	122-131	interleukin 17A	Mus musculus	5-11
31362906-8	2019	Anti-IL-17A or IL-23p19 antibody-treated imiquimod-applied mice showed a significant increase in the number of Foxp3+ IL-10+ Tregs.	Imiquimod	41-50	interleukin 23, alpha subunit p19	Mus musculus	15-23
31362906-10	2019	Anti-IL-17A or IL-23p19 antibody-induced Tregs significantly increased the number of Foxp3+ cells and IL-10 expression in imiquimod-induced psoriasiform dermatitis in recipient mice but anti-TNFalpha antibody-induced Tregs did not.	Imiquimod	122-131	interleukin 23, alpha subunit p19	Mus musculus	15-23
31362906-10	2019	Anti-IL-17A or IL-23p19 antibody-induced Tregs significantly increased the number of Foxp3+ cells and IL-10 expression in imiquimod-induced psoriasiform dermatitis in recipient mice but anti-TNFalpha antibody-induced Tregs did not.	Imiquimod	122-131	forkhead box P3	Mus musculus	85-90
31362906-10	2019	Anti-IL-17A or IL-23p19 antibody-induced Tregs significantly increased the number of Foxp3+ cells and IL-10 expression in imiquimod-induced psoriasiform dermatitis in recipient mice but anti-TNFalpha antibody-induced Tregs did not.	Imiquimod	122-131	interleukin 10	Mus musculus	102-107
31362906-11	2019	CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis.	Imiquimod	154-163	interleukin 17A	Mus musculus	17-23
31362906-11	2019	CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis.	Imiquimod	154-163	interleukin 23, alpha subunit p19	Mus musculus	27-35
31362906-11	2019	CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis.	Imiquimod	154-163	interleukin 17A	Mus musculus	17-22
31362906-11	2019	CONCLUSION: Anti-IL-17A or IL-23p19 antibody inhibits the IL-17/IL-23 signaling pathway, and induces expansion of Tregs and their suppressive capacity in imiquimod-induced psoriasiform dermatitis.	Imiquimod	154-163	interleukin 23, alpha subunit p19	Mus musculus	27-32
31136945-0	2019	Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.	Imiquimod	0-9	C-C motif chemokine ligand 2	Homo sapiens	80-85
31136945-0	2019	Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.	Imiquimod	0-9	interleukin 6	Homo sapiens	87-91
31136945-0	2019	Imiquimod and interferon-alpha augment monocyte-mediated astrocyte secretion of MCP-1, IL-6 and IP-10 in a human co-culture system.	Imiquimod	0-9	C-X-C motif chemokine ligand 10	Homo sapiens	96-101
31447855-3	2019	In our study, we observed that expression of complement component 5a receptor 1(C5aR1) was significantly increased in skin lesions of both imiquimod (IMQ) and IL23-induced psoriatic mice and patients with psoriasis.	Imiquimod	139-148	complement component 5a receptor 1	Mus musculus	45-79
31447855-3	2019	In our study, we observed that expression of complement component 5a receptor 1(C5aR1) was significantly increased in skin lesions of both imiquimod (IMQ) and IL23-induced psoriatic mice and patients with psoriasis.	Imiquimod	139-148	complement component 5a receptor 1	Mus musculus	80-85
31447855-3	2019	In our study, we observed that expression of complement component 5a receptor 1(C5aR1) was significantly increased in skin lesions of both imiquimod (IMQ) and IL23-induced psoriatic mice and patients with psoriasis.	Imiquimod	150-153	complement component 5a receptor 1	Mus musculus	45-79
31447855-3	2019	In our study, we observed that expression of complement component 5a receptor 1(C5aR1) was significantly increased in skin lesions of both imiquimod (IMQ) and IL23-induced psoriatic mice and patients with psoriasis.	Imiquimod	150-153	complement component 5a receptor 1	Mus musculus	80-85
31182284-0	2019	Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIgamma expression in keratinocytes.	Imiquimod	35-44	regenerating family member 3 alpha	Homo sapiens	98-103
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	complement component 5a receptor 1	Mus musculus	10-15
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	interferon alpha 1	Homo sapiens	280-289
31182284-0	2019	Ginsenoside compound K ameliorates imiquimod-induced psoriasis-like dermatitis through inhibiting REG3A/RegIIIgamma expression in keratinocytes.	Imiquimod	35-44	regenerating family member 3 gamma	Homo sapiens	104-115
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	tumor necrosis factor	Homo sapiens	295-322
31182284-13	2019	CONCLUSION: Ginsenoside CK ameliorated IMQ-induced psoriasis-like dermatitis possibly through inhibiting REG3A/RegIIIgamma expression in keratinocytes, which highlighted a therapeutic potential of ginsenoside CK in psoriasis.	Imiquimod	39-42	regenerating family member 3 alpha	Homo sapiens	105-110
31182284-13	2019	CONCLUSION: Ginsenoside CK ameliorated IMQ-induced psoriasis-like dermatitis possibly through inhibiting REG3A/RegIIIgamma expression in keratinocytes, which highlighted a therapeutic potential of ginsenoside CK in psoriasis.	Imiquimod	39-42	regenerating family member 3 gamma	Homo sapiens	111-122
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	tumor necrosis factor	Homo sapiens	324-333
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	340-373
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	51-54	fms related receptor tyrosine kinase 3 ligand	Homo sapiens	375-380
31447855-5	2019	Moreover, C5aR1 deficiency significantly decreased IMQ-induced infiltration of plasmacytoid dendritic cells (pDCs), monocytes and neutrophils in psoriatic skin lesions and functions of pDCs, evidenced by the remarkable reduction in the IMQ-induced production of interferon-alpha (IFN-alpha) and tumor necrosis factor alpha (TNF-alpha), and FMS-like tyrosine kinase 3 ligand (FLT3L)-dependent pDCs differentiation.	Imiquimod	236-239	complement component 5a receptor 1	Mus musculus	10-15
30738055-5	2019	Genetic deletion or IL-17E neutralization ameliorated skin inflammation induced by imiquimod application or tape stripping, with reductions in neutrophil and macrophage infiltration as assessed by t-distributed stochastic neighbor embedding-guided multiparameter flow cytometry analysis, in mice.	Imiquimod	83-92	interleukin 25	Mus musculus	20-26
31384541-2	2019	Herein, a chemo-immunotherapy was developed by encapsulating chemotherapeutic drug doxorubicin (DOX) and Toll-like receptor 7 agonist imiquimod (IMQ) in low molecular weight heparin (LMWH)-d-alpha-tocopheryl succinate (TOS) micelles (LT).	Imiquimod	134-143	toll like receptor 7	Homo sapiens	105-125
31319488-5	2019	In addition, we also found that withanolides suppressed the activation of STAT3, ERK1/2 and P38 signaling pathways in IMQ-stimulated HaCat cells.	Imiquimod	118-121	signal transducer and activator of transcription 3	Homo sapiens	74-79
31319488-5	2019	In addition, we also found that withanolides suppressed the activation of STAT3, ERK1/2 and P38 signaling pathways in IMQ-stimulated HaCat cells.	Imiquimod	118-121	mitogen-activated protein kinase 3	Homo sapiens	81-87
31319488-5	2019	In addition, we also found that withanolides suppressed the activation of STAT3, ERK1/2 and P38 signaling pathways in IMQ-stimulated HaCat cells.	Imiquimod	118-121	mitogen-activated protein kinase 1	Homo sapiens	92-95
31384541-2	2019	Herein, a chemo-immunotherapy was developed by encapsulating chemotherapeutic drug doxorubicin (DOX) and Toll-like receptor 7 agonist imiquimod (IMQ) in low molecular weight heparin (LMWH)-d-alpha-tocopheryl succinate (TOS) micelles (LT).	Imiquimod	145-148	toll like receptor 7	Homo sapiens	105-125
30913451-4	2019	Studies in imiquimod (IMQ)-induced mice with psoriatic inflammation confirmed a critical role for IL-33 in driving the disease.	Imiquimod	11-20	interleukin 33	Mus musculus	98-103
31111189-5	2019	Incubation of 21 recombinant human CYP enzymes with 0.5 microM IMQ and subsequent LC-MS analyses, in fact, identified CYP1A1 and CYP1A2 as being predominantly responsible for IMQ metabolism.	Imiquimod	63-66	cytochrome P450 family 4 subfamily F member 3	Homo sapiens	35-38
31111189-5	2019	Incubation of 21 recombinant human CYP enzymes with 0.5 microM IMQ and subsequent LC-MS analyses, in fact, identified CYP1A1 and CYP1A2 as being predominantly responsible for IMQ metabolism.	Imiquimod	63-66	cytochrome P450 family 1 subfamily A member 1	Homo sapiens	118-124
31111189-5	2019	Incubation of 21 recombinant human CYP enzymes with 0.5 microM IMQ and subsequent LC-MS analyses, in fact, identified CYP1A1 and CYP1A2 as being predominantly responsible for IMQ metabolism.	Imiquimod	63-66	cytochrome P450 family 1 subfamily A member 2	Homo sapiens	129-135
31111189-8	2019	Further studies with hepatic microsomes from CD-1 as well as solvent- and beta-naphthoflavone-treated CYP1A1/CYP1A2 double knock-out and respective control mice confirmed the critical contribution of CYP1A isoforms to IMQ metabolism.	Imiquimod	218-221	cytochrome P450, family 1, subfamily a, polypeptide 2	Mus musculus	109-115
31111189-9	2019	Hence, an exposure to life style-related, dietary, and environmental AHR ligands may affect the pharmacokinetics and, thus, treatment efficacy of IMQ.	Imiquimod	146-149	aryl hydrocarbon receptor	Homo sapiens	69-72
30913451-4	2019	Studies in imiquimod (IMQ)-induced mice with psoriatic inflammation confirmed a critical role for IL-33 in driving the disease.	Imiquimod	22-25	interleukin 33	Mus musculus	98-103
30913451-5	2019	IL-33 reduces the CD4+ and CD8+ cells, inhibits autophagy in IMQ-treated mouse skin, and promoted tyrosyl phosphorylation of STAT3.	Imiquimod	61-64	interleukin 33	Mus musculus	0-5
31005038-1	2019	Imiquimod (Imiq) is a synthetic imizoquinoline compound which can act on Toll-like receptor (TLR)7 and transduce signals involved in cell activation.	Imiquimod	0-9	toll-like receptor 7	Mus musculus	93-98
31005038-1	2019	Imiquimod (Imiq) is a synthetic imizoquinoline compound which can act on Toll-like receptor (TLR)7 and transduce signals involved in cell activation.	Imiquimod	0-4	toll-like receptor 7	Mus musculus	93-98
31075711-8	2019	In addition, the activation of JAK/STAT3 downregulates CEBPD in HaCaT cells and IMQ-induced BALB/c mice.	Imiquimod	80-83	signal transducer and activator of transcription 3	Homo sapiens	35-40
31181689-8	2019	Besides, EPD decreased the imiquimod-induced expression levels of TLR7, TLR8, TRAF6, MyD88, p-IKKalpha, p-IKBalpha, p-NF-kappaB, NLRP3, apoptosis-associated speck-like protein contained a caspase recruitment domain (ASC), cysteinyl aspartate specific proteinase 1 (caspase-1), and IL-1beta.	Imiquimod	27-36	myeloid differentiation primary response gene 88	Mus musculus	85-90
31111624-0	2019	Transient receptor potential ankyrin 1 (TRPA1) positively regulates imiquimod-induced, psoriasiform dermal inflammation in mice.	Imiquimod	68-77	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-38
31111624-0	2019	Transient receptor potential ankyrin 1 (TRPA1) positively regulates imiquimod-induced, psoriasiform dermal inflammation in mice.	Imiquimod	68-77	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	40-45
31111624-5	2019	Compared with WT mice, clinical scores, skin thickness change and TEWL scores were similar on day 3, but were significantly decreased on day 5 in IMQ-treated TRPA1 KO mice (vs WT mice), suggesting reduced inflammation and skin barrier defects.	Imiquimod	146-149	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	158-163
31181689-8	2019	Besides, EPD decreased the imiquimod-induced expression levels of TLR7, TLR8, TRAF6, MyD88, p-IKKalpha, p-IKBalpha, p-NF-kappaB, NLRP3, apoptosis-associated speck-like protein contained a caspase recruitment domain (ASC), cysteinyl aspartate specific proteinase 1 (caspase-1), and IL-1beta.	Imiquimod	27-36	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	118-127
31175175-6	2019	Il17rd deficiency in nonhemopoietic cells attenuated imiquimod-induced psoriasis-like skin inflammation.	Imiquimod	53-62	interleukin 17 receptor D	Homo sapiens	0-6
31181689-8	2019	Besides, EPD decreased the imiquimod-induced expression levels of TLR7, TLR8, TRAF6, MyD88, p-IKKalpha, p-IKBalpha, p-NF-kappaB, NLRP3, apoptosis-associated speck-like protein contained a caspase recruitment domain (ASC), cysteinyl aspartate specific proteinase 1 (caspase-1), and IL-1beta.	Imiquimod	27-36	NLR family, pyrin domain containing 3	Mus musculus	129-134
31181689-9	2019	CONCLUSION: This study demonstrated that EPD exhibited a protective effect on an imiquimod-induced psoriasis mice model by inhibiting the inflammatory response, which might be ascribed to the inhibition of the TLR7/8-MyD88-NF-kappab-NLRP3 inflammasome pathway.	Imiquimod	81-90	toll-like receptor 7	Mus musculus	210-216
31181689-9	2019	CONCLUSION: This study demonstrated that EPD exhibited a protective effect on an imiquimod-induced psoriasis mice model by inhibiting the inflammatory response, which might be ascribed to the inhibition of the TLR7/8-MyD88-NF-kappab-NLRP3 inflammasome pathway.	Imiquimod	81-90	myeloid differentiation primary response gene 88	Mus musculus	217-222
30615272-2	2019	The use of Aldara  , a cream that contains the TLR7 and TLR8 agonist imiquimod (IMQ), was found to exacerbate psoriasis in some patients with pre-existing disease.	Imiquimod	11-17	toll like receptor 7	Homo sapiens	47-51
31048012-3	2019	The aim of this work was to assess whether employing the TLR7 agonist imiquimod and the T-cell costimulatory molecule CD40 or the combination of both as adjuvants of a cell lysate vaccine could enhance the antitumor immune response using a murine T-cell lymphoma model.	Imiquimod	70-79	toll-like receptor 7	Mus musculus	57-61
30615272-2	2019	The use of Aldara  , a cream that contains the TLR7 and TLR8 agonist imiquimod (IMQ), was found to exacerbate psoriasis in some patients with pre-existing disease.	Imiquimod	11-17	toll like receptor 8	Homo sapiens	56-60
30615272-2	2019	The use of Aldara  , a cream that contains the TLR7 and TLR8 agonist imiquimod (IMQ), was found to exacerbate psoriasis in some patients with pre-existing disease.	Imiquimod	69-78	toll like receptor 8	Homo sapiens	56-60
30615272-2	2019	The use of Aldara  , a cream that contains the TLR7 and TLR8 agonist imiquimod (IMQ), was found to exacerbate psoriasis in some patients with pre-existing disease.	Imiquimod	80-83	toll like receptor 8	Homo sapiens	56-60
30615272-3	2019	Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease.	Imiquimod	59-65	interleukin 17A	Mus musculus	254-260
30615272-3	2019	Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease.	Imiquimod	59-65	interleukin 22	Mus musculus	262-267
30615272-3	2019	Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease.	Imiquimod	66-69	interleukin 17A	Mus musculus	254-260
30615272-3	2019	Intradermal injections of IL-23 and topical application of Aldara/IMQ induce skin inflammation in mice with features similar to psoriasis-including epidermal hyperplasia and accumulation of inflammatory cells in epidermis and dermis-which is mediated by IL-17A, IL-22, and other factors implicated in the human disease.	Imiquimod	66-69	interleukin 22	Mus musculus	262-267
30834454-4	2019	Both topical ceramidase and sphingosine kinase 1/2 inhibition, which blocks S1P generation, alleviated imiquimod-induced skin lesions and reduced the serum interleukin 17-A levels induced by application of imiquimod.	Imiquimod	103-112	sphingosine kinase 1	Mus musculus	28-50
30776434-8	2019	Administration of anti-IL-17A monoclonal antibody improved hyperglycemia in patients with psoriasis and imiquimod-treated mice with psoriasiform features.	Imiquimod	104-113	interleukin 17A	Homo sapiens	23-29
30834454-4	2019	Both topical ceramidase and sphingosine kinase 1/2 inhibition, which blocks S1P generation, alleviated imiquimod-induced skin lesions and reduced the serum interleukin 17-A levels induced by application of imiquimod.	Imiquimod	206-215	sphingosine kinase 1	Mus musculus	28-50
30834454-4	2019	Both topical ceramidase and sphingosine kinase 1/2 inhibition, which blocks S1P generation, alleviated imiquimod-induced skin lesions and reduced the serum interleukin 17-A levels induced by application of imiquimod.	Imiquimod	206-215	interleukin 17A	Mus musculus	156-172
30834454-6	2019	Inhibition of sphingosine kinase 2, but not sphingosine kinase 1, diminished levels of suppressor of cytokine signalling 1 and blocked T helper type 17 differentiation of naive CD4+ T cells; imiquimod-induced psoriasis-like skin symptoms were also ameliorated.	Imiquimod	191-200	sphingosine kinase 2	Mus musculus	14-34
30834454-6	2019	Inhibition of sphingosine kinase 2, but not sphingosine kinase 1, diminished levels of suppressor of cytokine signalling 1 and blocked T helper type 17 differentiation of naive CD4+ T cells; imiquimod-induced psoriasis-like skin symptoms were also ameliorated.	Imiquimod	191-200	CD4 antigen	Mus musculus	177-180
30684554-0	2019	Imiquimod-Induced Psoriasis in Mice Depends on the IL-17 Signaling of Keratinocytes.	Imiquimod	0-9	interleukin 17A	Mus musculus	51-56
30779113-6	2019	Upon stimulation with IMQ, TC-Mphi did not upregulate major histocompatibility complex (MHC II) molecules and unexpectedly expressed increased CD206.	Imiquimod	22-25	mannose receptor C-type 1	Homo sapiens	143-148
30902899-7	2019	To verify this hypothesis, we investigated the effects of sulfated CCK octapeptide (CCK8S) on the development of IMQ-induced psoriatic inflammation.	Imiquimod	113-116	cholecystokinin	Homo sapiens	67-70
30850088-0	2019	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline epsilon transcription through the induction of BCL6 expression in B cells.	Imiquimod	17-26	toll-like receptor 7	Mus musculus	4-8
30902899-9	2019	injection of CCK8S suppressed the IMQ-induced psoriatic inflammation accompanied by reduced mRNA expression of IL-17, IL-22, and IL-6 but not of IL-23.	Imiquimod	34-37	interleukin 17A	Homo sapiens	111-116
30902899-9	2019	injection of CCK8S suppressed the IMQ-induced psoriatic inflammation accompanied by reduced mRNA expression of IL-17, IL-22, and IL-6 but not of IL-23.	Imiquimod	34-37	interleukin 22	Homo sapiens	118-123
30902899-9	2019	injection of CCK8S suppressed the IMQ-induced psoriatic inflammation accompanied by reduced mRNA expression of IL-17, IL-22, and IL-6 but not of IL-23.	Imiquimod	34-37	interleukin 6	Homo sapiens	129-133
30995480-4	2019	We report an investigation in cellular targets of IL-38 during the progression of imiquimod-induced psoriasis.	Imiquimod	82-91	interleukin 1 family member 10	Homo sapiens	50-55
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	141-150	deoxyribonuclease I	Mus musculus	87-94
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	141-150	interleukin 17A	Mus musculus	204-210
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	141-150	lipocalin 2	Mus musculus	212-222
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	141-150	lipocalin 2	Mus musculus	224-228
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	141-150	interleukin 36G	Mus musculus	235-241
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	152-155	deoxyribonuclease I	Mus musculus	87-94
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	152-155	interleukin 17A	Mus musculus	204-210
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	152-155	lipocalin 2	Mus musculus	212-222
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	152-155	lipocalin 2	Mus musculus	224-228
31024570-3	2019	This activation is dependent upon NETs formation and integrity, as targeting NETs with DNase I or CI-amidine in vivo improves disease in the imiquimod (IMQ)-induced psoriasis-like mouse model, decreasing IL-17A, lipocalin2 (LCN2), and IL-36G expression.	Imiquimod	152-155	interleukin 36G	Mus musculus	235-241
30850088-0	2019	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline epsilon transcription through the induction of BCL6 expression in B cells.	Imiquimod	17-26	interleukin 4	Mus musculus	48-52
30850088-0	2019	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline epsilon transcription through the induction of BCL6 expression in B cells.	Imiquimod	17-26	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	91-95
30850088-0	2019	The TLR7 agonist imiquimod selectively inhibits IL-4-induced IgE production by suppressing IgG1/IgE class switching and germline epsilon transcription through the induction of BCL6 expression in B cells.	Imiquimod	17-26	B cell leukemia/lymphoma 6	Mus musculus	176-180
30850088-1	2019	Imiquimod (IMQ) is a selective toll-like receptor 7 (TLR7) agonist.	Imiquimod	0-9	toll-like receptor 7	Mus musculus	31-51
30850088-1	2019	Imiquimod (IMQ) is a selective toll-like receptor 7 (TLR7) agonist.	Imiquimod	0-9	toll-like receptor 7	Mus musculus	53-57
30850088-1	2019	Imiquimod (IMQ) is a selective toll-like receptor 7 (TLR7) agonist.	Imiquimod	11-14	toll-like receptor 7	Mus musculus	31-51
30850088-1	2019	Imiquimod (IMQ) is a selective toll-like receptor 7 (TLR7) agonist.	Imiquimod	11-14	toll-like receptor 7	Mus musculus	53-57
30850088-5	2019	IMQ selectively diminished IL-4-induced IgE and IgG1 production in anti-CD40-activated mouse B cells.	Imiquimod	0-3	interleukin 4	Mus musculus	27-31
30850088-5	2019	IMQ selectively diminished IL-4-induced IgE and IgG1 production in anti-CD40-activated mouse B cells.	Imiquimod	0-3	immunoglobulin heavy constant gamma 1 (G1m marker)	Mus musculus	48-52
30743203-5	2019	It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23.	Imiquimod	54-57	tumor necrosis factor	Mus musculus	270-279
30743203-5	2019	It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23.	Imiquimod	54-57	chemokine (C-C motif) ligand 2	Mus musculus	302-306
30743203-5	2019	It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23.	Imiquimod	54-57	interleukin 17A	Mus musculus	309-314
30743203-5	2019	It was found that genistein can significantly improve IMQ-induced pathological scores of cutaneous skin lesions in mice, reduce epidermal thickness, and inhibit the expression of inflammatory factors,including interleukin (IL)-1beta, IL-6, tumour necrosis factor-alpha (TNF-alpha), chemokine ligand 2 (CCL2), IL-17 and IL-23.	Imiquimod	54-57	interleukin 23, alpha subunit p19	Mus musculus	319-324
30741833-4	2019	METHODS: WT and IL-18 KO mice were divided into four groups, including imiquimod (IMQ)-treated IL-18 KO group (n = 11) and WT group (n = 13) as well as their respectively gene-matched control mice (receiving vaseline; n = 12).	Imiquimod	82-85	interleukin 18	Mus musculus	95-100
30935778-5	2019	METHODS: We addressed the role of the GPR15 L/GPR15 in the Aldara -induced psoriasiform dermatitis (AIPD) and the IL-23-induced dermatitis model.	Imiquimod	59-65	G protein-coupled receptor 15	Mus musculus	38-43
30935778-5	2019	METHODS: We addressed the role of the GPR15 L/GPR15 in the Aldara -induced psoriasiform dermatitis (AIPD) and the IL-23-induced dermatitis model.	Imiquimod	59-65	G protein-coupled receptor 15	Mus musculus	46-51
31167692-1	2019	Objective To investigate the role of interleukin 20 receptor 2 (IL-20R2) family signaling pathway in psoriasis via imiquimod (IMQ) treatment.	Imiquimod	115-124	interleukin 20 receptor beta	Mus musculus	37-62
31167692-1	2019	Objective To investigate the role of interleukin 20 receptor 2 (IL-20R2) family signaling pathway in psoriasis via imiquimod (IMQ) treatment.	Imiquimod	115-124	interleukin 20 receptor beta	Mus musculus	64-71
31167692-1	2019	Objective To investigate the role of interleukin 20 receptor 2 (IL-20R2) family signaling pathway in psoriasis via imiquimod (IMQ) treatment.	Imiquimod	126-129	interleukin 20 receptor beta	Mus musculus	37-62
31167692-1	2019	Objective To investigate the role of interleukin 20 receptor 2 (IL-20R2) family signaling pathway in psoriasis via imiquimod (IMQ) treatment.	Imiquimod	126-129	interleukin 20 receptor beta	Mus musculus	64-71
31167692-6	2019	Results Compared with wild type IL-20R2+/+mice, the IL-20R2-/- mice showed lower levels of both IL-20R2 protein and mRNA in the skin tissue, also exhibited a markedly less pathological changes after IMQ induction.	Imiquimod	199-202	interleukin 20 receptor beta	Mus musculus	52-59
31167692-6	2019	Results Compared with wild type IL-20R2+/+mice, the IL-20R2-/- mice showed lower levels of both IL-20R2 protein and mRNA in the skin tissue, also exhibited a markedly less pathological changes after IMQ induction.	Imiquimod	199-202	interleukin 20 receptor beta	Mus musculus	52-59
31167692-7	2019	Conclusion Knockdown of IL-20R2 gene can inhibit the development of psoriasis induced by IMQ in mice.	Imiquimod	89-92	interleukin 20 receptor beta	Mus musculus	24-31
30741833-10	2019	IMQ-induced IL-18 KO mice manifested larger areas of Munro microabscesses (11,467.83 +- 5112.09 vs. 4093.19 +- 2591.88 mum, P &lt; 0.01) and scales (100,935.24 +- 41,167.77 vs. 41,604.41 +- 14,184.10 mum, P &lt; 0.01) as compared with WT mice.	Imiquimod	0-3	interleukin 18	Mus musculus	12-17
30741833-13	2019	CONCLUSIONS: IL-18 may exacerbate prominent inflammation and influence pathological features in IMQ-induced mouse model of psoriasis.	Imiquimod	96-99	interleukin 18	Mus musculus	13-18
30551443-0	2019	Rutaecarpine inhibited imiquimod-induced psoriasis-like dermatitis via inhibiting the NF-kappaB and TLR7 pathways in mice.	Imiquimod	23-32	toll-like receptor 7	Mus musculus	100-104
30593001-6	2019	Our data show that R406 causes attenuation of IMQ-induced dermal inflammation as shown by reduction in ear/back skin thickness, acanthosis and myeloperoxidase activity.	Imiquimod	46-49	myeloperoxidase	Mus musculus	143-158
30593001-10	2019	IMQ-induced IL-6/IL-23 levels were significantly diminished by SYK inhibitor, R406 in splenocytic cultures.	Imiquimod	0-3	interleukin 6	Mus musculus	12-16
30593001-10	2019	IMQ-induced IL-6/IL-23 levels were significantly diminished by SYK inhibitor, R406 in splenocytic cultures.	Imiquimod	0-3	interleukin 23, alpha subunit p19	Mus musculus	17-22
30593001-10	2019	IMQ-induced IL-6/IL-23 levels were significantly diminished by SYK inhibitor, R406 in splenocytic cultures.	Imiquimod	0-3	spleen tyrosine kinase	Mus musculus	63-66
30718736-4	2019	Ghrelin expression was reduced in both the OXA-induced contact dermatitis and IMQ-induced psoriasis mouse models.	Imiquimod	78-81	ghrelin	Mus musculus	0-7
30513504-0	2019	PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3.	Imiquimod	22-25	heart and neural crest derivatives expressed 2	Mus musculus	131-134
30513504-0	2019	PSORI-CM02 alleviates IMQ-induced mouse dermatitis via differentially regulating pro- and anti-inflammatory cytokines targeting of Th2 specific transcript factor GATA3.	Imiquimod	22-25	GATA binding protein 3	Mus musculus	162-167
30513504-12	2019	Thus, we tentatively interpret that PSORI-CM02 impairs IMQ-induced psoriasis by promoting Th2 cell response targeting of GATA3.	Imiquimod	55-58	heart and neural crest derivatives expressed 2	Mus musculus	90-93
30513504-12	2019	Thus, we tentatively interpret that PSORI-CM02 impairs IMQ-induced psoriasis by promoting Th2 cell response targeting of GATA3.	Imiquimod	55-58	GATA binding protein 3	Mus musculus	121-126
30372845-7	2018	In addition, DTF was more efficient than etanercept in reducing the expression of keratins, decreasing the mRNA expression of Ly-6 G and Ly-6C, and enhancing the expression of filaggrin and caspase 14 in IMQ-induced psoriasis-like skin.	Imiquimod	204-207	caspase 14	Mus musculus	190-200
30481683-0	2019	ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.	Imiquimod	32-41	mitogen-activated protein kinase 1	Mus musculus	0-3
30481683-0	2019	ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.	Imiquimod	32-41	mitogen-activated protein kinase 1	Mus musculus	71-74
30481683-0	2019	ERK inhibitor JSI287 alleviates imiquimod-induced mice skin lesions by ERK/IL-17 signaling pathway.	Imiquimod	32-41	interleukin 17A	Mus musculus	75-80
30481683-6	2019	In this study, a small synthetic molecule JSI287 was found with the function of alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway during the screening of small molecule databases targeting ERK.	Imiquimod	92-95	mitogen-activated protein kinase 1	Mus musculus	130-133
30481683-6	2019	In this study, a small synthetic molecule JSI287 was found with the function of alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway during the screening of small molecule databases targeting ERK.	Imiquimod	92-95	interleukin 17A	Mus musculus	134-139
30481683-6	2019	In this study, a small synthetic molecule JSI287 was found with the function of alleviating IMQ-induced mice skin lesions through ERK/IL-17 signaling pathway during the screening of small molecule databases targeting ERK.	Imiquimod	92-95	mitogen-activated protein kinase 1	Mus musculus	217-220
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	toll-like receptor 7	Mus musculus	41-45
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	interleukin 1 beta	Mus musculus	109-116
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	interleukin 6	Mus musculus	118-121
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	chemokine (C-X-C motif) ligand 1	Mus musculus	123-128
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	22-31	matrix metallopeptidase 10	Mus musculus	181-186
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	toll-like receptor 7	Mus musculus	41-45
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	interleukin 1 beta	Mus musculus	109-116
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	interleukin 6	Mus musculus	118-121
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	chemokine (C-X-C motif) ligand 1	Mus musculus	123-128
30564235-2	2018	Cutaneous exposure to Imiquimod (IMQ), a TLR7 agonist, induced acute expression of pro-inflammatory factors (IL1beta, IL6, CXCL1) and neutrophil influx equally in both wildtype and Mmp10 -/- mice.	Imiquimod	33-36	matrix metallopeptidase 10	Mus musculus	181-186
30009832-3	2019	Here, we show that CRNN expression was increased in the lesioned epidermis from the patients with psoriasis vulgaris and skin lesions from the imiquimod (IMQ)-treated mice.	Imiquimod	154-157	cornulin	Homo sapiens	19-23
30120937-3	2019	Here, we show that IL-1beta is significantly elevated in psoriatic lesional skin and imiquimod-treated mouse skin.	Imiquimod	85-94	interleukin 1 beta	Mus musculus	19-27
30372845-8	2018	We conclude that DTF alleviates IMQ-induced psoriasis by attenuating inflammatory cascades, reducing keratinocytes proliferation and improving epidermal barrier function through suppressing TNF-alpha and IL-17 A signal pathways.	Imiquimod	32-35	tumor necrosis factor	Mus musculus	190-199
30372845-8	2018	We conclude that DTF alleviates IMQ-induced psoriasis by attenuating inflammatory cascades, reducing keratinocytes proliferation and improving epidermal barrier function through suppressing TNF-alpha and IL-17 A signal pathways.	Imiquimod	32-35	interleukin 17A	Mus musculus	204-211
30527377-2	2018	OBJECTIVE: To investigate the function of TRPV1 in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice.	Imiquimod	51-60	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	42-47
30527377-2	2018	OBJECTIVE: To investigate the function of TRPV1 in imiquimod (IMQ)-induced psoriasiform dermatitis (PsD) in mice.	Imiquimod	62-65	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	42-47
30527377-4	2018	RESULTS: Compared with WT mice, the clinical and TEWL scores, the extent of skin hyperplasia, the area of Munro microabscesses (MM) and angiogenesis of psoriasis were all significantly decreased in TRPV1 KO mice triggered with IMQ, suggesting a reduction in skin inflammation and barrier defects.	Imiquimod	227-230	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	198-203
30527377-5	2018	In addition, the infiltration of CD45+ leukocytes, mast cells as well as CD3+ T cells was all reduced in the IMQ-treated skin of TRPV1 KO mice.	Imiquimod	109-112	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	129-134
30460231-7	2018	A massive and selective intracellular delivery of IMQ may concentrate its effect specifically into the endosomes, where the TLR7 is expressed, magnifying its immunogenicity, at the same time reducing its systemic bioavailability, and therefore it"s in vivo adverse effects.	Imiquimod	50-53	toll-like receptor 7	Mus musculus	124-128
30352688-2	2018	In addition, it has been reported that IL-36alpha is crucial for development of imiquimod-induced psoriatic dermatitis in mice.	Imiquimod	80-89	interleukin 36A	Mus musculus	39-49
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	negative elongation factor complex member C/D	Homo sapiens	46-49
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	tumor necrosis factor	Homo sapiens	61-70
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interferon alpha 1	Homo sapiens	72-81
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interferon gamma	Homo sapiens	83-92
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interleukin 27	Homo sapiens	97-102
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interleukin 17A	Homo sapiens	124-130
30815354-11	2019	Moreover, IMQ-induced inflammatory cytokines; Th1 cytokines (TNF-alpha, IFN-alpha, IFN-gamma,and IL-27) and Th17 cytokines (IL-17A and IL-23), in the serum and skin showed marked inhibition by hE-MSCs.	Imiquimod	10-13	interleukin 23 subunit alpha	Homo sapiens	135-140
30460231-3	2018	Here we hypothesize that nanoARC made from Halorubrum tebenquichense archaebacteria, may constitute efficient carriers for the TLR7 agonist imiquimod (IMQ).	Imiquimod	140-149	toll-like receptor 7	Mus musculus	127-131
30460231-3	2018	Here we hypothesize that nanoARC made from Halorubrum tebenquichense archaebacteria, may constitute efficient carriers for the TLR7 agonist imiquimod (IMQ).	Imiquimod	151-154	toll-like receptor 7	Mus musculus	127-131
30460231-4	2018	NanoARC-IMQ takes advantage of the intense interaction between IMQ and the highly disordered, poorly fluid branched archaeolipid bilayers, rich in archaeol analog of methyl ester of phosphatidylglycerophosphate (PGP-Me), a natural ligand of scavenger receptor A1 (SR-A1).	Imiquimod	8-11	steroid receptor RNA activator 1	Mus musculus	241-262
30460231-4	2018	NanoARC-IMQ takes advantage of the intense interaction between IMQ and the highly disordered, poorly fluid branched archaeolipid bilayers, rich in archaeol analog of methyl ester of phosphatidylglycerophosphate (PGP-Me), a natural ligand of scavenger receptor A1 (SR-A1).	Imiquimod	8-11	steroid receptor RNA activator 1	Mus musculus	264-269
30120801-2	2018	This study aimed to determine the relationship between PRL and psoriasis through clinical case-control studies, and explore the function of PRL in the pathogenesis of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	167-176	prolactin	Homo sapiens	140-143
30120801-2	2018	This study aimed to determine the relationship between PRL and psoriasis through clinical case-control studies, and explore the function of PRL in the pathogenesis of imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	178-181	prolactin	Homo sapiens	140-143
30377293-8	2018	Finally, we demonstrate that administration of recombinant full-length IL-38 counteracts in vitro the biological processes induced by IL-36gamma in human keratinocytes and endothelial cells and attenuates in vivo the severity of the psoriasiform phenotype induced by IMQ in mice.	Imiquimod	267-270	interleukin 1 family member 10	Homo sapiens	71-76
30120801-9	2018	In IMQ-induced psoriasis-like mouse model, the mRNA and protein levels of PRL in skin lesions were significantly higher than CON group (P &lt; 0.01).	Imiquimod	3-6	prolactin	Mus musculus	74-77
29767328-1	2018	PURPOSE: TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) agonists, under investigation for the treatment of urothelial carcinoma.	Imiquimod	9-16	toll-like receptor 7	Rattus norvegicus	49-69
29767328-1	2018	PURPOSE: TMX-101 and TMX-202 are formulations of toll-like receptor 7 (TLR-7) agonists, under investigation for the treatment of urothelial carcinoma.	Imiquimod	9-16	toll-like receptor 7	Rattus norvegicus	71-76
30356086-2	2018	In support of that, IL-17C was demonstrated to contribute to development of T cell-dependent imiquimod-induced psoriatic dermatitis and T cell-independent dextran sodium sulfate-induced acute colitis using mice deficient in IL-17C and/or IL-17RE, which is a component of the receptor for IL-17C.	Imiquimod	93-102	interleukin 17C	Mus musculus	20-26
29225340-5	2018	First, an attenuated form of imiquimod-induced psoriasis-like skin inflammation was demonstrated in CD6-deficient mice, as deduced from lower epidermal thickness and local reduced production of pro-inflammatory cytokines, namely, interleukin-17A.	Imiquimod	29-38	CD6 antigen	Mus musculus	100-103
29225340-5	2018	First, an attenuated form of imiquimod-induced psoriasis-like skin inflammation was demonstrated in CD6-deficient mice, as deduced from lower epidermal thickness and local reduced production of pro-inflammatory cytokines, namely, interleukin-17A.	Imiquimod	29-38	interleukin 17A	Mus musculus	230-245
30177636-8	2018	High-cholesterol diet aggravated IL-23 expression in IMQ-treated B6.129S2-Apoetm1Unc/J mice, and oxLDL induced IL-23 expression mediated by LOX-1 in TNF-alpha-stimulated Hacat cells.	Imiquimod	53-56	interleukin 23, alpha subunit p19	Mus musculus	33-38
30132523-7	2018	WT1 mRNA and protein expression levels in lesional skins were slightly increased compared with those in non-lesional skins from patients with psoriasis (P=0.2510 and P=0.1690, respectively) and IMQ-treated mice (P=0.9590 and P=0.2552, respectively), although there were no statistical differences.	Imiquimod	194-197	WT1 transcription factor	Homo sapiens	0-3
29763944-8	2018	Baicalin also inhibited imiquimod-induced interleukin-17A production in skin draining lymph node cells.	Imiquimod	24-33	interleukin 17A	Mus musculus	42-57
30262916-0	2018	A requirement for slc15a4 in imiquimod-induced systemic inflammation and psoriasiform inflammation in mice.	Imiquimod	29-38	solute carrier family 15, member 4	Mus musculus	18-25
30262916-3	2018	slc15a4feeble treated with the topical TLR7-agonist imiquimod (IMQ) demonstrated decreased epidermal thickening 24 hours post-treatment which was more pronounced by day 5 as compared to wildtype mice.	Imiquimod	52-61	toll-like receptor 7	Mus musculus	39-43
30262916-3	2018	slc15a4feeble treated with the topical TLR7-agonist imiquimod (IMQ) demonstrated decreased epidermal thickening 24 hours post-treatment which was more pronounced by day 5 as compared to wildtype mice.	Imiquimod	63-66	toll-like receptor 7	Mus musculus	39-43
30262916-5	2018	Systemically, slc15a4 was required for IMQ-induced weight loss and cutaneous accumulation of CD4+ and Siglec H+, but not CD11b+ cells.	Imiquimod	39-42	solute carrier family 15 member 4	Homo sapiens	14-21
30177636-8	2018	High-cholesterol diet aggravated IL-23 expression in IMQ-treated B6.129S2-Apoetm1Unc/J mice, and oxLDL induced IL-23 expression mediated by LOX-1 in TNF-alpha-stimulated Hacat cells.	Imiquimod	53-56	oxidized low density lipoprotein (lectin-like) receptor 1	Mus musculus	140-145
30064075-0	2018	Indirubin ameliorates imiquimod-induced psoriasis-like skin lesions in mice by inhibiting inflammatory responses mediated by IL-17A-producing gammadelta T cells.	Imiquimod	22-31	interleukin 17A	Mus musculus	125-131
29781547-5	2018	In an imiquimod-induced psoriasis-like disease model in mice, diseased skins manifested similar MXRA7 expression pattern and change as in human samples, and MXRA7-deficient mice developed severer psoriasis-like diseases than wild-type mice did.	Imiquimod	6-15	matrix-remodelling associated 7	Mus musculus	96-101
30175192-7	2018	Imiquimod-induced expression of interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) was inhibited by TLR7 siRNA in HIOEC cells as determined by reverse transcription polymerase chain reaction (RT-PCR).	Imiquimod	0-9	interleukin 6	Homo sapiens	32-50
30175192-7	2018	Imiquimod-induced expression of interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) was inhibited by TLR7 siRNA in HIOEC cells as determined by reverse transcription polymerase chain reaction (RT-PCR).	Imiquimod	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	52-56
30175192-7	2018	Imiquimod-induced expression of interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) was inhibited by TLR7 siRNA in HIOEC cells as determined by reverse transcription polymerase chain reaction (RT-PCR).	Imiquimod	0-9	vascular endothelial growth factor A	Homo sapiens	62-96
30175192-7	2018	Imiquimod-induced expression of interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) was inhibited by TLR7 siRNA in HIOEC cells as determined by reverse transcription polymerase chain reaction (RT-PCR).	Imiquimod	0-9	vascular endothelial growth factor A	Homo sapiens	98-102
30175192-7	2018	Imiquimod-induced expression of interleukin (IL)-6, IL-8, and vascular endothelial growth factor (VEGF) was inhibited by TLR7 siRNA in HIOEC cells as determined by reverse transcription polymerase chain reaction (RT-PCR).	Imiquimod	0-9	toll like receptor 7	Homo sapiens	121-125
30064075-12	2018	CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing gammadelta T cells involving Jak3/Stat3 activation.	Imiquimod	33-36	interleukin 17A	Mus musculus	134-141
30064075-12	2018	CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing gammadelta T cells involving Jak3/Stat3 activation.	Imiquimod	33-36	Janus kinase 3	Mus musculus	181-185
30064075-12	2018	CONCLUSION: Indirubin alleviates IMQ-induced psoriasis-like dermatitis mainly through reducing the inflammatory responses mediated by IL-17 A-producing gammadelta T cells involving Jak3/Stat3 activation.	Imiquimod	33-36	signal transducer and activator of transcription 3	Mus musculus	186-191
29959474-11	2018	Gut Th17 cells induced by anti-CD3 express IL-17A and F together as skin gammadelta T cells of IMQ-treated mice.	Imiquimod	95-98	CD3 antigen, epsilon polypeptide	Mus musculus	31-34
29550417-1	2018	This study revealed the modulatory role of transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) cation channels in the Aldara-induced (5% imiquimod) murine psoriasis model using selective antagonists and genetically altered animals.	Imiquimod	137-143	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	83-88
30089718-3	2018	In mice, the development of psoriatic inflammation induced by imiquimod required keratinocyte TRAF6.	Imiquimod	62-71	TNF receptor-associated factor 6	Mus musculus	94-99
29550417-0	2018	TRPA1 Acts in a Protective Manner in Imiquimod-Induced Psoriasiform Dermatitis in Mice.	Imiquimod	37-46	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	0-5
29550417-1	2018	This study revealed the modulatory role of transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) cation channels in the Aldara-induced (5% imiquimod) murine psoriasis model using selective antagonists and genetically altered animals.	Imiquimod	137-143	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	43-81
29550417-1	2018	This study revealed the modulatory role of transient receptor potential ankyrin 1 (TRPA1) and vanilloid 1 (TRPV1) cation channels in the Aldara-induced (5% imiquimod) murine psoriasis model using selective antagonists and genetically altered animals.	Imiquimod	137-143	transient receptor potential cation channel, subfamily V, member 1	Mus musculus	107-112
29959474-11	2018	Gut Th17 cells induced by anti-CD3 express IL-17A and F together as skin gammadelta T cells of IMQ-treated mice.	Imiquimod	95-98	interleukin 17A	Mus musculus	43-49
29655588-11	2018	mLCs revealed a significantly greater level of IL-23 expression compared to rLCs in response to topical IMQ treatment.	Imiquimod	104-107	interleukin 23, alpha subunit p19	Mus musculus	47-52
29150843-5	2018	RESULTS: Topical treatment with imiquimod induced a form of psoriasiform dermatitis reminiscent of the human disorder, characterized by thickened and scaly skin, psoriasiform epidermal hyperplasia, altered keratinocyte differentiation and cutaneous overexpression of interleukin-17A.	Imiquimod	32-41	interleukin 17A	Homo sapiens	267-282
29661487-7	2018	TRAIL-neutralization-experiment was employed in an imiquimod-induced murine psoriasis model.	Imiquimod	51-60	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	0-5
29661487-12	2018	Moreover, TRAIL-neutralization in an imiquimod-induced murine psoriasis model remarkably improved skin phenotypes, such as ear thickness, and TNF-alpha expression in lesional skin.	Imiquimod	37-46	tumor necrosis factor (ligand) superfamily, member 10	Mus musculus	10-15
29661487-12	2018	Moreover, TRAIL-neutralization in an imiquimod-induced murine psoriasis model remarkably improved skin phenotypes, such as ear thickness, and TNF-alpha expression in lesional skin.	Imiquimod	37-46	tumor necrosis factor	Mus musculus	142-151
29847604-0	2018	Correction: PAMs ameliorates the imiquimod-induced psoriasis-like skin disease in mice by inhibition of translocation of NF-kappaB and production of inflammatory cytokines.	Imiquimod	33-42	nuclear factor of kappa light polypeptide gene enhancer in B cells 1, p105	Mus musculus	121-130
29872130-7	2018	Local depletion of C10orf99 by lentiviral vectors expressing C10orf99 shRNA effectively ameliorated IMQ-induced dermatitis.	Imiquimod	100-103	chromosome 10 open reading frame 99	Homo sapiens	19-27
29872130-7	2018	Local depletion of C10orf99 by lentiviral vectors expressing C10orf99 shRNA effectively ameliorated IMQ-induced dermatitis.	Imiquimod	100-103	chromosome 10 open reading frame 99	Homo sapiens	61-69
29750958-5	2018	We further show that the heterozygous mutation of the STAT1 gene results in elevated levels of IL-22 production and induces much severer skin inflammation in an imiquimod (IMQ)-induced murine psoriasis model.	Imiquimod	172-175	signal transducer and activator of transcription 1	Mus musculus	54-59
29867905-7	2018	Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control.	Imiquimod	162-165	interleukin 17A	Mus musculus	141-147
29867905-7	2018	Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control.	Imiquimod	162-165	interleukin 23, alpha subunit p19	Mus musculus	153-158
29867905-7	2018	Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control.	Imiquimod	162-165	interleukin 19	Mus musculus	134-139
29867905-7	2018	Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control.	Imiquimod	170-173	interleukin 17A	Mus musculus	141-147
29867905-7	2018	Further, mRNA expression analysis indicated a significant increase in gene expression levels of pro-inflammatory cytokines, including IL-19, IL-17A, and IL-23 in IMQ and IMQ plus vaseline treated groups than that of the control.	Imiquimod	170-173	interleukin 23, alpha subunit p19	Mus musculus	153-158
29377339-6	2018	In IMQ-induced psoriasis-like mouse models, the Psoriasis Area and Severity Index score of ACE (50 mg/ml; ACE50)-treated group was significantly lower than that of IMQ group on Day 4 (p &lt; .05).	Imiquimod	3-6	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	91-94
29377339-6	2018	In IMQ-induced psoriasis-like mouse models, the Psoriasis Area and Severity Index score of ACE (50 mg/ml; ACE50)-treated group was significantly lower than that of IMQ group on Day 4 (p &lt; .05).	Imiquimod	164-167	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	91-94
29377339-7	2018	After topical application of ACE on psoriasis-like lesion for 4 days, the epidermal thickness of (IMQ + ACE50) group was significantly lower than that of IMQ group (p &lt; .05).	Imiquimod	98-101	angiotensin I converting enzyme	Homo sapiens	29-32
29679037-4	2018	Topical application of imiquimod (IMQ), a toll-like receptor (TLR)7 agonist and potent immune system activator, can induce and exacerbate psoriasis.	Imiquimod	23-32	toll-like receptor 7	Mus musculus	42-67
29679037-4	2018	Topical application of imiquimod (IMQ), a toll-like receptor (TLR)7 agonist and potent immune system activator, can induce and exacerbate psoriasis.	Imiquimod	34-37	toll-like receptor 7	Mus musculus	42-67
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	25-34	toll-like receptor 7	Mus musculus	12-16
29653697-4	2018	Here we have shown that IL-25, also highly expressed in the lesional skin of psoriasis patients, was regulated by IL-17 in murine skin of a imiquimod (IMQ)-induced psoriasis model.	Imiquimod	151-154	interleukin 17A	Homo sapiens	114-119
29653697-5	2018	IL-25 injection induced skin inflammation, whereas germline or keratinocyte-specific deletion of IL-25 caused resistance to IMQ-induced psoriasis.	Imiquimod	124-127	interleukin 25	Homo sapiens	97-102
29305258-2	2018	Topical application of imiquimod (IMQ), a TLR7 ligand, induces psoriasis-like skin lesions in mice.	Imiquimod	23-32	toll-like receptor 7	Mus musculus	42-46
29305258-2	2018	Topical application of imiquimod (IMQ), a TLR7 ligand, induces psoriasis-like skin lesions in mice.	Imiquimod	34-37	toll-like receptor 7	Mus musculus	42-46
29305258-3	2018	OBJECTIVE: The aim of this study was to investigate whether IRF-2 gene status would influence severity of skin disease in IMQ-treated mice.	Imiquimod	122-125	interferon regulatory factor 2	Mus musculus	60-65
29305258-6	2018	RESULTS: IMQ-induced skin inflammation assessed by clinical findings and histology was more severe in IRF-2+/- mice than in wild-type mice.	Imiquimod	9-12	interferon regulatory factor 2	Mus musculus	102-107
29305258-10	2018	Moreover, elevated mRNA expression of inducible nitric oxide synthase was observed only in IMQ-stimulated macrophages derived from IRF-2+/- mice, which correlated with angiogenesis in IMQ-treated ears of IRF-2+/- mice.	Imiquimod	91-94	nitric oxide synthase 2, inducible	Mus musculus	38-69
29305258-10	2018	Moreover, elevated mRNA expression of inducible nitric oxide synthase was observed only in IMQ-stimulated macrophages derived from IRF-2+/- mice, which correlated with angiogenesis in IMQ-treated ears of IRF-2+/- mice.	Imiquimod	91-94	interferon regulatory factor 2	Mus musculus	131-136
29305258-10	2018	Moreover, elevated mRNA expression of inducible nitric oxide synthase was observed only in IMQ-stimulated macrophages derived from IRF-2+/- mice, which correlated with angiogenesis in IMQ-treated ears of IRF-2+/- mice.	Imiquimod	91-94	interferon regulatory factor 2	Mus musculus	204-209
29653697-4	2018	Here we have shown that IL-25, also highly expressed in the lesional skin of psoriasis patients, was regulated by IL-17 in murine skin of a imiquimod (IMQ)-induced psoriasis model.	Imiquimod	151-154	interleukin 25	Homo sapiens	24-29
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	25-34	interleukin 22 receptor, alpha 2	Mus musculus	126-133
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	36-39	toll-like receptor 7	Mus musculus	12-16
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	36-39	interleukin 22 receptor, alpha 2	Mus musculus	126-133
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	209-212	toll-like receptor 7	Mus musculus	12-16
29572462-4	2018	We used the TLR7 agonist Imiquimod (IMQ) to induce a psoriasis-like skin disease in mice and found a strong downregulation of IL-22BP in the affected skin as well as in the lymph nodes of animals treated with IMQ.	Imiquimod	209-212	interleukin 22 receptor, alpha 2	Mus musculus	126-133
29155016-0	2018	Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17.	Imiquimod	64-73	S-adenosylhomocysteine hydrolase	Mus musculus	37-41
29561265-4	2018	In the zebrafish, imiquimod-evoked somatosensory neuronal responses and behaviors were entirely dependent upon TRPA1, while in the mouse TRPA1 was required for the direct activation of somatosensory neurons and partially responsible for behaviors elicited by this pruritogen.	Imiquimod	18-27	transient receptor potential cation channel, subfamily A, member 1a	Danio rerio	111-116
29561265-4	2018	In the zebrafish, imiquimod-evoked somatosensory neuronal responses and behaviors were entirely dependent upon TRPA1, while in the mouse TRPA1 was required for the direct activation of somatosensory neurons and partially responsible for behaviors elicited by this pruritogen.	Imiquimod	18-27	transient receptor potential cation channel, subfamily A, member 1	Mus musculus	137-142
29619028-3	2018	In this study, we found that the expression of MKP-1 was decreased in the imiquimod (IMQ)-induced psoriasiform mouse skin.	Imiquimod	74-83	dual specificity phosphatase 1	Mus musculus	47-52
29619028-3	2018	In this study, we found that the expression of MKP-1 was decreased in the imiquimod (IMQ)-induced psoriasiform mouse skin.	Imiquimod	85-88	dual specificity phosphatase 1	Mus musculus	47-52
29619028-4	2018	MKP-1-deficient (MKP-1-/-) mice were highly susceptible to IMQ-induced skin inflammation, which was associated with increased production of inflammatory cytokines and chemokines.	Imiquimod	59-62	dual specificity phosphatase 1	Mus musculus	0-5
29619028-7	2018	Moreover, MKP-1 deficiency in the non-hematopoietic compartments led to an enhanced IL-22 receptor signaling and higher expression of CXCL1 and CXCL2 upon IMQ treatment.	Imiquimod	155-158	chemokine (C-X-C motif) ligand 1	Mus musculus	134-139
29619028-7	2018	Moreover, MKP-1 deficiency in the non-hematopoietic compartments led to an enhanced IL-22 receptor signaling and higher expression of CXCL1 and CXCL2 upon IMQ treatment.	Imiquimod	155-158	chemokine (C-X-C motif) ligand 2	Mus musculus	144-149
29554104-6	2018	At the peak of IMQ-induced inflammation, skin Il-38 mRNA levels were reduced, whereas Il-36ra mRNA expression increased.	Imiquimod	15-18	interleukin 36 receptor antagonist	Mus musculus	86-93
29535261-2	2018	In a mouse model of imiquimod-induced psoriasiform skin inflammation, we found that p38alpha activity in Langerhans cells (LCs), a skin-resident subset of DCs, promoted the generation of T cells that produce IL-17, a proinflammatory cytokine that is implicated in autoimmune disease.	Imiquimod	20-29	mitogen-activated protein kinase 14	Mus musculus	84-92
29535261-2	2018	In a mouse model of imiquimod-induced psoriasiform skin inflammation, we found that p38alpha activity in Langerhans cells (LCs), a skin-resident subset of DCs, promoted the generation of T cells that produce IL-17, a proinflammatory cytokine that is implicated in autoimmune disease.	Imiquimod	20-29	interleukin 17A	Mus musculus	208-213
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	144-147	notch 1	Mus musculus	69-75
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	144-147	hes family bHLH transcription factor 1	Mus musculus	77-82
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	144-147	interleukin 17A	Mus musculus	98-104
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	144-147	interleukin 17A	Mus musculus	114-120
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	229-232	notch 1	Mus musculus	69-75
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	229-232	hes family bHLH transcription factor 1	Mus musculus	77-82
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	229-232	interleukin 17A	Mus musculus	98-104
29523162-11	2018	The increased expression of splenic Th17 cell percentage, along with Notch1, Hes-1, RORgammat and IL-17A mRNA and IL-17A serum concentration in IMQ-treated mice were significantly decreased when experimental mice were treated by IMQ and DAPT combinedly.	Imiquimod	229-232	interleukin 17A	Mus musculus	114-120
29523162-12	2018	Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells.	Imiquimod	37-40	notch 1	Mus musculus	86-92
29523162-12	2018	Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells.	Imiquimod	37-40	notch 1	Mus musculus	195-201
29523162-12	2018	Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells.	Imiquimod	37-40	hes family bHLH transcription factor 1	Mus musculus	203-208
29523162-12	2018	Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells.	Imiquimod	37-40	interleukin 17A	Mus musculus	224-230
29523162-12	2018	Data obtained from in vitro study in IMQ-treated mice also demonstrated that blocking Notch1 signaling by DAPT can result in a dose-dependent decrease of Th17 cell proportion, mRNA expression of Notch1, Hes-1, RORgammat and IL-17A as well as IL-17A secretion in splenic CD4+ T cells.	Imiquimod	37-40	interleukin 17A	Mus musculus	242-248
29349514-7	2018	The ears of mice treated with imiquimod (IMQ) and irradiated by NB-UVB were taken to examine K17 expression by qRT-PCR, western blot analysis, and immunofluorescence.	Imiquimod	30-39	keratin 17	Mus musculus	93-96
29454234-7	2018	RESULTS: We demonstrated DCK suppressed DC uptake of FITC-labeled ovalbumin (OVA) and DC maturation characterized by decreased MHCII, CD80 and CD86 following imiquimod (IMQ) stimulation.	Imiquimod	158-167	deoxycytidine kinase	Mus musculus	25-28
29454234-7	2018	RESULTS: We demonstrated DCK suppressed DC uptake of FITC-labeled ovalbumin (OVA) and DC maturation characterized by decreased MHCII, CD80 and CD86 following imiquimod (IMQ) stimulation.	Imiquimod	169-172	deoxycytidine kinase	Mus musculus	25-28
29454234-9	2018	Importantly, DCK significantly reduced the production of proinflammatory cytokines including IL-12, IL-6 and IL-1beta by IMQ-stimulated DCs.	Imiquimod	121-124	deoxycytidine kinase	Mus musculus	13-16
29454234-11	2018	Furthermore, DCK treatment greatly reduced phosphorylation of p65-associated cell signaling pathway in IMQ-stimulated DCs.	Imiquimod	103-106	deoxycytidine kinase	Mus musculus	13-16
28870465-6	2018	The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression.	Imiquimod	4-7	interleukin 12b	Mus musculus	32-37
28870465-6	2018	The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression.	Imiquimod	4-7	interleukin 23, alpha subunit p19	Mus musculus	42-47
28870465-6	2018	The IMQ-induced upregulation of Il12b and Il23a was marked in the epidermis and was abrogated by CAL application, suggesting CAL-mediated suppression of IL-23 expression.	Imiquimod	4-7	interleukin 23, alpha subunit p19	Mus musculus	153-158
29155016-0	2018	Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17.	Imiquimod	64-73	tumor necrosis factor	Mus musculus	137-146
29155016-0	2018	Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17.	Imiquimod	64-73	interferon gamma	Mus musculus	147-156
29155016-0	2018	Topical administration of reversible SAHH inhibitor ameliorates imiquimod-induced psoriasis-like skin lesions in mice via suppression of TNF-alpha/IFN-gamma-induced inflammatory response in keratinocytes and T cell-derived IL-17.	Imiquimod	64-73	interleukin 17A	Mus musculus	223-228
29247486-7	2018	Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated.	Imiquimod	53-56	caspase 1	Mus musculus	0-9
29247486-6	2018	IL-17A mRNA expression was significantly increased in the skin of IMQ-treated HFD mice; the expression of IL-22, IL-23 and TNF-alpha mRNA was not enhanced.	Imiquimod	66-69	interleukin 17A	Mus musculus	0-6
29386832-6	2018	Results: CTGF expression was observed in the dermis from both IMQ-induced psoriatic mice and psoriasis patients.	Imiquimod	62-65	cellular communication network factor 2	Mus musculus	9-13
29386832-7	2018	CTGF inhibition using an anti-CTGF antibody slightly worsened IMQ-induced dermatitis.	Imiquimod	62-65	cellular communication network factor 2	Homo sapiens	0-4
29386832-7	2018	CTGF inhibition using an anti-CTGF antibody slightly worsened IMQ-induced dermatitis.	Imiquimod	62-65	cellular communication network factor 2	Homo sapiens	30-34
29247486-7	2018	Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated.	Imiquimod	53-56	interleukin 1 beta	Mus musculus	14-22
29247486-7	2018	Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated.	Imiquimod	53-56	interleukin 17A	Mus musculus	100-106
29247486-7	2018	Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated.	Imiquimod	53-56	tumor necrosis factor	Mus musculus	108-117
29247486-7	2018	Caspase-1 and IL-1beta were activated in the skin of IMQ-treated HFD mice, and their serum level of IL-17A, TNF-alpha and IL-1beta was significantly upregulated.	Imiquimod	53-56	interleukin 1 beta	Mus musculus	122-130
28825602-7	2017	Treatment of imiquimod-challenged mice with an NRTN-neutralizing antibody significantly reduced nonpeptidergic nerve density as well as spontaneous scratching.	Imiquimod	13-22	neurturin	Mus musculus	47-51
28677206-9	2018	IL-10 deficient mice also showed significantly higher serum levels of imiquimod-induced IL-17A and tumor necrosis factor-alpha by enzyme-linked immunosorbent assay on day 15.	Imiquimod	70-79	interleukin 10	Mus musculus	0-5
28677206-9	2018	IL-10 deficient mice also showed significantly higher serum levels of imiquimod-induced IL-17A and tumor necrosis factor-alpha by enzyme-linked immunosorbent assay on day 15.	Imiquimod	70-79	interleukin 17A	Mus musculus	88-126
29150564-6	2018	Instead, a bone marrow chimera study suggested that CARD14 in radio-sensitive hematopoietic cells was required for IMQ-induced psoriasiform skin inflammation, controlling the number of Vgamma4+ T cells producing IL-17 or IL-22 infiltrating through the dermis to the inflamed epidermis.	Imiquimod	115-118	caspase recruitment domain family, member 14	Mus musculus	52-58
29150564-6	2018	Instead, a bone marrow chimera study suggested that CARD14 in radio-sensitive hematopoietic cells was required for IMQ-induced psoriasiform skin inflammation, controlling the number of Vgamma4+ T cells producing IL-17 or IL-22 infiltrating through the dermis to the inflamed epidermis.	Imiquimod	115-118	interleukin 17A	Mus musculus	212-217
29150564-6	2018	Instead, a bone marrow chimera study suggested that CARD14 in radio-sensitive hematopoietic cells was required for IMQ-induced psoriasiform skin inflammation, controlling the number of Vgamma4+ T cells producing IL-17 or IL-22 infiltrating through the dermis to the inflamed epidermis.	Imiquimod	115-118	interleukin 22	Mus musculus	221-226
28597172-5	2017	Topically applied IMQ caused twofold greater ear swelling in BALB/c mice compared to C57BL/6 mice, which encode a partial loss-of-function missense mutation in the P2RX7 gene.	Imiquimod	18-21	purinergic receptor P2X, ligand-gated ion channel, 7	Mus musculus	164-169
28597172-12	2017	Flow cytometric analysis of IMQ-treated skin from C57BL/6 and P2X7 KO mice demonstrated similar leukocyte infiltration, including neutrophils, macrophages and T cells.	Imiquimod	28-31	purinergic receptor P2X 7	Homo sapiens	62-66
29137840-11	2018	RvD1 markedly inhibited IMQ-induced activation of ERK1/2, p38, JNK (c-Jun N-terminal protein kinase, a subfamily of MAPKs), and NF-kappaB.	Imiquimod	24-27	mitogen-activated protein kinase 3	Mus musculus	50-56
29137840-11	2018	RvD1 markedly inhibited IMQ-induced activation of ERK1/2, p38, JNK (c-Jun N-terminal protein kinase, a subfamily of MAPKs), and NF-kappaB.	Imiquimod	24-27	mitogen-activated protein kinase 14	Mus musculus	58-61
29137840-11	2018	RvD1 markedly inhibited IMQ-induced activation of ERK1/2, p38, JNK (c-Jun N-terminal protein kinase, a subfamily of MAPKs), and NF-kappaB.	Imiquimod	24-27	mitogen-activated protein kinase 8	Mus musculus	63-66
29137840-11	2018	RvD1 markedly inhibited IMQ-induced activation of ERK1/2, p38, JNK (c-Jun N-terminal protein kinase, a subfamily of MAPKs), and NF-kappaB.	Imiquimod	24-27	mitogen-activated protein kinase 8	Mus musculus	68-99
28580633-6	2017	RESULTS: Smad7 was highly expressed in keratinocytes of patients with psoriasis and of mice treated with Aldara.	Imiquimod	105-111	SMAD family member 7	Homo sapiens	9-14
28736282-8	2017	Curcumin inhibited the proliferation of IMQ-induced differentiated HaCaT cells (Psoriatic-like cells) by down-regulation of pro-inflammatory cytokines, interleukin-17, tumor necrosis factor-alpha, interferon-gamma, and interleukin-6.	Imiquimod	40-43	tumor necrosis factor	Homo sapiens	152-195
28736282-8	2017	Curcumin inhibited the proliferation of IMQ-induced differentiated HaCaT cells (Psoriatic-like cells) by down-regulation of pro-inflammatory cytokines, interleukin-17, tumor necrosis factor-alpha, interferon-gamma, and interleukin-6.	Imiquimod	40-43	interferon gamma	Homo sapiens	197-213
28736282-8	2017	Curcumin inhibited the proliferation of IMQ-induced differentiated HaCaT cells (Psoriatic-like cells) by down-regulation of pro-inflammatory cytokines, interleukin-17, tumor necrosis factor-alpha, interferon-gamma, and interleukin-6.	Imiquimod	40-43	interleukin 6	Homo sapiens	219-232
28963556-6	2017	IL-17A neutralization increased the expressions of iNOS and phospho-STAT1 in the IMQ-treated skin, but it decreased the expressions of CD206 and phospho-STAT3 proteins in the skin of Flg ft mice, suggesting that macrophages to change from the M2 to the M1 state in the skin of these mice.	Imiquimod	81-84	interleukin 17A	Mus musculus	0-6
28579438-9	2017	CONCLUSIONS: Imiquimod-induced ApoE-/- mice model presented the pathological features of psoriasis and dyslipideamia, which could be an ideal composite animal model for the study of pathogenesis and pharmacotherapeutics of psoriasis and dyslipideamia comorbidity.	Imiquimod	13-22	apolipoprotein E	Mus musculus	31-35
28576737-8	2017	In mice of imiquimod-induced psoriasis-like dermatitis, topical application of Nrf2 small interfering RNA alleviated the epidermal hyperplasia with reduced expression of these keratins.	Imiquimod	11-20	nuclear factor, erythroid derived 2, like 2	Mus musculus	79-83
28963556-6	2017	IL-17A neutralization increased the expressions of iNOS and phospho-STAT1 in the IMQ-treated skin, but it decreased the expressions of CD206 and phospho-STAT3 proteins in the skin of Flg ft mice, suggesting that macrophages to change from the M2 to the M1 state in the skin of these mice.	Imiquimod	81-84	nitric oxide synthase 2, inducible	Mus musculus	51-55
29137353-8	2017	The frequency of tartrate-resistant acid phosphatase (TRAP)-positive cells in the bone marrow of an imiquimod (IMQ)-induced psoriasis mouse model was decreased following T-CM injection.	Imiquimod	111-114	acid phosphatase 5, tartrate resistant	Mus musculus	17-52
28642279-0	2017	Role of MyD88 signaling in the imiquimod-induced mouse model of psoriasis: focus on innate myeloid cells.	Imiquimod	31-40	myeloid differentiation primary response gene 88	Mus musculus	8-13
29137353-8	2017	The frequency of tartrate-resistant acid phosphatase (TRAP)-positive cells in the bone marrow of an imiquimod (IMQ)-induced psoriasis mouse model was decreased following T-CM injection.	Imiquimod	111-114	acid phosphatase 5, tartrate resistant	Mus musculus	54-58
28570931-12	2017	Furthermore, anti-IL17A antibody also led to a reduction in imiquimod-induced depression-like symptoms, as well as NFkappaB/p38MAPK signaling.	Imiquimod	60-69	interleukin 17A	Mus musculus	18-23
28642279-4	2017	However, both Myd88-/- mouse strains developed some degree of epidermal thickening during the initial stages of IMQ-induced psoriasis, even in the absence of hematopoietic cell activation and infiltration into the skin, suggesting a contribution of MyD88-independent mechanisms in skin-resident stromal cells.	Imiquimod	112-115	myeloid differentiation primary response gene 88	Mus musculus	14-19
28601430-0	2017	Imiquimod-induced autophagy is regulated by ER stress-mediated PKR activation in cancer cells.	Imiquimod	0-9	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	63-66
27943421-6	2017	We hypothesized that a shift of the TRIM21-ubiquitinating mode of action may explain the lack of chronicity in the IMQ-induced psoriasis-like mouse model.	Imiquimod	115-118	tripartite motif-containing 21	Mus musculus	36-42
27943421-7	2017	We showed that TRIM21 expression is increased in lesional psoriatic skin and in the early phase of IMQ-induced inflammation both in vitro and in vivo.	Imiquimod	99-102	tripartite motif-containing 21	Mus musculus	15-21
27943421-8	2017	Surprisingly, inflammation was significantly less pronounced in TRIM21 knockout mice than in wild-type mice as shown by ear thickness measured at days 8, 9 and 10 after treatment start, by spleen weight as a marker of systemic effect of IMQ at 10 days after treatment start and by expression of IL-12p40 at days 3 and 10 after treatment start and IL-17A at day 3 after treatment start.	Imiquimod	237-240	tripartite motif-containing 21	Mus musculus	64-70
28601430-3	2017	Imiquimod (IMQ), a Toll-like receptor (TLR) 7 ligand, possesses anti-tumor and anti-viral activities in vitro and in vivo.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	39-42
28601430-3	2017	Imiquimod (IMQ), a Toll-like receptor (TLR) 7 ligand, possesses anti-tumor and anti-viral activities in vitro and in vivo.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	39-42
28601430-8	2017	The relationship between ER stress and IMQ-induced autophagy were analyzed by ER stress inhibitors, a PERK inhibitor and the genetic silencing of PERK.	Imiquimod	39-42	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	102-106
28601430-8	2017	The relationship between ER stress and IMQ-induced autophagy were analyzed by ER stress inhibitors, a PERK inhibitor and the genetic silencing of PERK.	Imiquimod	39-42	eukaryotic translation initiation factor 2 alpha kinase 3	Homo sapiens	146-150
28601430-9	2017	The role of double-strand RNA-dependent protein kinase (PKR) activation in IMQ-induced autophagy was assessed by inhibiting PKR and genetically silencing PKR.	Imiquimod	75-78	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	56-59
28601430-9	2017	The role of double-strand RNA-dependent protein kinase (PKR) activation in IMQ-induced autophagy was assessed by inhibiting PKR and genetically silencing PKR.	Imiquimod	75-78	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	124-127
28601430-9	2017	The role of double-strand RNA-dependent protein kinase (PKR) activation in IMQ-induced autophagy was assessed by inhibiting PKR and genetically silencing PKR.	Imiquimod	75-78	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	124-127
28601430-10	2017	The IMQ-induced autophagy was evaluated by immunoblotting and EGFP-LC3 puncta formation.	Imiquimod	4-7	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	67-70
28601430-12	2017	Additionally, IMQ markedly induced ER stress via ROS production and increased autophagosome formation in a dose- and time-dependent manner in both TLR7/8-expressing and TLR7/8-deficient cancer cells.	Imiquimod	14-17	toll like receptor 7	Homo sapiens	147-151
28601430-12	2017	Additionally, IMQ markedly induced ER stress via ROS production and increased autophagosome formation in a dose- and time-dependent manner in both TLR7/8-expressing and TLR7/8-deficient cancer cells.	Imiquimod	14-17	toll like receptor 7	Homo sapiens	169-173
28601430-13	2017	Pharmacological or genetic inhibition of ER stress dramatically reduced LC3-II expression and EGFP-LC3 puncta formation in IMQ-treated cancer cells.	Imiquimod	123-126	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	72-75
28601430-13	2017	Pharmacological or genetic inhibition of ER stress dramatically reduced LC3-II expression and EGFP-LC3 puncta formation in IMQ-treated cancer cells.	Imiquimod	123-126	microtubule associated protein 1 light chain 3 alpha	Homo sapiens	99-102
28601430-14	2017	IMQ-induced autophagy was markedly reduced by depletion and/or inhibition of PKR, a downstream effector of ER stress.	Imiquimod	0-3	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	77-80
28601430-15	2017	CONCLUSION: IMQ-induced autophagy is dependent on PKR activation, which is mediated by ROS-triggered ER stress.	Imiquimod	12-15	eukaryotic translation initiation factor 2 alpha kinase 2	Homo sapiens	50-53
28600817-9	2017	Additionally, studies in the imiquimod-induced psoriasis-like mouse model revealed that ACDs in psoriasis are IL17A-dependent.	Imiquimod	29-38	interleukin 17A	Mus musculus	110-115
28168735-4	2017	AIMS/OBJECTIVES: In order to improve NB-UVB therapy, we sought to determine whether skin pre-treatment with the TLR7 agonist imiquimod (IMQ) would help increase the efficiency of the former at resolving psoriatic plaques.	Imiquimod	125-134	toll like receptor 7	Homo sapiens	112-116
28168735-4	2017	AIMS/OBJECTIVES: In order to improve NB-UVB therapy, we sought to determine whether skin pre-treatment with the TLR7 agonist imiquimod (IMQ) would help increase the efficiency of the former at resolving psoriatic plaques.	Imiquimod	136-139	toll like receptor 7	Homo sapiens	112-116
28168735-11	2017	Although upregulation of genes MxA, GRAMD1A and DMXL2 suggested that IMQ treatment did induce skin changes in psoriasis patients, more optimal dosing of IMQ and NB-UVB might be necessary to achieve desired treatment responses.	Imiquimod	69-72	MX dynamin like GTPase 1	Homo sapiens	31-34
28168735-11	2017	Although upregulation of genes MxA, GRAMD1A and DMXL2 suggested that IMQ treatment did induce skin changes in psoriasis patients, more optimal dosing of IMQ and NB-UVB might be necessary to achieve desired treatment responses.	Imiquimod	69-72	GRAM domain containing 1A	Homo sapiens	36-43
28168735-11	2017	Although upregulation of genes MxA, GRAMD1A and DMXL2 suggested that IMQ treatment did induce skin changes in psoriasis patients, more optimal dosing of IMQ and NB-UVB might be necessary to achieve desired treatment responses.	Imiquimod	69-72	Dmx like 2	Homo sapiens	48-53
28389593-0	2017	CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells.	Imiquimod	18-27	chemokine (C-X-C motif) ligand 17	Mus musculus	0-6
27910163-11	2017	RESULTS: SAA was highly expressed in skin lesions of IMQ-treated psoriasis-like mice and neutralising SAA attenuated epidermal hyperplasia and inflammation.	Imiquimod	53-56	serum amyloid A cluster	Mus musculus	9-12
28365081-12	2017	On the other hand, scratching induced by imiquimod was increased in DPPIV overexpressing-mice.	Imiquimod	41-50	dipeptidylpeptidase 4	Mus musculus	68-73
28456630-4	2017	We observed increases in dermal mast cells in imiquimod-induced psoriatic dermatitis in mice accompanied by the expression of epidermal stem cell factor (SCF), a critical mast cell growth factor.	Imiquimod	46-55	kit ligand	Mus musculus	136-152
28456630-4	2017	We observed increases in dermal mast cells in imiquimod-induced psoriatic dermatitis in mice accompanied by the expression of epidermal stem cell factor (SCF), a critical mast cell growth factor.	Imiquimod	46-55	kit ligand	Mus musculus	154-157
28389593-6	2017	As CXCL17 mRNA expression was increased by treatment with imiquimod (IMQ), we examined the effects of CXCL17 in IMQ-induced psoriasis-like skin inflammation.	Imiquimod	69-72	chemokine (C-X-C motif) ligand 17	Mus musculus	3-9
28389593-11	2017	Taken together, CXCL17 attenuates IMQ-induced psoriasis-like skin inflammation by recruiting MDSCs and Tregs, which may be important for regulating excessive inflammation in psoriasis skin.	Imiquimod	34-37	chemokine (C-X-C motif) ligand 17	Mus musculus	16-22
28469254-5	2017	Using a murine model of psoriasis induced by TLR7 agonist imiquimod (IMQ), we show that VISTA deficiency exacerbated psoriasiform inflammation.	Imiquimod	58-67	V-set immunoregulatory receptor	Mus musculus	88-93
28469254-5	2017	Using a murine model of psoriasis induced by TLR7 agonist imiquimod (IMQ), we show that VISTA deficiency exacerbated psoriasiform inflammation.	Imiquimod	69-72	V-set immunoregulatory receptor	Mus musculus	88-93
28377495-5	2017	RIG-I is also critical for a full development of skin inflammation in imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	70-79	DEAD/H box helicase 58	Mus musculus	0-5
28377495-5	2017	RIG-I is also critical for a full development of skin inflammation in imiquimod (IMQ)-induced psoriasis-like mouse model.	Imiquimod	81-84	DEAD/H box helicase 58	Mus musculus	0-5
28249219-9	2017	Treatment either with general antioxidant, N-acetyl cysteine or NOX/iNOS inhibitors led to improvement of IMQ-induced renal dysfunction and oxidative stress.	Imiquimod	106-109	nitric oxide synthase 2, inducible	Mus musculus	68-72
27376341-2	2017	Here, we demonstrated that KdPT, a tripeptide structurally related to the C-terminal amino acids of alpha-melanocyte-stimulating hormone, which was previously shown to exhibit anti-inflammatory effects in intestinal inflammation, ameliorated ongoing disease in the mouse model of imiquimod-induced psoriasis-like skin inflammation and in the small xenotransplant mouse model of psoriasis.	Imiquimod	280-289	pro-opiomelanocortin-alpha	Mus musculus	100-136
28339016-8	2017	Paeonol inhibited IMQ-induced mRNA expression of IL-23, but not IL-12 and IL-1beta in BMDCs, along with significantly lower levels of DCs expressing MHCII, CD80 and CD86 in vitro.	Imiquimod	18-21	interleukin 23, alpha subunit p19	Mus musculus	49-54
28339016-8	2017	Paeonol inhibited IMQ-induced mRNA expression of IL-23, but not IL-12 and IL-1beta in BMDCs, along with significantly lower levels of DCs expressing MHCII, CD80 and CD86 in vitro.	Imiquimod	18-21	CD80 antigen	Mus musculus	156-160
28339016-8	2017	Paeonol inhibited IMQ-induced mRNA expression of IL-23, but not IL-12 and IL-1beta in BMDCs, along with significantly lower levels of DCs expressing MHCII, CD80 and CD86 in vitro.	Imiquimod	18-21	CD86 antigen	Mus musculus	165-169
27943400-4	2017	Abundant cytoplasmic expression of HMGB1 was observed in lesional skin from IMQ-treated skin.	Imiquimod	76-79	high mobility group box 1	Mus musculus	35-40
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	high mobility group box 1	Homo sapiens	17-22
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	myeloperoxidase	Homo sapiens	139-154
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	integrin subunit alpha X	Homo sapiens	172-177
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	interleukin 6	Homo sapiens	279-297
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	tumor necrosis factor	Homo sapiens	299-332
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	interferon gamma	Homo sapiens	334-356
27943400-5	2017	The injection of HMGB1 into the IMQ-treated skin further aggravated the psoriasis-like disease, enhanced the infiltration of CD3+ T cells, myeloperoxidase+ neutrophils and CD11c+ dendritic cells, increased the number of gammadelta T cells, and upregulated the mRNA expression of interleukin (IL)-6, tumor necrosis factor (TNF)-alpha, interferon (IFN)-gamma and IL-17 compared with the PBS injection.	Imiquimod	32-35	interleukin 17A	Homo sapiens	361-366
27943400-7	2017	Our data suggest that HMGB1 may act as a pro-inflammatory cytokine, and contribute to the development of IMQ-induced psoriasis-like inflammation.	Imiquimod	105-108	high mobility group box 1	Mus musculus	22-27
28448022-10	2017	Using this method, an alternatively spliced IL-15 isoform with partially deleted exon 7 (IL-15DeltaE7) was expressed in the skin and subsequently treated with a Toll-like receptor 7 (TLR7) agonist, imiquimod (IMQ), to induce inflammation.	Imiquimod	209-212	interleukin 15	Mus musculus	44-49
28212561-2	2017	This study was performed to evaluate the synergistic anti-cancer and anti-metastatic effects of the TLR7 agonist imiquimod (IMQ) during radiotherapy for melanoma.	Imiquimod	113-122	toll-like receptor 7	Mus musculus	100-104
28212561-2	2017	This study was performed to evaluate the synergistic anti-cancer and anti-metastatic effects of the TLR7 agonist imiquimod (IMQ) during radiotherapy for melanoma.	Imiquimod	124-127	toll-like receptor 7	Mus musculus	100-104
28338767-4	2017	Our results showed that the level of CD1d in B cells was decreased during the early stages of B6.MRLlpr SLE mice and imiquimod-treated (IMQ-treated) mice, while the level of CD86 was significantly increased at the late stage.	Imiquimod	136-139	CD1d1 antigen	Mus musculus	37-41
28338767-4	2017	Our results showed that the level of CD1d in B cells was decreased during the early stages of B6.MRLlpr SLE mice and imiquimod-treated (IMQ-treated) mice, while the level of CD86 was significantly increased at the late stage.	Imiquimod	136-139	CD86 antigen	Mus musculus	174-178
28338767-5	2017	Moreover, the expression of CD1d showed a significantly negative correlation with CD86 level in B cells from IMQ-treated mice (r = -05741; P = 0.0022), B6.MRLlpr mice (r = -0.7091; P = 0.0268), and SLE patients (r = -0.4125; P = 0.0404).	Imiquimod	109-112	CD1d1 antigen	Mus musculus	28-32
28338767-5	2017	Moreover, the expression of CD1d showed a significantly negative correlation with CD86 level in B cells from IMQ-treated mice (r = -05741; P = 0.0022), B6.MRLlpr mice (r = -0.7091; P = 0.0268), and SLE patients (r = -0.4125; P = 0.0404).	Imiquimod	109-112	CD86 antigen	Mus musculus	82-86
27488462-12	2017	In conclusion, leptin deficiency attenuated IMQ-induced psoriasis-like skin inflammation in a mouse model, and leptin stimulation induced a pro-inflammatory phenotype in human keratinocytes, thus, supporting an aggravating role of leptin in psoriasis.	Imiquimod	44-47	leptin	Mus musculus	15-21
28096316-13	2017	NLRP3 KO animals showed a reduced total histological score but persistent mild acanthosis, dermal thickness and expression of pNF-kappaB and pSTAT3, following IMQ application.	Imiquimod	159-162	NLR family, pyrin domain containing 3	Mus musculus	0-5
27856305-8	2017	IMQ-induced psoriasis-like mice were treated with anti-Cyr61monoclonal antibodies (mAb), or IgG1 as a control.	Imiquimod	0-3	cellular communication network factor 1	Mus musculus	55-60
27939414-12	2017	Moreover, subcutaneous administration of IL-27 recombinant protein lessened severity of IMQ-induced psoriasis-like cutaneous lesions, whereas IL-27p28 antagonist exaggerated the disease severity.	Imiquimod	88-91	interleukin 27	Mus musculus	41-46
27939414-14	2017	Also administration of IL-27 decreased IL-17A level while IL-27p28 antagonist increased IL-17A level in serum and psoriasis-like lesion in the IMQ-treated mice.	Imiquimod	143-146	interleukin 27	Mus musculus	23-28
27939414-14	2017	Also administration of IL-27 decreased IL-17A level while IL-27p28 antagonist increased IL-17A level in serum and psoriasis-like lesion in the IMQ-treated mice.	Imiquimod	143-146	interleukin 27	Mus musculus	58-66
27939414-14	2017	Also administration of IL-27 decreased IL-17A level while IL-27p28 antagonist increased IL-17A level in serum and psoriasis-like lesion in the IMQ-treated mice.	Imiquimod	143-146	interleukin 17A	Mus musculus	88-94
27964879-6	2017	RESULTS: The severity of IMQ-induced dermatitis in langerin-DTA mice was significantly lower than that of wild-type mice, as evidenced by decreased level of ear thickness, inflammatory cell infiltration (gammadelta T cells and neutrophils) and inflammatory cytokine expression (IL-17, IL-22, IL-23 and tumor necrosis factor-alpha).	Imiquimod	25-28	CD207 antigen	Mus musculus	51-59
27964879-6	2017	RESULTS: The severity of IMQ-induced dermatitis in langerin-DTA mice was significantly lower than that of wild-type mice, as evidenced by decreased level of ear thickness, inflammatory cell infiltration (gammadelta T cells and neutrophils) and inflammatory cytokine expression (IL-17, IL-22, IL-23 and tumor necrosis factor-alpha).	Imiquimod	25-28	interleukin 17A	Mus musculus	278-283
27964879-6	2017	RESULTS: The severity of IMQ-induced dermatitis in langerin-DTA mice was significantly lower than that of wild-type mice, as evidenced by decreased level of ear thickness, inflammatory cell infiltration (gammadelta T cells and neutrophils) and inflammatory cytokine expression (IL-17, IL-22, IL-23 and tumor necrosis factor-alpha).	Imiquimod	25-28	interleukin 22	Mus musculus	285-290
27964879-6	2017	RESULTS: The severity of IMQ-induced dermatitis in langerin-DTA mice was significantly lower than that of wild-type mice, as evidenced by decreased level of ear thickness, inflammatory cell infiltration (gammadelta T cells and neutrophils) and inflammatory cytokine expression (IL-17, IL-22, IL-23 and tumor necrosis factor-alpha).	Imiquimod	25-28	interleukin 23, alpha subunit p19	Mus musculus	292-329
27964879-7	2017	After application with IMQ, LCs expanded in epidermis and showed increased expression of CD80 and CD86, and migrated to draining lymph node within 48h.	Imiquimod	23-26	CD80 antigen	Mus musculus	89-93
27964879-7	2017	After application with IMQ, LCs expanded in epidermis and showed increased expression of CD80 and CD86, and migrated to draining lymph node within 48h.	Imiquimod	23-26	CD86 antigen	Mus musculus	98-102
29046894-5	2017	Conjugation of a model antigen, ovalbumin (OVA), to the corona of IMQ-loaded LMA50 micelles enhanced in vitro antigen uptake and cross-presentation on MHC class I (MHC-I).	Imiquimod	66-69	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	32-41
29046894-5	2017	Conjugation of a model antigen, ovalbumin (OVA), to the corona of IMQ-loaded LMA50 micelles enhanced in vitro antigen uptake and cross-presentation on MHC class I (MHC-I).	Imiquimod	66-69	serine (or cysteine) peptidase inhibitor, clade B, member 1, pseudogene	Mus musculus	43-46
27773660-9	2017	Treatment with IL-17A further aggravated, whereas treatment with anti-IL17A antibody ameliorated IMQ-induced changes in hepatic injury/inflammation and protein/lipid metabolism.	Imiquimod	97-100	interleukin 17A	Mus musculus	70-75
27393705-10	2017	Innovation and Conclusion: Our observation that Del inhibits key kinases involved in psoriasis pathogenesis and alleviates IMQ-induced murine psoriasis-like disease suggests a novel PI3K/AKT/mTOR pathway modulator that could be developed to treat psoriasis.	Imiquimod	123-126	thymoma viral proto-oncogene 1	Mus musculus	187-190
27393705-10	2017	Innovation and Conclusion: Our observation that Del inhibits key kinases involved in psoriasis pathogenesis and alleviates IMQ-induced murine psoriasis-like disease suggests a novel PI3K/AKT/mTOR pathway modulator that could be developed to treat psoriasis.	Imiquimod	123-126	mechanistic target of rapamycin kinase	Mus musculus	191-195
28761880-3	2017	Imiquimod (IMQ), a TLR7/8 agonist, has been used to induce psoriasis in a mouse model.	Imiquimod	0-9	toll-like receptor 7	Mus musculus	19-25
28761880-3	2017	Imiquimod (IMQ), a TLR7/8 agonist, has been used to induce psoriasis in a mouse model.	Imiquimod	11-14	toll-like receptor 7	Mus musculus	19-25
27829595-0	2016	Imiquimod-induced CCR9 Ameliorates murine TNBS Colitis.	Imiquimod	0-9	chemokine (C-C motif) receptor 9	Mus musculus	18-22
27829595-10	2016	In the colons of IMQ-treated mice, mRNA expression of TNF-alpha was decreased, and strong expressions of IL-6, IFN-beta and TGF-beta were detected.	Imiquimod	17-20	tumor necrosis factor	Mus musculus	54-63
27829595-10	2016	In the colons of IMQ-treated mice, mRNA expression of TNF-alpha was decreased, and strong expressions of IL-6, IFN-beta and TGF-beta were detected.	Imiquimod	17-20	interleukin 6	Mus musculus	105-109
27829595-10	2016	In the colons of IMQ-treated mice, mRNA expression of TNF-alpha was decreased, and strong expressions of IL-6, IFN-beta and TGF-beta were detected.	Imiquimod	17-20	interferon beta 1, fibroblast	Mus musculus	111-119
27829595-10	2016	In the colons of IMQ-treated mice, mRNA expression of TNF-alpha was decreased, and strong expressions of IL-6, IFN-beta and TGF-beta were detected.	Imiquimod	17-20	transforming growth factor, beta 1	Mus musculus	124-132
27829595-12	2016	In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-beta, TGF-beta and Foxp3 mRNA were detected.	Imiquimod	10-13	toll-like receptor 7	Mus musculus	50-54
27829595-12	2016	In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-beta, TGF-beta and Foxp3 mRNA were detected.	Imiquimod	10-13	interferon beta 1, fibroblast	Mus musculus	56-64
27829595-12	2016	In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-beta, TGF-beta and Foxp3 mRNA were detected.	Imiquimod	10-13	transforming growth factor, beta 1	Mus musculus	66-74
27829595-12	2016	In MLN of IMQ-treated mice, strong expressions of TLR7, IFN-beta, TGF-beta and Foxp3 mRNA were detected.	Imiquimod	10-13	forkhead box P3	Mus musculus	79-84
27829595-13	2016	IL-10 production from MLN cells was also increased in the IMQ-treated group.	Imiquimod	58-61	interleukin 10	Mus musculus	0-5
27829595-14	2016	Finally, Tregs in the inflamed colon and CCR9 in MLN of IMQ-treated mice were detected.	Imiquimod	56-59	chemokine (C-C motif) receptor 9	Mus musculus	41-45
27829595-15	2016	CONCLUSION: These results suggest that IMQ protects mice from TNBS colitis through induction of CCR9, which regulates accumulation of Tregs in the inflamed colon.	Imiquimod	39-42	chemokine (C-C motif) receptor 9	Mus musculus	96-100
27934944-5	2016	Unexpectedly, in GILZ-Tg mice, the severity of IMQ-induced psoriasis-like skin lesions as well as induction of cytokines commonly up-regulated in human psoriasis (Il-17, Il-22, Il-23, Il-6, S100a8/a9, and Stat3) was significantly more pronounced relative to GILZ-Wt mice.	Imiquimod	47-50	TSC22 domain family, member 3	Mus musculus	17-21
27934944-6	2016	The increased susceptibility to IMQ-induced psoriasis of GILZ-Tg mice was significantly associated with skin-specific over-activation of TGF-beta1-mediated signaling via SMAD2/3.	Imiquimod	32-35	TSC22 domain family, member 3	Mus musculus	57-61
27934944-6	2016	The increased susceptibility to IMQ-induced psoriasis of GILZ-Tg mice was significantly associated with skin-specific over-activation of TGF-beta1-mediated signaling via SMAD2/3.	Imiquimod	32-35	transforming growth factor, beta 1	Mus musculus	137-146
27934944-6	2016	The increased susceptibility to IMQ-induced psoriasis of GILZ-Tg mice was significantly associated with skin-specific over-activation of TGF-beta1-mediated signaling via SMAD2/3.	Imiquimod	32-35	SMAD family member 2	Mus musculus	170-177
27365293-3	2016	Similarly, the imiquimod (IMQ)- and Il23-induced mouse psoriasis was associated with a substantial upregulation of Trex2, which was recruited into fragmented chromatin in keratinocytes that were undergoing impaired proliferation, differentiation, and cell death, indicating an important role in DNA processing.	Imiquimod	15-24	three prime repair exonuclease 2	Mus musculus	115-120
27936237-4	2016	In addition, imiquimod is a potent inducer of apoptosis in human tumour cell lines via TLR7 independent mechanisms.	Imiquimod	13-22	toll like receptor 7	Homo sapiens	87-91
27365293-3	2016	Similarly, the imiquimod (IMQ)- and Il23-induced mouse psoriasis was associated with a substantial upregulation of Trex2, which was recruited into fragmented chromatin in keratinocytes that were undergoing impaired proliferation, differentiation, and cell death, indicating an important role in DNA processing.	Imiquimod	26-29	three prime repair exonuclease 2	Mus musculus	115-120
27365293-4	2016	Using Trex2 knockout mice, we have found that Trex2 deficiency attenuated IMQ-induced psoriasis-like skin inflammation and enhanced IMQ-induced parakeratosis.	Imiquimod	74-77	three prime repair exonuclease 2	Mus musculus	46-51
27365293-4	2016	Using Trex2 knockout mice, we have found that Trex2 deficiency attenuated IMQ-induced psoriasis-like skin inflammation and enhanced IMQ-induced parakeratosis.	Imiquimod	132-135	three prime repair exonuclease 2	Mus musculus	46-51
27365293-6	2016	Transcriptome analysis identified multiple genes that were deregulated by Trex2 loss after treatment with IMQ.	Imiquimod	106-109	three prime repair exonuclease 2	Mus musculus	74-79
27365293-8	2016	Interestingly, Trex2 deficiency led to decreased IMQ-induced keratinocyte death via both cell autonomous and noncell autonomous mechanisms.	Imiquimod	49-52	three prime repair exonuclease 2	Mus musculus	15-20
26144250-8	2016	To further confirm our results, we established another lupus model by topically treating C57BL/6 (B6) mice with the TLR-7 agonist imiquimod (IMQ) for 8 weeks according to the previously described protocol.	Imiquimod	130-139	toll-like receptor 7	Mus musculus	116-121
27708240-5	2016	Furthermore, in Nrip1 knockout mice, IMQ-induced inflammation of skin was delayed and the RelA/p65 expression in lesions was reduced.	Imiquimod	37-40	nuclear receptor interacting protein 1	Mus musculus	16-21
26144250-8	2016	To further confirm our results, we established another lupus model by topically treating C57BL/6 (B6) mice with the TLR-7 agonist imiquimod (IMQ) for 8 weeks according to the previously described protocol.	Imiquimod	141-144	toll-like receptor 7	Mus musculus	116-121
26144250-9	2016	Expectedly, topical treatment with IMQ also significantly increased CCND3 and decreased miR-15b in B cells of B6 mice.	Imiquimod	35-38	microRNA 15b	Mus musculus	88-95
27584056-0	2016	A PPARdelta-selective antagonist ameliorates IMQ-induced psoriasis-like inflammation in mice.	Imiquimod	45-48	peroxisome proliferator activator receptor delta	Mus musculus	2-11
27584056-4	2016	In the current study, we showed that PPARdelta was highly expressed in the skin of IMQ-induced psoriasis mice.	Imiquimod	83-86	peroxisome proliferator activator receptor delta	Mus musculus	37-46
27584056-6	2016	We found that PPARdelta was highly expressed in both psoriatic lesions and normal skin in IMQ-induced psoriasis mice.	Imiquimod	90-93	peroxisome proliferator activator receptor delta	Mus musculus	14-23
27369778-3	2016	The severity of imiquimod-induced psoriasiform inflammation was greatly exacerbated in skin of mice deficient in IFNAR1 ubiquitination (Ifnar1(SA)).	Imiquimod	16-25	interferon (alpha and beta) receptor 1	Mus musculus	113-119
27449383-3	2016	OBJECTIVE: To investigate the effects of AZM on the induction of DC maturation and activation by imiquimod (IMQ), a synthetic TLR7 agonist, as well as its potential as a therapeutic agent for psoriasis.	Imiquimod	97-106	toll-like receptor 7	Mus musculus	126-130
27449383-8	2016	AZM treatment impaired lysosomal acidification, interrupted TLR7 maturation in the lysosome, and ultimately blocked the IMQ-induced NF-kappaB and IRF-7 nuclear translocation in DCs.	Imiquimod	120-123	interferon regulatory factor 7	Mus musculus	146-151
27449383-12	2016	CONCLUSION: AZM impaired IMQ-induced DC activation by decreasing lysosomal acidification and disrupting TLR7 maturation and signaling.	Imiquimod	25-28	toll-like receptor 7	Mus musculus	104-108
27377695-7	2016	The expression of the anagen-inhibiting factor BMP-4 was reduced by IMQ treatment as well as the activating factors Wnt showing that IMQ-induced hair follicle stem cell activation occurs by a Wnt-independent mechanism involving inflammatory cytokines such as CCL2 and TNF-alpha.	Imiquimod	68-71	bone morphogenetic protein 4	Mus musculus	47-52
27476970-9	2016	Moreover, downregulation of betaTrCP through lentiviral shRNA ameliorates IMQ-induced psoriasis-like skin lesions in vivo.	Imiquimod	74-77	beta-transducin repeat containing protein	Mus musculus	28-36
27592361-5	2016	Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not.	Imiquimod	111-114	interleukin 17A	Mus musculus	68-74
27592361-5	2016	Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not.	Imiquimod	111-114	interleukin 23, alpha subunit p19	Mus musculus	79-84
27592361-5	2016	Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not.	Imiquimod	111-114	negative elongation factor complex member C/D, Th1l	Mus musculus	52-55
27592361-5	2016	Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not.	Imiquimod	111-114	tumor necrosis factor	Mus musculus	219-228
27592361-5	2016	Subsequent analyses revealed that the production of Th17 cytokines (IL-17A and IL-23) in the serum and skin of IMQ-induced mice was significantly inhibited by agonistic anti-4-1BB Abs (10mg/kg), although Th1 cytokines (TNF-alpha and IFN-gamma) were not.	Imiquimod	111-114	interferon gamma	Mus musculus	233-242
27540765-0	2016	MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.	Imiquimod	25-34	interleukin 23, alpha subunit p19	Mus musculus	85-90
27540765-0	2016	MAD ointment ameliorates Imiquimod-induced psoriasiform dermatitis by inhibiting the IL-23/IL-17 axis in mice.	Imiquimod	25-34	interleukin 17A	Mus musculus	91-96
27369778-3	2016	The severity of imiquimod-induced psoriasiform inflammation was greatly exacerbated in skin of mice deficient in IFNAR1 ubiquitination (Ifnar1(SA)).	Imiquimod	16-25	interferon (alpha and beta) receptor 1	Mus musculus	136-142
27265145-0	2016	Andrographolide alleviates imiquimod-induced psoriasis in mice via inducing autophagic proteolysis of MyD88.	Imiquimod	27-36	myeloid differentiation primary response gene 88	Mus musculus	102-107
28239073-5	2016	IMQ-induced skin inflammation was associated with increased levels of mRNA transcripts expression of signature cytokines of T helper (Th)1/Th17 cells, i.e., interferon-gamma, interleukin (IL)-17 and IL-22 on Day 5.	Imiquimod	0-3	interferon gamma	Mus musculus	157-173
28239073-5	2016	IMQ-induced skin inflammation was associated with increased levels of mRNA transcripts expression of signature cytokines of T helper (Th)1/Th17 cells, i.e., interferon-gamma, interleukin (IL)-17 and IL-22 on Day 5.	Imiquimod	0-3	interleukin 22	Mus musculus	199-204
28239073-6	2016	In addition, levels of mRNA expression of the markers of keratinocytes, i.e., IL-1beta, S100A8, and S100A9, were dramatically elevated in IMQ-treated mice.	Imiquimod	138-141	interleukin 1 beta	Mus musculus	78-86
27000947-0	2016	AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model.	Imiquimod	68-77	aryl-hydrocarbon receptor	Mus musculus	0-3
27537524-10	2016	Furthermore, to confirm the above results in vivo, TLR7 agonist imiquimod (IMQ)-induced lupus mouse model was prepared.	Imiquimod	64-73	toll-like receptor 7	Mus musculus	51-55
27537524-10	2016	Furthermore, to confirm the above results in vivo, TLR7 agonist imiquimod (IMQ)-induced lupus mouse model was prepared.	Imiquimod	75-78	toll-like receptor 7	Mus musculus	51-55
27537524-11	2016	Splenic macrophages from IMQ-treated mice exhibited increased autophagy and cell death as well as enhanced expressions of Notch1 and Hes-1.	Imiquimod	25-28	notch 1	Mus musculus	122-128
27537524-11	2016	Splenic macrophages from IMQ-treated mice exhibited increased autophagy and cell death as well as enhanced expressions of Notch1 and Hes-1.	Imiquimod	25-28	hes family bHLH transcription factor 1	Mus musculus	133-138
27537526-8	2016	Dissection of the IL-22 signalling pathway, activated by IMQ treatment, demonstrates that LUT-7G impairs the nuclear translocation of phosphorylated (activated) STAT3, blocking the IL-22 signalling cascade.	Imiquimod	57-60	interleukin 22	Mus musculus	18-23
27180111-8	2016	In the mouse model of imiquimod-induced psoriasis, Zc3h12a expression was abrogated in Il17ra(-/-) mice.	Imiquimod	22-31	zinc finger CCCH type containing 12A	Mus musculus	51-58
27180111-8	2016	In the mouse model of imiquimod-induced psoriasis, Zc3h12a expression was abrogated in Il17ra(-/-) mice.	Imiquimod	22-31	interleukin 17 receptor A	Mus musculus	87-93
26702876-3	2016	We examined the in vivo effects of LCN2 on topical imiquimod (IMQ)-induced psoriasiform skin in BALB/c mice and in vitro on human keratinocytes (KC).	Imiquimod	51-60	lipocalin 2	Mus musculus	35-39
27221314-6	2016	As compared with the IMQ-treated mice or IMQ-treated Th1-type CHS mice, the mice with Th2-type CHS treated with IMQ exhibited more serious psoriasis-like inflammation with increased epidermal thickness and infiltrating cells in the derma.	Imiquimod	41-44	negative elongation factor complex member C/D, Th1l	Mus musculus	53-56
27221314-6	2016	As compared with the IMQ-treated mice or IMQ-treated Th1-type CHS mice, the mice with Th2-type CHS treated with IMQ exhibited more serious psoriasis-like inflammation with increased epidermal thickness and infiltrating cells in the derma.	Imiquimod	41-44	negative elongation factor complex member C/D, Th1l	Mus musculus	53-56
27221314-10	2016	In conclusion, these data demonstrate that Th2-type CHS exacerbated the IMQ-treated psoriatic inflammation of mice via the IL-23/IL-17 axis.	Imiquimod	72-75	heart and neural crest derivatives expressed 2	Mus musculus	43-46
27221314-10	2016	In conclusion, these data demonstrate that Th2-type CHS exacerbated the IMQ-treated psoriatic inflammation of mice via the IL-23/IL-17 axis.	Imiquimod	72-75	interleukin 23, alpha subunit p19	Mus musculus	123-128
27221314-10	2016	In conclusion, these data demonstrate that Th2-type CHS exacerbated the IMQ-treated psoriatic inflammation of mice via the IL-23/IL-17 axis.	Imiquimod	72-75	interleukin 17A	Mus musculus	129-134
27000947-0	2016	AhR modulates the IL-22-producing cell proliferation/recruitment in imiquimod-induced psoriasis mouse model.	Imiquimod	68-77	interleukin 22	Mus musculus	18-23
27000947-4	2016	Our results indicate that IL-22 is expressed in the ear of imiquimod-treated Ahr(-/-) mice but less than in wild-type mice.	Imiquimod	59-68	interleukin 22	Mus musculus	26-31
27000947-4	2016	Our results indicate that IL-22 is expressed in the ear of imiquimod-treated Ahr(-/-) mice but less than in wild-type mice.	Imiquimod	59-68	aryl-hydrocarbon receptor	Mus musculus	77-80
27222343-0	2016	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.	Imiquimod	16-25	nuclear factor of activated T cells 1	Homo sapiens	0-6
26976687-15	2016	Moreover, transfer of macrophages from WT mice normalized IMQ-induced psoriasis-like inflammation in CX3CR1(-/-) mice, suggesting that macrophages contributed to the decreased inflammation resulted from CX3CR1 deficiency.	Imiquimod	58-61	chemokine (C-X3-C motif) receptor 1	Mus musculus	101-107
26976687-15	2016	Moreover, transfer of macrophages from WT mice normalized IMQ-induced psoriasis-like inflammation in CX3CR1(-/-) mice, suggesting that macrophages contributed to the decreased inflammation resulted from CX3CR1 deficiency.	Imiquimod	58-61	chemokine (C-X3-C motif) receptor 1	Mus musculus	203-209
26900758-0	2016	Inhibitory Effect of Imiquimod-Induced Psoriasis-Like Skin Inflammation in Mice by Histamine H4 Receptor Agonist 4-Methylhistamine.	Imiquimod	21-30	histamine receptor H4	Mus musculus	83-104
27222343-0	2016	NFATc1 supports imiquimod-induced skin inflammation by suppressing IL-10 synthesis in B cells.	Imiquimod	16-25	interleukin 10	Homo sapiens	67-72
27222343-1	2016	Epicutaneous application of Aldara cream containing the TLR7 agonist imiquimod (IMQ) to mice induces skin inflammation that exhibits many aspects of psoriasis, an inflammatory human skin disease.	Imiquimod	69-78	toll-like receptor 7	Mus musculus	56-60
27222343-2	2016	Here we show that mice depleted of B cells or bearing interleukin (IL)-10-deficient B cells show a fulminant inflammation upon IMQ exposure, whereas ablation of NFATc1 in B cells results in a suppression of Aldara-induced inflammation.	Imiquimod	127-130	interleukin 10	Mus musculus	54-73
27222343-2	2016	Here we show that mice depleted of B cells or bearing interleukin (IL)-10-deficient B cells show a fulminant inflammation upon IMQ exposure, whereas ablation of NFATc1 in B cells results in a suppression of Aldara-induced inflammation.	Imiquimod	207-213	nuclear factor of activated T cells, cytoplasmic, calcineurin dependent 1	Mus musculus	161-167
27222343-3	2016	In vitro, IMQ induces the proliferation and IL-10 expression by B cells that is blocked by BCR signals inducing NFATc1.	Imiquimod	10-13	interleukin 10	Homo sapiens	44-49
27222343-3	2016	In vitro, IMQ induces the proliferation and IL-10 expression by B cells that is blocked by BCR signals inducing NFATc1.	Imiquimod	10-13	nuclear factor of activated T cells 1	Homo sapiens	112-118
27003259-5	2016	We further confirmed this by showing that IMQ could still induce ER stress in mouse Tlr7(-/-) cells.	Imiquimod	42-45	toll-like receptor 7	Mus musculus	84-88
26775629-2	2016	Imiquimod (IMQ), a synthetic toll-like receptor (TLR) 7 ligand for the treatment of superficial basal cell carcinoma (BCC), eliminates cancer cells by activating cell-mediated immunity and directly inducing apoptosis and autophagy in cancer cells.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	49-52
26614407-2	2016	OBJECTIVES: To study the impact of constitutive deficiency of tumour necrosis factor (TNF)-alpha and its upstream regulator mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK-2, herein MK2) in the Aldara-induced psoriasis-like skin inflammation model.	Imiquimod	215-221	tumor necrosis factor	Mus musculus	62-96
26614407-2	2016	OBJECTIVES: To study the impact of constitutive deficiency of tumour necrosis factor (TNF)-alpha and its upstream regulator mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK-2, herein MK2) in the Aldara-induced psoriasis-like skin inflammation model.	Imiquimod	215-221	MAP kinase-activated protein kinase 2	Mus musculus	124-183
26614407-2	2016	OBJECTIVES: To study the impact of constitutive deficiency of tumour necrosis factor (TNF)-alpha and its upstream regulator mitogen-activated protein kinase-activated protein kinase 2 (MAPKAPK-2, herein MK2) in the Aldara-induced psoriasis-like skin inflammation model.	Imiquimod	215-221	MAP kinase-activated protein kinase 2	Mus musculus	185-194
27164085-4	2016	However, SARS-CoV PLPro significantly inhibited IMQ-induced cytokine production through suppressing the activation of transcription factors IRF-3, NF-kappaB and AP-1.	Imiquimod	48-51	nuclear factor kappa B subunit 1	Homo sapiens	147-156
27164085-4	2016	However, SARS-CoV PLPro significantly inhibited IMQ-induced cytokine production through suppressing the activation of transcription factors IRF-3, NF-kappaB and AP-1.	Imiquimod	48-51	JunB proto-oncogene, AP-1 transcription factor subunit	Homo sapiens	161-165
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	interleukin 23, alpha subunit p19	Mus musculus	148-156
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	interleukin 12b	Mus musculus	158-166
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	interleukin 17A	Mus musculus	168-174
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	interleukin 22	Mus musculus	176-181
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	S100 calcium binding protein A8 (calgranulin A)	Mus musculus	186-192
26614407-6	2016	At the molecular level, we demonstrated that the Aldara-induced mRNA expression of the psoriasis-related inflammatory markers interleukin (IL)-17C, IL-23p19, IL-12p40, IL-17A, IL-22 and S100A8 was significantly decreased in TNF-alpha KO mice compared with WT mice.	Imiquimod	49-55	tumor necrosis factor	Mus musculus	224-233
26999594-3	2016	Recently, it was shown that the IL-23/ IL-17 axis plays a deciding role in the pathogenesis of human psoriasis, as well as in the mouse model of IMQ-induced psoriasis-like skin disease.	Imiquimod	145-148	interleukin 23 subunit alpha	Homo sapiens	32-37
26999594-3	2016	Recently, it was shown that the IL-23/ IL-17 axis plays a deciding role in the pathogenesis of human psoriasis, as well as in the mouse model of IMQ-induced psoriasis-like skin disease.	Imiquimod	145-148	interleukin 17A	Homo sapiens	39-44
26513536-0	2016	Selective CD28 antagonist prevents Aldara-induced skin inflammation in non-human primates.	Imiquimod	35-41	CD28 molecule	Homo sapiens	10-14
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	interleukin 17A	Mus musculus	219-225
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	tumor necrosis factor	Mus musculus	227-236
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	interleukin 6	Mus musculus	238-242
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	interferon gamma	Mus musculus	244-253
26784569-6	2016	Administration of astilbin ameliorated IMQ-induced keratinocyte proliferation, infiltration of CD3+ cells to psoriatic lesions and ameliorated elevations in circulating CD4+ and CD8+ T cells and inflammatory cytokines (IL-17A, TNF-alpha, IL-6, IFN-gamma and IL-2).	Imiquimod	39-42	interleukin 2	Mus musculus	258-262
26775629-12	2016	CONCLUSION: IMQ induced ROS production to stimulate ATM/ATR pathways and contributed to p53-dependent apoptosis in a skin basal cell carcinoma cell line BCC/KMC1.	Imiquimod	12-15	ATM serine/threonine kinase	Homo sapiens	52-55
26775629-12	2016	CONCLUSION: IMQ induced ROS production to stimulate ATM/ATR pathways and contributed to p53-dependent apoptosis in a skin basal cell carcinoma cell line BCC/KMC1.	Imiquimod	12-15	ATR serine/threonine kinase	Homo sapiens	56-59
26775629-12	2016	CONCLUSION: IMQ induced ROS production to stimulate ATM/ATR pathways and contributed to p53-dependent apoptosis in a skin basal cell carcinoma cell line BCC/KMC1.	Imiquimod	12-15	tumor protein p53	Homo sapiens	88-91
26775629-2	2016	Imiquimod (IMQ), a synthetic toll-like receptor (TLR) 7 ligand for the treatment of superficial basal cell carcinoma (BCC), eliminates cancer cells by activating cell-mediated immunity and directly inducing apoptosis and autophagy in cancer cells.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	49-52
26775629-6	2016	The role of p53 in IMQ-induced apoptosis and autophagy was assessed by genetically silencing p53 and evaluated by a DNA content assay, immunoblotting, LC3 puncta detection and acridine orange staining.	Imiquimod	19-22	tumor protein p53	Homo sapiens	12-15
26775629-6	2016	The role of p53 in IMQ-induced apoptosis and autophagy was assessed by genetically silencing p53 and evaluated by a DNA content assay, immunoblotting, LC3 puncta detection and acridine orange staining.	Imiquimod	19-22	tumor protein p53	Homo sapiens	93-96
26775629-7	2016	RESULTS: IMQ induced p53 mRNA expression and protein accumulation, increased Ser15 phosphorylation, promoted nuclear translocation and up-regulated its target genes in skin cancer cells in a TLR7/8-independent manner.	Imiquimod	9-12	tumor protein p53	Homo sapiens	21-24
26775629-7	2016	RESULTS: IMQ induced p53 mRNA expression and protein accumulation, increased Ser15 phosphorylation, promoted nuclear translocation and up-regulated its target genes in skin cancer cells in a TLR7/8-independent manner.	Imiquimod	9-12	toll like receptor 7	Homo sapiens	191-195
26775629-8	2016	In BCC/KMC1 cells, the induction of p53 by IMQ was achieved through increased ROS production to stimulate the ATM/ATR-Chk1/Chk2 axis but was not mediated by inducing DNA damage.	Imiquimod	43-46	tumor protein p53	Homo sapiens	36-39
26775629-8	2016	In BCC/KMC1 cells, the induction of p53 by IMQ was achieved through increased ROS production to stimulate the ATM/ATR-Chk1/Chk2 axis but was not mediated by inducing DNA damage.	Imiquimod	43-46	ATM serine/threonine kinase	Homo sapiens	110-113
26775629-8	2016	In BCC/KMC1 cells, the induction of p53 by IMQ was achieved through increased ROS production to stimulate the ATM/ATR-Chk1/Chk2 axis but was not mediated by inducing DNA damage.	Imiquimod	43-46	ATR serine/threonine kinase	Homo sapiens	114-117
26775629-8	2016	In BCC/KMC1 cells, the induction of p53 by IMQ was achieved through increased ROS production to stimulate the ATM/ATR-Chk1/Chk2 axis but was not mediated by inducing DNA damage.	Imiquimod	43-46	checkpoint kinase 1	Homo sapiens	118-122
26775629-8	2016	In BCC/KMC1 cells, the induction of p53 by IMQ was achieved through increased ROS production to stimulate the ATM/ATR-Chk1/Chk2 axis but was not mediated by inducing DNA damage.	Imiquimod	43-46	checkpoint kinase 2	Homo sapiens	123-127
26775629-9	2016	The pharmacological inhibition of ATM/ATR significantly suppressed IMQ-induced p53 activation and apoptosis.	Imiquimod	67-70	ATM serine/threonine kinase	Homo sapiens	34-37
26775629-9	2016	The pharmacological inhibition of ATM/ATR significantly suppressed IMQ-induced p53 activation and apoptosis.	Imiquimod	67-70	ATR serine/threonine kinase	Homo sapiens	38-41
26775629-9	2016	The pharmacological inhibition of ATM/ATR significantly suppressed IMQ-induced p53 activation and apoptosis.	Imiquimod	67-70	tumor protein p53	Homo sapiens	79-82
26775629-10	2016	Silencing of p53 significantly decreased the IMQ-induced caspase cascade activation and apoptosis but enhanced autophagy.	Imiquimod	45-48	tumor protein p53	Homo sapiens	13-16
26775629-11	2016	Mutant p53 skin cancer cell lines were more resistant to IMQ-induced apoptosis than wildtype p53 skin cancer cell lines.	Imiquimod	57-60	tumor protein p53	Homo sapiens	7-10
26462411-3	2016	We explored the feasibility of using extracellular superoxide dismutase (SOD3)-transduced allogeneic MSCs as a novel therapeutic approach in a mouse model of imiquimod (IMQ)-induced psoriasis-like inflammation and investigated the poorly understood underlying mechanism.	Imiquimod	158-167	superoxide dismutase 3, extracellular	Mus musculus	73-77
26462411-3	2016	We explored the feasibility of using extracellular superoxide dismutase (SOD3)-transduced allogeneic MSCs as a novel therapeutic approach in a mouse model of imiquimod (IMQ)-induced psoriasis-like inflammation and investigated the poorly understood underlying mechanism.	Imiquimod	169-172	superoxide dismutase 3, extracellular	Mus musculus	73-77
26462411-5	2016	RESULTS: Subcutaneous injection of allogeneic SOD3-transduced MSCs significantly prevented psoriasis development in our IMQ-induced mouse model, likely through a suppression of proliferation and infiltration of various effector cells into skin with a concomitant modulated cytokine and chemokine expression and inhibition of signaling pathways such as toll-like receptor-7, nuclear factor-kappa B, p38 mitogen-activated kinase, and Janus kinase-signal transducer and activator of transcription, as well as adenosine receptor activation.	Imiquimod	120-123	superoxide dismutase 3, extracellular	Mus musculus	46-50
26738780-10	2016	These results suggest that PF inhibits IMQ-induced psoriasis by regulating Th17 cell response and cytokine secretion via phosphorylation of Stat3.	Imiquimod	39-42	signal transducer and activator of transcription 3	Mus musculus	140-145
26582563-0	2016	Percutaneous delivery of alpha-melanocyte-stimulating hormone for the treatment of imiquimod-induced psoriasis.	Imiquimod	83-92	pro-opiomelanocortin-alpha	Mus musculus	25-61
26578344-0	2016	Imiquimod-induced apoptosis of melanoma cells is mediated by ER stress-dependent Noxa induction and enhanced by NF-kappaB inhibition.	Imiquimod	0-9	phorbol-12-myristate-13-acetate-induced protein 1	Homo sapiens	81-85
26733387-3	2016	Our study evaluated the influence of imiquimod (IMQ) on VEGF in IMQ-induced mouse model.	Imiquimod	37-46	vascular endothelial growth factor A	Mus musculus	56-60
26733387-3	2016	Our study evaluated the influence of imiquimod (IMQ) on VEGF in IMQ-induced mouse model.	Imiquimod	48-51	vascular endothelial growth factor A	Mus musculus	56-60
26733387-9	2016	The IMQ-induced mouse psoriatic model showed an upregulation of VEGF in the skin lesions mimicking human psoriasis but the circulating VEGF-A levels showed no difference.	Imiquimod	4-7	vascular endothelial growth factor A	Mus musculus	64-68
26549648-5	2016	Furthermore, blocking of autophagy by 3-MA exerted an inhibitory effect on imiquimod-induced apoptosis, which indicated that autophagy can function as a mechanism which, upon activation, directly leads to apoptosis and cell death of SGC-7901 cells.	Imiquimod	75-84	sarcoglycan beta	Homo sapiens	233-236
26291684-6	2015	We found that Clock mutation ameliorated IMQ-induced dermatitis, whereas the Per2 mutation exaggerated IMQ-induced dermatitis, when compared with wild-type mice associated with decreased or increased IL-23 receptor (IL-23R) expression in gamma/delta+ T cells, respectively.	Imiquimod	103-106	period circadian clock 2	Mus musculus	77-81
26466959-2	2015	Previous studies showed that short-term, 5-7 d-long application of imiquimod (IMQ), a TLR7 agonist, to the skin of mice triggers a psoriasis-like inflammation.	Imiquimod	67-76	toll-like receptor 7	Mus musculus	86-90
26466959-2	2015	Previous studies showed that short-term, 5-7 d-long application of imiquimod (IMQ), a TLR7 agonist, to the skin of mice triggers a psoriasis-like inflammation.	Imiquimod	78-81	toll-like receptor 7	Mus musculus	86-90
25734813-0	2015	SIRT1 Activation Ameliorates Aldara-Induced Psoriasiform Phenotype and Histology in Mice.	Imiquimod	29-35	sirtuin 1	Mus musculus	0-5
26332438-4	2015	IL-17A/F-producing Vgamma4(+) Vdelta4(+) T cells populate and persist in the dermis for long periods of time after initial stimulation with Aldara.	Imiquimod	140-146	interleukin 17A	Mus musculus	0-6
26149470-0	2015	Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.	Imiquimod	0-9	RAR-related orphan receptor gamma	Mus musculus	110-114
26149470-0	2015	Imiquimod-induced psoriasis-like skin inflammation is suppressed by BET bromodomain inhibitor in mice through RORC/IL-17A pathway modulation.	Imiquimod	0-9	interleukin 17A	Mus musculus	115-121
25662483-11	2015	In the mouse model of Aldara-induced skin inflammation, the level of miR-146a increased, whereas no regulation was seen for miR-203, miR-214-3p, miR-125a, miR-23b or let-7d-5p.	Imiquimod	22-28	microRNA 146	Mus musculus	69-77
26048148-6	2015	Three-fold increases in the percentage of IL-17A(+) GDL T cells were observed in skin cell suspensions derived from IMQ-treated PD-1KO mice (versus WT controls), suggesting that the lack of PD-1 has a functional effect not only on alphabeta T cells, but also on GDL T cells, and that PD-1 may play a regulatory role in PsD.	Imiquimod	116-119	interleukin 17A	Mus musculus	42-48
26048148-6	2015	Three-fold increases in the percentage of IL-17A(+) GDL T cells were observed in skin cell suspensions derived from IMQ-treated PD-1KO mice (versus WT controls), suggesting that the lack of PD-1 has a functional effect not only on alphabeta T cells, but also on GDL T cells, and that PD-1 may play a regulatory role in PsD.	Imiquimod	116-119	programmed cell death 1	Mus musculus	128-132
26099024-3	2015	Here we demonstrate that CCN1 (also called Cyr61, which is short for cysteine-rich 61), an extracellular matrix protein that is also considered a pro-inflammatory factor, is highly expressed in the lesional skin of psoriasis patients, as well as in that of imiquimod (IMQ)- and IL-23-treated psoriasis-like mice.	Imiquimod	268-271	cellular communication network factor 1	Homo sapiens	25-29
26099024-3	2015	Here we demonstrate that CCN1 (also called Cyr61, which is short for cysteine-rich 61), an extracellular matrix protein that is also considered a pro-inflammatory factor, is highly expressed in the lesional skin of psoriasis patients, as well as in that of imiquimod (IMQ)- and IL-23-treated psoriasis-like mice.	Imiquimod	268-271	cellular communication network factor 1	Homo sapiens	43-48
26460049-5	2015	Using genetically modified mice, we found that imiquimod-induced psoriasis-like skin inflammation was completely absent in IkappaBzeta-deficient mice, whereas skin inflammation was still inducible in IL-17A- and TNFalpha-deficient mice.	Imiquimod	47-56	nuclear factor of kappa light polypeptide gene enhancer in B cells inhibitor, zeta	Mus musculus	123-134
26474319-4	2015	RESULTS: SLURP1 expression was up-regulated in the skin of IMQ-induced psoriasis model mice.	Imiquimod	59-62	secreted Ly6/Plaur domain containing 1	Mus musculus	9-15
26147228-0	2015	IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.	Imiquimod	0-3	interleukin 1 receptor, type I	Mus musculus	54-60
26147228-0	2015	IMQ-induced skin inflammation in mice is dependent on IL-1R1 and MyD88 signaling but independent of the NLRP3 inflammasome.	Imiquimod	0-3	myeloid differentiation primary response gene 88	Mus musculus	65-70
26147228-3	2015	IMQ-induced skin inflammation was partially reduced in mice deficient for both IL-1alpha/IL-1beta or for IL-1 receptor type 1 (IL-1R1), but not in IL-1alpha- or IL-1beta-deficient mice, demonstrating the redundant activity of IL-1alpha and IL-1beta for skin inflammation.	Imiquimod	0-3	interleukin 1 alpha	Mus musculus	79-88
26147228-3	2015	IMQ-induced skin inflammation was partially reduced in mice deficient for both IL-1alpha/IL-1beta or for IL-1 receptor type 1 (IL-1R1), but not in IL-1alpha- or IL-1beta-deficient mice, demonstrating the redundant activity of IL-1alpha and IL-1beta for skin inflammation.	Imiquimod	0-3	interleukin 1 beta	Mus musculus	89-97
26147228-3	2015	IMQ-induced skin inflammation was partially reduced in mice deficient for both IL-1alpha/IL-1beta or for IL-1 receptor type 1 (IL-1R1), but not in IL-1alpha- or IL-1beta-deficient mice, demonstrating the redundant activity of IL-1alpha and IL-1beta for skin inflammation.	Imiquimod	0-3	interleukin 1 receptor, type I	Mus musculus	105-125
26147228-3	2015	IMQ-induced skin inflammation was partially reduced in mice deficient for both IL-1alpha/IL-1beta or for IL-1 receptor type 1 (IL-1R1), but not in IL-1alpha- or IL-1beta-deficient mice, demonstrating the redundant activity of IL-1alpha and IL-1beta for skin inflammation.	Imiquimod	0-3	interleukin 1 receptor, type I	Mus musculus	127-133
26147228-5	2015	However, IMQ-induced skin inflammation was abolished in the absence of MyD88, the adaptor protein shared by IL-1R and TLR signaling pathways.	Imiquimod	9-12	toll-like receptor 7	Mus musculus	118-121
26147228-6	2015	These results are consistent with the TLR7 dependence of IMQ-induced skin inflammation.	Imiquimod	57-60	toll-like receptor 7	Mus musculus	38-42
26147228-7	2015	Thus, IL-1R1 contributes to the IMQ-induced skin inflammation, and disruption of MyD88 signaling completely abrogates this response.	Imiquimod	32-35	interleukin 1 receptor, type I	Mus musculus	6-12
25777289-6	2015	When compared to imiquimod-treated control mice, imiquimod-treated obese mice expressed higher levels of psoriasis mediators, interleukin-17A (IL-17A) and IL-22 in the skin.	Imiquimod	49-58	interleukin 17A	Mus musculus	126-141
26046540-9	2015	Intradermal injection of TNIP1 shRNA in BALB/c mice led to exaggerated psoriatic conditions in imiquimod (IMQ)-induced psoriasis-like dermatitis.	Imiquimod	106-109	TNFAIP3 interacting protein 1	Mus musculus	25-30
25660383-11	2015	In the pharmacodynamic analysis, urinary interleukin 1 receptor agonist (IL-1ra) represents the most sensitive and uniform response after TMX-101 instillation.	Imiquimod	138-145	interleukin 1 receptor antagonist	Homo sapiens	41-71
25660383-11	2015	In the pharmacodynamic analysis, urinary interleukin 1 receptor agonist (IL-1ra) represents the most sensitive and uniform response after TMX-101 instillation.	Imiquimod	138-145	interleukin 1 receptor antagonist	Homo sapiens	73-79
25777289-6	2015	When compared to imiquimod-treated control mice, imiquimod-treated obese mice expressed higher levels of psoriasis mediators, interleukin-17A (IL-17A) and IL-22 in the skin.	Imiquimod	49-58	interleukin 17A	Mus musculus	143-149
25777289-6	2015	When compared to imiquimod-treated control mice, imiquimod-treated obese mice expressed higher levels of psoriasis mediators, interleukin-17A (IL-17A) and IL-22 in the skin.	Imiquimod	49-58	interleukin 22	Mus musculus	155-160
25767074-3	2015	Cucurbitacin B significantly inhibited imiquimod-induced expression of crucial psoriatic cytokines, such as IL-8 and CCL20, via down-regulation of NF-kappaB and STAT3 signaling pathway in human keratinocytes.	Imiquimod	39-48	C-X-C motif chemokine ligand 8	Homo sapiens	108-112
25766763-0	2015	Imiquimod-induced AMPK activation causes translation attenuation and apoptosis but not autophagy.	Imiquimod	0-9	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	18-22
25766763-3	2015	OBJECTIVE: To evaluate the role of AMPK in IMQ-induced apoptosis and autophagy.	Imiquimod	43-46	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	35-39
25766763-7	2015	The role of AMPK activation in IMQ-induced autophagy and apoptosis was assessed by inhibiting AMPK, genetically silencing AMPK and over-expressing AMPK dominant-negative mutants.	Imiquimod	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	12-16
25766763-7	2015	The role of AMPK activation in IMQ-induced autophagy and apoptosis was assessed by inhibiting AMPK, genetically silencing AMPK and over-expressing AMPK dominant-negative mutants.	Imiquimod	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
25766763-7	2015	The role of AMPK activation in IMQ-induced autophagy and apoptosis was assessed by inhibiting AMPK, genetically silencing AMPK and over-expressing AMPK dominant-negative mutants.	Imiquimod	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
25766763-7	2015	The role of AMPK activation in IMQ-induced autophagy and apoptosis was assessed by inhibiting AMPK, genetically silencing AMPK and over-expressing AMPK dominant-negative mutants.	Imiquimod	31-34	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	94-98
25766763-10	2015	IMQ caused ATP depletion and induced LKB1-mediated AMPK activation.	Imiquimod	0-3	serine/threonine kinase 11	Homo sapiens	37-41
25766763-10	2015	IMQ caused ATP depletion and induced LKB1-mediated AMPK activation.	Imiquimod	0-3	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	51-55
25766763-11	2015	The down-regulation of AMPK activity via pharmacological inhibition and genetic silencing resulted in reduced IMQ-induced apoptosis but did not influence autophagy, and this rescue effect was associated with the retention of translation factor activity and anti-apoptotic Bcl-2 family member Mcl-1 protein expression levels.	Imiquimod	110-113	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	23-27
25766763-11	2015	The down-regulation of AMPK activity via pharmacological inhibition and genetic silencing resulted in reduced IMQ-induced apoptosis but did not influence autophagy, and this rescue effect was associated with the retention of translation factor activity and anti-apoptotic Bcl-2 family member Mcl-1 protein expression levels.	Imiquimod	110-113	BCL2 apoptosis regulator	Homo sapiens	272-277
25766763-11	2015	The down-regulation of AMPK activity via pharmacological inhibition and genetic silencing resulted in reduced IMQ-induced apoptosis but did not influence autophagy, and this rescue effect was associated with the retention of translation factor activity and anti-apoptotic Bcl-2 family member Mcl-1 protein expression levels.	Imiquimod	110-113	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	292-297
25766763-12	2015	CONCLUSION: IMQ induces AMPK activation independent of TLR7/8 expression, resulting in translation inhibition and subsequent apoptosis through ATP depletion and LKB1 signaling, in skin tumor cells.	Imiquimod	12-15	protein kinase AMP-activated catalytic subunit alpha 2	Homo sapiens	24-28
25766763-12	2015	CONCLUSION: IMQ induces AMPK activation independent of TLR7/8 expression, resulting in translation inhibition and subsequent apoptosis through ATP depletion and LKB1 signaling, in skin tumor cells.	Imiquimod	12-15	serine/threonine kinase 11	Homo sapiens	161-165
25911755-6	2015	Additionally, TNFR1 knockout mice showed sustained type I IFN production in response to Aldara.	Imiquimod	88-94	tumor necrosis factor receptor superfamily, member 1a	Mus musculus	14-19
25911755-7	2015	Double knockout mice lacking both receptors showed superior protection to Aldara in comparison with the single knockout mice and displayed reduced levels of IL-12p40, IL-17F, and S100A8, indicating that the TNF and type I IFN pathways contribute significantly to inflammation upon treatment with Aldara.	Imiquimod	74-80	tumor necrosis factor	Mus musculus	207-210
25911755-7	2015	Double knockout mice lacking both receptors showed superior protection to Aldara in comparison with the single knockout mice and displayed reduced levels of IL-12p40, IL-17F, and S100A8, indicating that the TNF and type I IFN pathways contribute significantly to inflammation upon treatment with Aldara.	Imiquimod	296-302	interleukin 12b	Mus musculus	157-165
25911755-7	2015	Double knockout mice lacking both receptors showed superior protection to Aldara in comparison with the single knockout mice and displayed reduced levels of IL-12p40, IL-17F, and S100A8, indicating that the TNF and type I IFN pathways contribute significantly to inflammation upon treatment with Aldara.	Imiquimod	296-302	tumor necrosis factor	Mus musculus	207-210
25767074-3	2015	Cucurbitacin B significantly inhibited imiquimod-induced expression of crucial psoriatic cytokines, such as IL-8 and CCL20, via down-regulation of NF-kappaB and STAT3 signaling pathway in human keratinocytes.	Imiquimod	39-48	C-C motif chemokine ligand 20	Homo sapiens	117-122
25767074-3	2015	Cucurbitacin B significantly inhibited imiquimod-induced expression of crucial psoriatic cytokines, such as IL-8 and CCL20, via down-regulation of NF-kappaB and STAT3 signaling pathway in human keratinocytes.	Imiquimod	39-48	signal transducer and activator of transcription 3	Homo sapiens	161-166
25567751-4	2015	In the present study, we evaluated the anticancer effect of the TLR7 agonist, imiquimod (IMQ), in the absence of iNOS.	Imiquimod	78-87	toll-like receptor 7	Mus musculus	64-68
25567751-4	2015	In the present study, we evaluated the anticancer effect of the TLR7 agonist, imiquimod (IMQ), in the absence of iNOS.	Imiquimod	89-92	toll-like receptor 7	Mus musculus	64-68
25567751-5	2015	The administration of IMQ in iNOS-knockout (KO) mice implanted with tumor cells significantly suppressed tumor progression as compared to that in wild-type mice and improved the survival rate.	Imiquimod	22-25	nitric oxide synthase 2, inducible	Mus musculus	29-33
25322876-4	2015	In the present study, we evaluated the anti-cancer effect of the TLR7 agonist, imiquimod (IMQ), in the absence of IDO activity.	Imiquimod	79-88	toll-like receptor 7	Mus musculus	65-69
25664647-10	2015	Topical application of IFI27 siRNA on imiquimod-induced psoriatic lesion in a mouse model reduced epidermal thickness, formation of rete ridges and PCNA expression.	Imiquimod	38-47	interferon, alpha-inducible protein 27	Mus musculus	23-28
25664647-10	2015	Topical application of IFI27 siRNA on imiquimod-induced psoriatic lesion in a mouse model reduced epidermal thickness, formation of rete ridges and PCNA expression.	Imiquimod	38-47	proliferating cell nuclear antigen	Mus musculus	148-152
25322876-4	2015	In the present study, we evaluated the anti-cancer effect of the TLR7 agonist, imiquimod (IMQ), in the absence of IDO activity.	Imiquimod	90-93	toll-like receptor 7	Mus musculus	65-69
25322876-5	2015	The administration of IMQ in IDO knockout (KO) mice inoculated with tumour cells significantly suppressed tumour progression compared with that in wild-type (WT) mice, and improved the survival rate.	Imiquimod	22-25	indoleamine 2,3-dioxygenase 1	Mus musculus	29-32
25322876-6	2015	Moreover, injection with IMQ enhanced the tumour antigen-specific T helper type 1 response in IDO-KO mice with tumours.	Imiquimod	25-28	indoleamine 2,3-dioxygenase 1	Mus musculus	94-97
25156366-0	2014	Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.	Imiquimod	40-49	tyrosine kinase 2	Mus musculus	14-18
25655893-0	2015	Osteopontin deficiency affects imiquimod-induced psoriasis-like murine skin inflammation and lymphocyte distribution in skin, draining lymph nodes and spleen.	Imiquimod	31-40	secreted phosphoprotein 1	Mus musculus	0-11
25655893-3	2015	OPN-/- mice treated with IMQ showed delayed onset ear swelling and attracted less inflammatory cells to the skin.	Imiquimod	25-28	secreted phosphoprotein 1	Mus musculus	0-3
25518732-4	2014	We therefore tested the efficacy of the TLR7 agonist imiquimod (IMQ) combined with agonistic anti-CD40 in an incomplete debulking model of malignant mesothelioma.	Imiquimod	53-62	toll-like receptor 7	Mus musculus	40-44
24304413-7	2014	Intraperitoneal PRL increased the numbers of CD3(+) and GR-1(+) cells in the dermis of imiquimod-treated skin.	Imiquimod	87-96	prolactin	Mus musculus	16-19
24980460-12	2015	IL-6 and tumour necrosis factor-alpha were preferentially expressed in Aldara-treated skin.	Imiquimod	71-77	interleukin 6	Homo sapiens	0-37
24980460-13	2015	Adaptive immune system activation occurred only partially: IL-23p19 and IL-22 were similarly overexpressed in Aldara-treated and lesional psoriatic skin, but IL-17A and IL-12p40 were significantly underexpressed in Aldara-treated skin compared with lesional psoriatic skin.	Imiquimod	110-116	interleukin 22	Homo sapiens	72-77
24980460-13	2015	Adaptive immune system activation occurred only partially: IL-23p19 and IL-22 were similarly overexpressed in Aldara-treated and lesional psoriatic skin, but IL-17A and IL-12p40 were significantly underexpressed in Aldara-treated skin compared with lesional psoriatic skin.	Imiquimod	215-221	interleukin 17A	Homo sapiens	158-164
24980460-14	2015	IL-10 was significantly overexpressed in Aldara-treated skin.	Imiquimod	41-47	interleukin 10	Homo sapiens	0-5
25572557-7	2015	Epidermal hyperplasia induced by IMQ treatment was impaired in periostin-deficient mice, along with decreased skin swelling.	Imiquimod	33-36	periostin, osteoblast specific factor	Mus musculus	63-72
25572557-9	2015	CONCLUSIONS: Periostin plays an important role during epidermal hyperplasia in IMQ-induced skin inflammation, independently of the IL-23-IL-17/IL-22 axis.	Imiquimod	79-82	periostin, osteoblast specific factor	Mus musculus	13-22
24751730-1	2014	Imiquimod (IMQ) is a synthetic Toll-like receptor (TLR7/8) ligand that can trigger antiviral and antitumor activities.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	51-55
24751730-1	2014	Imiquimod (IMQ) is a synthetic Toll-like receptor (TLR7/8) ligand that can trigger antiviral and antitumor activities.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	51-55
24751730-6	2014	IMQ also drastically impeded tumor vascularization by inducing the downregulation of angiogenic factors vascular endothelial growth factor, angiogenin, IL-8, and fibroblast growth factor.	Imiquimod	0-3	angiogenin, ribonuclease, RNase A family, 5	Mus musculus	140-150
24751730-6	2014	IMQ also drastically impeded tumor vascularization by inducing the downregulation of angiogenic factors vascular endothelial growth factor, angiogenin, IL-8, and fibroblast growth factor.	Imiquimod	0-3	chemokine (C-X-C motif) ligand 15	Mus musculus	152-156
25156366-0	2014	Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.	Imiquimod	40-49	Janus kinase 1	Mus musculus	23-27
25156366-0	2014	Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.	Imiquimod	40-49	interleukin 22	Mus musculus	98-103
25156366-0	2014	Inhibition of TYK2 and JAK1 ameliorates imiquimod-induced psoriasis-like dermatitis by inhibiting IL-22 and the IL-23/IL-17 axis.	Imiquimod	40-49	interleukin 23, alpha subunit p19	Mus musculus	112-123
24909816-9	2014	Treatment of mice with imiquimod, a TLR7 agonist, prior to JEV infection resulted in their increased survival.	Imiquimod	23-32	toll-like receptor 7	Mus musculus	36-40
25594066-4	2014	In this perspective article we highlight recent findings showing that the Toll-like receptor-7/8 (TLR7/8) agonist imiquimod (IMQ), an immune modulator approved for the treatment of basal cell carcinoma, can also act as a potent cell autonomous inhibitor of oncogenic HH signaling.	Imiquimod	125-128	toll like receptor 7	Homo sapiens	74-96
25594066-4	2014	In this perspective article we highlight recent findings showing that the Toll-like receptor-7/8 (TLR7/8) agonist imiquimod (IMQ), an immune modulator approved for the treatment of basal cell carcinoma, can also act as a potent cell autonomous inhibitor of oncogenic HH signaling.	Imiquimod	125-128	toll like receptor 7	Homo sapiens	98-104
25594066-6	2014	We here highlight the molecular mechanisms of IMQ-mediated repression of HH/GLI and discuss the possible benefits as well as challenges of using ADORA agonists for the treatment of HH-associated cancer.	Imiquimod	46-49	GLI family zinc finger 1	Homo sapiens	76-79
28837000-3	2014	Immune analyses of these long-term disease-free breast cancer patients previously treated with imiquimod (IMQ) suggest in-situ vaccination is achieved by topical application of the TLR-7 agonist directly onto tumors.	Imiquimod	95-104	toll like receptor 7	Homo sapiens	181-186
28837000-3	2014	Immune analyses of these long-term disease-free breast cancer patients previously treated with imiquimod (IMQ) suggest in-situ vaccination is achieved by topical application of the TLR-7 agonist directly onto tumors.	Imiquimod	106-109	toll like receptor 7	Homo sapiens	181-186
24824846-1	2014	Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis.	Imiquimod	70-79	interleukin 17A	Mus musculus	186-191
24825342-5	2014	Moreover, Aldara-treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70.	Imiquimod	10-16	CD86 molecule	Homo sapiens	82-86
24825342-5	2014	Moreover, Aldara-treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70.	Imiquimod	10-16	CD83 molecule	Homo sapiens	88-92
24825342-5	2014	Moreover, Aldara-treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70.	Imiquimod	10-16	CD40 molecule	Homo sapiens	94-98
24825342-5	2014	Moreover, Aldara-treated DCs showed highest levels of the costimulatory molecules CD86, CD83, CD40, and CD70.	Imiquimod	10-16	CD70 molecule	Homo sapiens	104-108
24825342-7	2014	When combined with intradermal peptide vaccination, Aldara-stimulated DCs showed enhanced cross-presentation of the melanoma antigen MART-1, which resulted in increased priming and activation of MART-1-specific CD8(+) T cells.	Imiquimod	52-58	retrotransposon Gag like 1	Homo sapiens	133-139
24825342-7	2014	When combined with intradermal peptide vaccination, Aldara-stimulated DCs showed enhanced cross-presentation of the melanoma antigen MART-1, which resulted in increased priming and activation of MART-1-specific CD8(+) T cells.	Imiquimod	52-58	retrotransposon Gag like 1	Homo sapiens	195-201
24825342-7	2014	When combined with intradermal peptide vaccination, Aldara-stimulated DCs showed enhanced cross-presentation of the melanoma antigen MART-1, which resulted in increased priming and activation of MART-1-specific CD8(+) T cells.	Imiquimod	52-58	CD8a molecule	Homo sapiens	211-214
24971541-8	2014	However, 2APB, an IP3 receptor blocker, inhibited the imiquimod-induced [Ca(2+)]i increase.	Imiquimod	54-63	inositol 1,4,5-triphosphate receptor 3	Mus musculus	18-30
24824846-0	2014	Skin-penetrating methotrexate alleviates imiquimod-induced psoriasiform dermatitis via decreasing IL-17-producing gamma delta T cells.	Imiquimod	41-50	interleukin 17A	Mus musculus	98-103
24824846-1	2014	Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis.	Imiquimod	70-79	interleukin 23, alpha subunit p19	Mus musculus	180-185
24824846-1	2014	Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis.	Imiquimod	81-84	interleukin 23, alpha subunit p19	Mus musculus	180-185
24824846-1	2014	Accumulating evidence has shown that the Toll-like receptor 7 agonist imiquimod (IMQ) induces psoriasiform skin inflammation in mice and that this inflammation is dependent on the IL-23/IL-17 axis.	Imiquimod	81-84	interleukin 17A	Mus musculus	186-191
24966637-11	2014	CONCLUSION: Imiquimod may elicit an anti-invasive effect on human melanoma cells by regulating MMPs and TIMPs.	Imiquimod	12-21	matrix metallopeptidase 2	Homo sapiens	95-99
24569709-0	2014	IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells.	Imiquimod	63-72	interleukin 23, alpha subunit p19	Mus musculus	0-5
24569709-0	2014	IL-23 from Langerhans cells is required for the development of imiquimod-induced psoriasis-like dermatitis by induction of IL-17A-producing gammadelta T cells.	Imiquimod	63-72	interleukin 17A	Mus musculus	123-129
24569709-8	2014	Moreover, the IMQ-treated skin of LC-depleted mice showed a decreased number of IL-17A-producing CCR6+ gammadelta T cells.	Imiquimod	14-17	interleukin 17A	Mus musculus	80-86
24569709-8	2014	Moreover, the IMQ-treated skin of LC-depleted mice showed a decreased number of IL-17A-producing CCR6+ gammadelta T cells.	Imiquimod	14-17	chemokine (C-C motif) receptor 6	Mus musculus	97-101
24663678-4	2014	In this article, we show that orchestrated action of CXCR2 and leukotriene B4 receptor BLT1 plays a key role in neutrophil recruitment during the development of imiquimod (IMQ)-induced psoriatic skin lesions in mice.	Imiquimod	172-175	leukotriene B4 receptor 1	Mus musculus	63-91
24718773-0	2014	Endogenous n-3 polyunsaturated fatty acids protect against imiquimod-induced psoriasis-like inflammation via the IL-17/IL-23 axis.	Imiquimod	59-68	interleukin 17A	Mus musculus	113-124
24718773-6	2014	Flow cytometry and an enzyme-linked immunosorbent assay were used to measure the differences in the content of inflammatory factors in the blood serum and to determine which of CD4+ T cells were present in the spleen between IMQ-induced fat-1 mice and WT mice.	Imiquimod	225-228	FAT atypical cadherin 1	Mus musculus	237-242
24663678-4	2014	In this article, we show that orchestrated action of CXCR2 and leukotriene B4 receptor BLT1 plays a key role in neutrophil recruitment during the development of imiquimod (IMQ)-induced psoriatic skin lesions in mice.	Imiquimod	161-170	chemokine (C-X-C motif) receptor 2	Mus musculus	53-58
24663678-6	2014	Furthermore, CXCR2 and BLT1 coordinately promote neutrophil infiltration into the skin during the early phase of IMQ-induced inflammation.	Imiquimod	113-116	chemokine (C-X-C motif) receptor 2	Mus musculus	13-18
24663678-4	2014	In this article, we show that orchestrated action of CXCR2 and leukotriene B4 receptor BLT1 plays a key role in neutrophil recruitment during the development of imiquimod (IMQ)-induced psoriatic skin lesions in mice.	Imiquimod	161-170	leukotriene B4 receptor 1	Mus musculus	63-91
24663678-4	2014	In this article, we show that orchestrated action of CXCR2 and leukotriene B4 receptor BLT1 plays a key role in neutrophil recruitment during the development of imiquimod (IMQ)-induced psoriatic skin lesions in mice.	Imiquimod	172-175	chemokine (C-X-C motif) receptor 2	Mus musculus	53-58
24663678-6	2014	Furthermore, CXCR2 and BLT1 coordinately promote neutrophil infiltration into the skin during the early phase of IMQ-induced inflammation.	Imiquimod	113-116	leukotriene B4 receptor 1	Mus musculus	23-27
24663678-8	2014	In agreement with the increased IL-19 expression in IMQ-treated mouse skin, IL-1beta markedly upregulated expression of acanthosis-inducing cytokine IL-19 in human keratinocytes.	Imiquimod	52-55	interleukin 19	Mus musculus	32-37
24663678-8	2014	In agreement with the increased IL-19 expression in IMQ-treated mouse skin, IL-1beta markedly upregulated expression of acanthosis-inducing cytokine IL-19 in human keratinocytes.	Imiquimod	52-55	interleukin 1 beta	Mus musculus	76-84
24663678-8	2014	In agreement with the increased IL-19 expression in IMQ-treated mouse skin, IL-1beta markedly upregulated expression of acanthosis-inducing cytokine IL-19 in human keratinocytes.	Imiquimod	52-55	interleukin 19	Mus musculus	149-154
24743316-5	2014	When A20 was overexpressed, imiquimod-induced apoptosis was markedly inhibited.	Imiquimod	28-37	immunoglobulin kappa variable 1-27	Homo sapiens	5-8
24743316-6	2014	Conversely, knockdown of A20 potentiated imiquimod-induced apoptosis.	Imiquimod	41-50	immunoglobulin kappa variable 1-27	Homo sapiens	25-28
24743316-8	2014	Finally, imiquimod-induced apoptosis of SCC12 cells was taken place in a TLR7-independent manner.	Imiquimod	9-18	toll like receptor 7	Homo sapiens	73-77
24658058-6	2014	Moreover, the glucose analog 2-DG and the Hsp90 inhibitor 17-AAG, which destabilizes the HIF-1alpha protein, synergized with IMQ to induce tumor cell apoptosis in vitro and significantly inhibited tumor growth in vivo.	Imiquimod	125-128	heat shock protein 90 alpha family class A member 1	Homo sapiens	42-47
24658058-6	2014	Moreover, the glucose analog 2-DG and the Hsp90 inhibitor 17-AAG, which destabilizes the HIF-1alpha protein, synergized with IMQ to induce tumor cell apoptosis in vitro and significantly inhibited tumor growth in vivo.	Imiquimod	125-128	hypoxia inducible factor 1 subunit alpha	Homo sapiens	89-99
24658058-2	2014	Imiquimod (IMQ), a synthetic Toll-like receptor (TLR) 7/8 ligand, exerts anti-tumor effects directly by inducing cell death in cancer cells and/or indirectly by activating cellular immune responses against tumor cells.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	49-52
24658058-2	2014	Imiquimod (IMQ), a synthetic Toll-like receptor (TLR) 7/8 ligand, exerts anti-tumor effects directly by inducing cell death in cancer cells and/or indirectly by activating cellular immune responses against tumor cells.	Imiquimod	11-14	toll like receptor 7	Homo sapiens	49-52
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	30-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
24658058-4	2014	In this study, we demonstrated that IMQ can enhance aerobic glycolysis by up-regulating HIF-1alpha expression at the transcriptional and translational levels via ROS mediated STAT3- and Akt-dependent pathways, independent of TLR7/8 signaling.	Imiquimod	36-39	hypoxia inducible factor 1 subunit alpha	Homo sapiens	88-98
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	30-33	hypoxia inducible factor 1 subunit alpha	Homo sapiens	212-222
24658058-4	2014	In this study, we demonstrated that IMQ can enhance aerobic glycolysis by up-regulating HIF-1alpha expression at the transcriptional and translational levels via ROS mediated STAT3- and Akt-dependent pathways, independent of TLR7/8 signaling.	Imiquimod	36-39	signal transducer and activator of transcription 3	Homo sapiens	175-180
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	155-158	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
24658058-4	2014	In this study, we demonstrated that IMQ can enhance aerobic glycolysis by up-regulating HIF-1alpha expression at the transcriptional and translational levels via ROS mediated STAT3- and Akt-dependent pathways, independent of TLR7/8 signaling.	Imiquimod	36-39	AKT serine/threonine kinase 1	Homo sapiens	186-189
24658058-5	2014	The genetic silencing of HIF-1alpha not only repressed IMQ-induced aerobic glycolysis but also sensitized cells to IMQ-induced apoptosis due to faster ATP and Mcl-1 depletion.	Imiquimod	55-58	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-35
24658058-5	2014	The genetic silencing of HIF-1alpha not only repressed IMQ-induced aerobic glycolysis but also sensitized cells to IMQ-induced apoptosis due to faster ATP and Mcl-1 depletion.	Imiquimod	115-118	hypoxia inducible factor 1 subunit alpha	Homo sapiens	25-35
24658058-5	2014	The genetic silencing of HIF-1alpha not only repressed IMQ-induced aerobic glycolysis but also sensitized cells to IMQ-induced apoptosis due to faster ATP and Mcl-1 depletion.	Imiquimod	115-118	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	159-164
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	155-158	hypoxia inducible factor 1 subunit alpha	Homo sapiens	212-222
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	155-158	hypoxia inducible factor 1 subunit alpha	Homo sapiens	59-69
24658058-7	2014	Thus, we hypothesize that the IMQ-induced up-regulation of HIF-1alpha and aerobic glycolysis is a protective response to the metabolic stress generated by IMQ treatment, and thus, co-treatment with inhibitors of HIF-1alpha and/or glycolysis may be a useful therapeutic strategy to enhance the anti-tumor effects of IMQ in clinical settings.	Imiquimod	155-158	hypoxia inducible factor 1 subunit alpha	Homo sapiens	212-222
24286371-2	2014	In this study, we report the effects of topical calcipotriol, camptothecin, clobetasol and tazarotene on the treatment of imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which is dependent on the IL-23/IL-17A axis.	Imiquimod	122-131	interleukin 23, alpha subunit p19	Mus musculus	220-225
24286371-7	2014	Calcipotriol, camptothecin and tazarotene not only failed to inhibit this proliferation but also enhanced retinoic acid-related orphan receptor gamma (RORgamma) expression in IMQ-induced psoriasis-like inflammation.	Imiquimod	175-178	RAR-related orphan receptor gamma	Mus musculus	151-159
24286371-2	2014	In this study, we report the effects of topical calcipotriol, camptothecin, clobetasol and tazarotene on the treatment of imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which is dependent on the IL-23/IL-17A axis.	Imiquimod	122-131	interleukin 17A	Mus musculus	226-232
24387343-1	2014	Topical application of imiquimod (IMQ), a Toll-like receptor (TLR)7 ligand, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.	Imiquimod	23-32	toll-like receptor 7	Mus musculus	62-67
24387343-1	2014	Topical application of imiquimod (IMQ), a Toll-like receptor (TLR)7 ligand, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder.	Imiquimod	34-37	toll-like receptor 7	Mus musculus	62-67
24387343-2	2014	In a mouse model of IMQ-induced psoriasis-like skin inflammation, T-helper (Th)17 cells and interleukin (IL)-17/IL-22-producing gammadelta-T cells have been shown to play a pivotal role.	Imiquimod	20-23	interleukin 17A	Mus musculus	92-111
24387343-2	2014	In a mouse model of IMQ-induced psoriasis-like skin inflammation, T-helper (Th)17 cells and interleukin (IL)-17/IL-22-producing gammadelta-T cells have been shown to play a pivotal role.	Imiquimod	20-23	interleukin 22	Mus musculus	112-117
24387343-7	2014	In an in vitro study using plasmacytoid dendritic cells (DCs), IMQ induced production of interferon (IFN)-alpha, IL-23, IL-6 and tumor necrosis factor (TNF)-alpha.	Imiquimod	63-66	interferon alpha	Mus musculus	89-111
24387343-7	2014	In an in vitro study using plasmacytoid dendritic cells (DCs), IMQ induced production of interferon (IFN)-alpha, IL-23, IL-6 and tumor necrosis factor (TNF)-alpha.	Imiquimod	63-66	interleukin 23, alpha subunit p19	Mus musculus	113-118
24387343-7	2014	In an in vitro study using plasmacytoid dendritic cells (DCs), IMQ induced production of interferon (IFN)-alpha, IL-23, IL-6 and tumor necrosis factor (TNF)-alpha.	Imiquimod	63-66	interleukin 6	Mus musculus	120-124
24387343-7	2014	In an in vitro study using plasmacytoid dendritic cells (DCs), IMQ induced production of interferon (IFN)-alpha, IL-23, IL-6 and tumor necrosis factor (TNF)-alpha.	Imiquimod	63-66	tumor necrosis factor	Mus musculus	129-162
24387343-9	2014	These in vitro effects of IMQ were also mediated via TLR7 and the synergistic effect of IMQ, and IFN-alpha was suggested to be caused by upregulation of TLR7 expression by IFN-alpha.	Imiquimod	26-29	toll-like receptor 7	Mus musculus	53-57
24387343-9	2014	These in vitro effects of IMQ were also mediated via TLR7 and the synergistic effect of IMQ, and IFN-alpha was suggested to be caused by upregulation of TLR7 expression by IFN-alpha.	Imiquimod	26-29	interferon alpha	Mus musculus	97-106
24387343-9	2014	These in vitro effects of IMQ were also mediated via TLR7 and the synergistic effect of IMQ, and IFN-alpha was suggested to be caused by upregulation of TLR7 expression by IFN-alpha.	Imiquimod	26-29	toll-like receptor 7	Mus musculus	153-157
24387343-9	2014	These in vitro effects of IMQ were also mediated via TLR7 and the synergistic effect of IMQ, and IFN-alpha was suggested to be caused by upregulation of TLR7 expression by IFN-alpha.	Imiquimod	26-29	interferon alpha	Mus musculus	172-181
24067228-0	2013	[Expression of NLRP3 inflammasome in BALB/c mice with imiquimod-induced psoriasis-like inflammation and therapeutic effect of mustard seed (Sinapis Alba Linn)].	Imiquimod	54-63	NLR family, pyrin domain containing 3	Mus musculus	15-20
22431065-7	2013	Topical IMQ treatment induced T cell and plasmacytoid dendritic cell infiltrates at the tumor sites, where levels of IL-12/23p40, IL-12p35, IL-23p19, IL-17A, and IFN-gamma mRNAs were up-regulated.	Imiquimod	8-11	interferon gamma	Mus musculus	162-171
23945140-3	2013	We report that Tir8/Sigirr-deficient mice develop more severe psoriatic inflammation in both the chemical (Aldara)- and cytokine (rIL-23)-induced models of psoriasis.	Imiquimod	107-113	single immunoglobulin and toll-interleukin 1 receptor (TIR) domain	Mus musculus	15-19
25341693-7	2014	Immunostaining of kidney sections of nephritic MRL/lpr mice revealed that CD11c was expressed in the infiltrated tubulointerstitial cells, and confocal microscopic analysis of renal CD11c+MHCII+, CD11c+CD80+, and CD11c+)CD86+ cells showed an immature phenotype with low levels of CD80, CD86, and MHCII in imiquimod-treated MRL/lpr mice.	Imiquimod	305-314	integrin alpha X	Mus musculus	74-79
23995793-4	2013	Here we show that IMQ can also directly repress HH signalling by negatively modulating GLI activity in BCC and medulloblastoma cells.	Imiquimod	18-21	GLI family zinc finger 1	Homo sapiens	87-90
22431065-7	2013	Topical IMQ treatment induced T cell and plasmacytoid dendritic cell infiltrates at the tumor sites, where levels of IL-12/23p40, IL-12p35, IL-23p19, IL-17A, and IFN-gamma mRNAs were up-regulated.	Imiquimod	8-11	interleukin 12a	Mus musculus	130-138
22431065-7	2013	Topical IMQ treatment induced T cell and plasmacytoid dendritic cell infiltrates at the tumor sites, where levels of IL-12/23p40, IL-12p35, IL-23p19, IL-17A, and IFN-gamma mRNAs were up-regulated.	Imiquimod	8-11	interleukin 23, alpha subunit p19	Mus musculus	140-148
22431065-7	2013	Topical IMQ treatment induced T cell and plasmacytoid dendritic cell infiltrates at the tumor sites, where levels of IL-12/23p40, IL-12p35, IL-23p19, IL-17A, and IFN-gamma mRNAs were up-regulated.	Imiquimod	8-11	interleukin 17A	Mus musculus	150-156
23754427-2	2013	Topical application of Aldara cream containing the Toll-like receptor (TLR)7 agonist Imiquimod (IMQ) onto patients induces flares of psoriasis.	Imiquimod	85-94	toll like receptor 7	Homo sapiens	71-76
23885825-3	2013	Despite the approved clinical use of the topical TLR7 agonist, imiquimod (Aldara( ) Imiquimod 5% cream; 3M, MN, USA), for external genital warts, superficial basal cell carcinoma and actinic keratosis, no vaccines using TLR7, TLR8 or TLR7/8 agonists have progressed beyond early-phase clinical studies thus far.	Imiquimod	63-72	toll like receptor 7	Homo sapiens	49-53
23885825-3	2013	Despite the approved clinical use of the topical TLR7 agonist, imiquimod (Aldara( ) Imiquimod 5% cream; 3M, MN, USA), for external genital warts, superficial basal cell carcinoma and actinic keratosis, no vaccines using TLR7, TLR8 or TLR7/8 agonists have progressed beyond early-phase clinical studies thus far.	Imiquimod	63-72	toll like receptor 7	Homo sapiens	220-224
23885825-3	2013	Despite the approved clinical use of the topical TLR7 agonist, imiquimod (Aldara( ) Imiquimod 5% cream; 3M, MN, USA), for external genital warts, superficial basal cell carcinoma and actinic keratosis, no vaccines using TLR7, TLR8 or TLR7/8 agonists have progressed beyond early-phase clinical studies thus far.	Imiquimod	63-72	toll like receptor 8	Homo sapiens	226-230
23885825-3	2013	Despite the approved clinical use of the topical TLR7 agonist, imiquimod (Aldara( ) Imiquimod 5% cream; 3M, MN, USA), for external genital warts, superficial basal cell carcinoma and actinic keratosis, no vaccines using TLR7, TLR8 or TLR7/8 agonists have progressed beyond early-phase clinical studies thus far.	Imiquimod	63-72	toll like receptor 7	Homo sapiens	220-224
23885825-3	2013	Despite the approved clinical use of the topical TLR7 agonist, imiquimod (Aldara( ) Imiquimod 5% cream; 3M, MN, USA), for external genital warts, superficial basal cell carcinoma and actinic keratosis, no vaccines using TLR7, TLR8 or TLR7/8 agonists have progressed beyond early-phase clinical studies thus far.	Imiquimod	74-81	toll like receptor 7	Homo sapiens	49-53
23825622-0	2013	Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice.	Imiquimod	18-27	interleukin 1 beta	Mus musculus	78-86
23825622-0	2013	Curcumin inhibits imiquimod-induced psoriasis-like inflammation by inhibiting IL-1beta and IL-6 production in mice.	Imiquimod	18-27	interleukin 6	Mus musculus	91-95
23825622-4	2013	Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis.	Imiquimod	82-91	interleukin 23, alpha subunit p19	Mus musculus	177-182
23825622-4	2013	Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis.	Imiquimod	82-91	interleukin 17A	Mus musculus	183-189
23825622-4	2013	Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis.	Imiquimod	93-96	interleukin 23, alpha subunit p19	Mus musculus	177-182
23825622-4	2013	Here, we report that topical use of a curcumin gel formulation strongly inhibited imiquimod (IMQ)-induced psoriasis-like inflammation, the development of which was based on the IL-23/IL-17A axis.	Imiquimod	93-96	interleukin 17A	Mus musculus	183-189
23754427-2	2013	Topical application of Aldara cream containing the Toll-like receptor (TLR)7 agonist Imiquimod (IMQ) onto patients induces flares of psoriasis.	Imiquimod	96-99	toll like receptor 7	Homo sapiens	71-76
23588478-4	2013	Treatment with imiquimod induced cell cycle arrest at the G2/M phase in TRMPA-C2 cells, confirmed by the changes of G2/M checkpoint regulators such as reduction of cyclin B1 expression and increase of phospho-CDC2 and p21 in TRAMP-C2 cells treated with imiquimod.	Imiquimod	15-24	cyclin B1	Mus musculus	164-173
23588478-4	2013	Treatment with imiquimod induced cell cycle arrest at the G2/M phase in TRMPA-C2 cells, confirmed by the changes of G2/M checkpoint regulators such as reduction of cyclin B1 expression and increase of phospho-CDC2 and p21 in TRAMP-C2 cells treated with imiquimod.	Imiquimod	15-24	cyclin-dependent kinase 1	Mus musculus	209-213
23588478-4	2013	Treatment with imiquimod induced cell cycle arrest at the G2/M phase in TRMPA-C2 cells, confirmed by the changes of G2/M checkpoint regulators such as reduction of cyclin B1 expression and increase of phospho-CDC2 and p21 in TRAMP-C2 cells treated with imiquimod.	Imiquimod	15-24	cyclin-dependent kinase inhibitor 1A (P21)	Mus musculus	218-221
23588478-4	2013	Treatment with imiquimod induced cell cycle arrest at the G2/M phase in TRMPA-C2 cells, confirmed by the changes of G2/M checkpoint regulators such as reduction of cyclin B1 expression and increase of phospho-CDC2 and p21 in TRAMP-C2 cells treated with imiquimod.	Imiquimod	15-24	translocating chain-associating membrane protein 1	Mus musculus	225-230
25069238-6	2013	In addition, imiquimod induced IFN-alpha mRNA expression in the hippocampus, whereas it prevented long-term potentiation in the Schaffer-CA1 pathway (i.e., hippocampal synaptic plasticity).	Imiquimod	13-22	interferon alpha	Mus musculus	31-40
25069238-6	2013	In addition, imiquimod induced IFN-alpha mRNA expression in the hippocampus, whereas it prevented long-term potentiation in the Schaffer-CA1 pathway (i.e., hippocampal synaptic plasticity).	Imiquimod	13-22	carbonic anhydrase 1	Mus musculus	137-140
22951728-4	2013	IMQ-treated skin showed an increase of IL-27 mRNA levels and the infiltration of IL-27-producing cells in the papillary dermis.	Imiquimod	0-3	interleukin 27	Homo sapiens	39-44
23634104-1	2013	In the title compound, C14H16N4, the six-membered hexa-hydro-pyrimidine ring adopts a chair conformation.	Imiquimod	23-31	hexosaminidase subunit alpha	Homo sapiens	50-54
22733292-1	2013	Topical TLR7 agonists such as imiquimod are highly effective for the treatment of dermatological malignancies; however, their efficacy in the treatment of nondermatological tumors has been less successful.	Imiquimod	30-39	toll like receptor 7	Homo sapiens	8-12
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	interleukin 17 receptor A	Homo sapiens	22-29
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	tumor necrosis factor	Mus musculus	82-109
22951728-4	2013	IMQ-treated skin showed an increase of IL-27 mRNA levels and the infiltration of IL-27-producing cells in the papillary dermis.	Imiquimod	0-3	interleukin 27	Homo sapiens	81-86
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	interleukin 6	Mus musculus	111-115
22951728-5	2013	The injection of IL-27 to the IMQ-treated skin exacerbated the disease compared with PBS injection.	Imiquimod	30-33	interleukin 27	Homo sapiens	17-22
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	interleukin 22	Mus musculus	121-126
22951726-7	2013	Upon IMQ treatment of IL-17RA(del) mice, these cells secreted elevated amounts of tumor necrosis factor-alpha, IL-6, and IL-22, accompanied by increased levels of the chemokine CXCL2, suggesting an alternative pathway of neutrophil and macrophage skin infiltration.	Imiquimod	5-8	chemokine (C-X-C motif) ligand 2	Mus musculus	177-182
22951728-7	2013	Finally, IL-27 antagonism attenuated the upregulation of IFN-gamma, CXCL9, CXCL10, CXCL11, and TNF-alpha mRNA levels, and induced clinical and histological improvement in the IMQ-treated skin.	Imiquimod	175-178	interleukin 27	Homo sapiens	9-14
22951728-8	2013	These results indicate that IL-27 would act in a proinflammatory manner, and thereby exacerbate the psoriasis-like skin inflammation induced by IMQ.	Imiquimod	144-147	interleukin 27	Homo sapiens	28-33
23457497-9	2013	The combination of TLR agonists poly I:C and imiquimod induced PGE2 and beta2 adrenoceptor desensitization on ASMC as did the RNA extracted from RV-induced conditioned medium.	Imiquimod	45-54	adrenoceptor beta 2	Homo sapiens	72-90
23463003-0	2013	Aldara activates TLR7-independent immune defence.	Imiquimod	0-6	toll-like receptor 7	Mus musculus	17-21
23048078-8	2012	RESULTS: Treatment with imiquimod significantly inhibited tumor growth, an effect that was associated with increased tumor infiltration by CD11c(+), CD4(+), and CD8(+) cells, and abolished by depletion of CD8(+) cells.	Imiquimod	24-33	integrin subunit alpha X	Homo sapiens	139-144
23048078-8	2012	RESULTS: Treatment with imiquimod significantly inhibited tumor growth, an effect that was associated with increased tumor infiltration by CD11c(+), CD4(+), and CD8(+) cells, and abolished by depletion of CD8(+) cells.	Imiquimod	24-33	CD4 molecule	Homo sapiens	149-152
23048078-8	2012	RESULTS: Treatment with imiquimod significantly inhibited tumor growth, an effect that was associated with increased tumor infiltration by CD11c(+), CD4(+), and CD8(+) cells, and abolished by depletion of CD8(+) cells.	Imiquimod	24-33	CD8a molecule	Homo sapiens	161-164
23048078-8	2012	RESULTS: Treatment with imiquimod significantly inhibited tumor growth, an effect that was associated with increased tumor infiltration by CD11c(+), CD4(+), and CD8(+) cells, and abolished by depletion of CD8(+) cells.	Imiquimod	24-33	CD8a molecule	Homo sapiens	205-208
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	99-102	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	51-60
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	88-97	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Mus musculus	38-47
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	99-102	interleukin 17A	Mus musculus	164-169
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	88-97	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	51-60
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	88-97	interleukin 17A	Mus musculus	164-169
23024273-4	2012	TCRgammadelta T cells were the major IL-17-producing population in the draining lymph nodes and were significantly diminished in IMQ-treated PI3Kdelta knockin and PI3Kgamma knockout mice.	Imiquimod	129-132	interleukin 17A	Mus musculus	37-42
23024273-3	2012	We found that mice lacking functional PI3Kdelta or PI3Kgamma are largely protected from imiquimod (IMQ)-induced psoriasis-like dermatitis, correlating with reduced IL-17 levels in the lesions, serum, and the draining lymph nodes.	Imiquimod	99-102	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Mus musculus	38-47
23024273-4	2012	TCRgammadelta T cells were the major IL-17-producing population in the draining lymph nodes and were significantly diminished in IMQ-treated PI3Kdelta knockin and PI3Kgamma knockout mice.	Imiquimod	129-132	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit delta	Mus musculus	141-150
23024273-4	2012	TCRgammadelta T cells were the major IL-17-producing population in the draining lymph nodes and were significantly diminished in IMQ-treated PI3Kdelta knockin and PI3Kgamma knockout mice.	Imiquimod	129-132	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	163-172
23024273-6	2012	In addition, inhibition of PI3Kgamma, but not PI3Kdelta, blocked chemotaxis of CCR6(+)IL-17-producing cells from IMQ-treated mice or healthy human donors.	Imiquimod	113-116	phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit gamma	Mus musculus	27-36
23024273-6	2012	In addition, inhibition of PI3Kgamma, but not PI3Kdelta, blocked chemotaxis of CCR6(+)IL-17-producing cells from IMQ-treated mice or healthy human donors.	Imiquimod	113-116	chemokine (C-C motif) receptor 6	Mus musculus	79-83
23024273-6	2012	In addition, inhibition of PI3Kgamma, but not PI3Kdelta, blocked chemotaxis of CCR6(+)IL-17-producing cells from IMQ-treated mice or healthy human donors.	Imiquimod	113-116	interleukin 17A	Mus musculus	86-91
22787201-10	2012	Imiquimod-induced anti-HSV-1 activity was observed in other cells, such as HeLa, SiHa, and CaSki cells, in a manner consistent with the cystatin A induction by imiquimod.	Imiquimod	0-9	cystatin A	Homo sapiens	136-146
22577802-8	2012	Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7.	Imiquimod	0-9	interleukin 6	Homo sapiens	18-22
22577802-8	2012	Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7.	Imiquimod	0-9	C-X-C motif chemokine ligand 8	Homo sapiens	27-31
22577802-8	2012	Imiquimod induced IL-6 and IL-8 production in OSCC cells, suggesting the functional expression of TLR7.	Imiquimod	0-9	toll like receptor 7	Homo sapiens	98-102
21953855-8	2012	RESULTS: Oral administration of Imiquimod induced type I IFN expression in the gastrointestinal mucosa and ameliorated DSS-induced acute colitis as assessed by clinical parameters, histology, and mRNA expression of proinflammatory cytokines.	Imiquimod	32-41	interferon alpha 1	Homo sapiens	57-60
22231699-9	2012	Interestingly, suboptimal doses of IMQ and IFN-alpha exhibited synergistic action, leading to optimal TRAIL expression and melanoma cell lysis by pDCs.	Imiquimod	35-38	TNF superfamily member 10	Homo sapiens	102-107
22116053-14	2012	At a dose of 5 mg/kg, imiquimod causes rather moderate brain-inflammatory responses, which are related to peripheral IFN-expression and possibly mediated by brain-intrinsic activation of NF-IL6 and induction of a proinflammatory cocktail.	Imiquimod	22-31	CCAAT/enhancer binding protein beta	Rattus norvegicus	187-193
22305615-5	2012	The mechanisms of imiquimod-induced decrease in Mcl-1 protein were evaluated by addition of cycloheximide, MG132 proteasome inhibitor or pan-caspase inhibitor.	Imiquimod	18-27	MCL1 apoptosis regulator, BCL2 family member	Homo sapiens	48-53
22131335-0	2012	IL-22 is required for imiquimod-induced psoriasiform skin inflammation in mice.	Imiquimod	22-31	interleukin 22	Mus musculus	0-5